Skip to main content

METLIFE INC

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

MET$102.44+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Notes to the Consolidated Financial Statements

  1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. In the fourth quarter of 2025, MetLife executed a reorganization to align with its strategic initiative to accelerate growth in asset management. As part of this reorganization, the Company adjusted its segment structure. MetLife Investment Management, the Company’s institutional asset management business (“MIM”), which was previously reported in Corporate & Other, became a reportable segment. MetLife Holdings was removed as a reportable segment, and its business is now primarily reported in Corporate & Other. These changes were applied retrospectively for all years presented. Additionally, certain products formerly reported in MetLife Holdings have been moved to Group Benefits and Retirement and Income Solutions (“RIS”). This change was applied only for the year ended December 31, 2025. The foregoing changes did not impact prior period consolidated net income (loss) or consolidated adjusted earnings, and are collectively referred to as the “Strategic Reorganization.” As a result of the Strategic Reorganization, MetLife is organized into the followingsix segments: Group Benefits; RIS; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MIM. In addition, the Company continues to report certain of its results of operations in Corporate & Other.

See Note 2 for further information on the Company’s segments and Corporate & Other.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.

Consolidation

The accompanying consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions are eliminated.

The Company uses either the equity method of accounting or the fair value option (“FVO”) for its investments in real estate joint ventures (“REJVs”) and other limited partnership interests (“OLPI”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.

Effective January 1, 2025, certain operating joint ventures engaged in insurance underwriting activities, for which the Company uses the equity method of accounting, adopted the accounting pronouncement related to targeted improvements to the accounting for long-duration contracts. See Note 19 for further information.

Held-for-Sale

The Company classifies a business, an asset or an asset group as held-for-sale when management has approved or received approval to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current estimated fair value and certain other specified criteria are met (“Disposal Group”). The Disposal Group classified as held-for-sale is recorded at the lower of the carrying value and estimated fair value, less cost to sell. If the carrying value of the Disposal Group exceeds its estimated fair value, less cost to sell, a loss is recognized and reported in net investment gains (losses). If the estimated fair value subsequently increases prior to sale, a gain is recognized and reported in net investment gains (losses) but will not exceed the losses recognized since the Disposal Group was classified as held-for-sale. Assets and liabilities related to the Disposal Group classified as held-for-sale are separately reported in the Company's consolidated balance sheets in the period in which the Disposal Group first meets all the criteria to be classified as held-for-sale and in each reporting period thereafter until sold. If a component of the Company has either been disposed of or is classified as held-for-sale and represents a strategic shift that has or will have a major effect on the Company’s operations and financial results, the results of the component are reported in discontinued operations.

Separate Accounts

Separate accounts are established in conformity with insurance laws. Generally, the assets of the separate accounts cannot be used to settle the liabilities that arise from any other business of the Company. Separate account assets are subject to general account claims only to the extent the value of such assets exceeds the separate account liabilities. The Company separately reports, as separate account assets and liabilities, investments held in separate accounts and corresponding policyholder liabilities of the same amount if all of the following criteria are met:

such separate accounts are legally recognized;

assets supporting the contract liabilities are legally insulated from the Company’s general account liabilities;

investment objectives are directed by the contractholder; and

all investment performance, net of contract fees and assessments, is passed through to the contractholder.

The Company reports separate account assets at their fair value which is based on the estimated fair values of the underlying assets comprising the individual separate account portfolios. Investment performance (including investment income, net investment gains (losses) and changes in unrealized gains (losses)) and the corresponding amounts credited to contractholders of such separate accounts are offset within the same line on the statements of operations. Separate accounts credited with a contractual investment return are not reported as separate account assets and liabilities and are combined on a line-by-line basis with the Company’s general account assets, liabilities, revenues and expenses and the accounting for these investments is consistent with the methodologies described herein for similar financial instruments held within the general account. Unit-linked separate account investments that are directed by contractholders but do not meet one or more of the other above criteria are included in contractholder-directed equity securities with the corresponding liability included in policyholder account balances (“PABs”) on the balance sheets. Investment performance is reported within net investment income and a corresponding amount reported as interest credited to PABs in the statements of operations.

The Company’s revenues reflect fees charged to the separate accounts, including mortality charges, risk charges, policy administration fees, investment management fees and surrender charges. Such fees are included in universal life and investment-type product policy fees on the statements of operations.

Summary of Significant Accounting Policies

The following table presents the Company’s significant accounting policies with cross-references to the notes which provide additional information on such policies.

Accounting PolicyNote
Acquisitions3
Future Policy Benefit Liabilities4
Policyholder Account Balances5
Market Risk Benefits6
Deferred Policy Acquisition Costs, Value of Business Acquired, Unearned Revenue and Other Intangibles8
Reinsurance9
Investments11
Derivatives12
Fair Value13
Goodwill15
Employee Benefit Plans21
Income Tax22
Litigation Contingencies24

Future Policy Benefit Liabilities

Traditional Non-participating and Limited-payment Long-duration products

The Company establishes future policy benefit liabilities (“FPBs”) for amounts payable under traditional non-participating and limited-payment long-duration insurance and reinsurance policies which include, but are not limited to, most whole and term life & endowment products, accident & health, fixed annuities, pension risk transfers, structured settlements, institutional income annuities and long-term care products. Effective January 1, 2023, the Company adopted an accounting pronouncement related to targeted improvements to the accounting for long-duration contracts (“LDTI”) with a January 1, 2021 transition date (the “LDTI Transition Date”). Generally, amounts are payable over an extended period of time and the related liabilities are calculated as the present value of future expected benefits and claim settlement expenses to be paid, reduced by the present value of future expected net premiums.

FPBs are measured as cohorts (e.g., groups of long-duration contracts), with the exception of pension risk transfer and longevity reinsurance solutions contracts, each of which is generally considered its own cohort. Contracts from different subsidiaries or branches, issue years, benefit currencies and product types are not grouped together in the same cohort.

Such liabilities are established based on methods and underlying assumptions in accordance with GAAP and applicable actuarial standards. A net premium ratio (“NPR”) approach is utilized. Under this NPR approach, net premiums are calculated as the portion of gross premiums required to fund expected insurance benefits and claim settlement expenses. The NPR used to accrue the FPB in each period is determined by using the historical experience and present value of expected future benefits and claim settlement expenses for the cohort divided by the historical experience and present value of expected future gross premiums for the cohort.

Cash flow assumptions are incorporated into the calculation of a cohort's NPR and FPB reserve. These assumptions are used to project the amount and timing of expected benefits and claim settlement expenses to be paid and the expected amount of premiums to be collected for a cohort. The principal inputs used in the establishment of FPBs are actual premiums, actual benefits, in-force policies, and best estimate cash flow assumptions to project future premium and benefit amounts. The Company’s primary best estimate cash flow assumptions include expectations related to mortality, morbidity, termination, claim settlement expense, policy lapse, renewal, retirement, disability incidence, disability terminations, inflation and other contingent events as appropriate to the respective product type and geographical area. Generally, the NPR and FPB reserve are updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in future cash flow assumptions, except for claim settlement expenses, for which the Company has elected to lock in assumptions at the LDTI Transition Date or inception (for contracts sold after the LDTI Transition Date). The resulting remeasurement (gain) loss is recorded through net income and reflects the impact of the change in the NPR as of the end of the quarter applied to the cumulative premiums received from the inception of the cohort (or from the LDTI Transition Date for contracts issued prior to the LDTI Transition Date) to the beginning of the quarter. Changes in the NPR during the quarter are based on any variance between actual experience during the quarter and the assumptions used as of the beginning of the quarter, along with any changes to assumptions during the quarter. If net premiums exceed gross premiums (i.e., expected benefits exceed expected gross premiums), the FPB is increased, and a corresponding adjustment is recognized immediately in net income.

The present value of future expected benefits and claim settlement expenses and the present value of future expected net premiums are calculated based on a current upper-medium grade discount rate.

The Company generally interprets the upper-medium grade discount rate to be a rate comparable to that of a corporate single A rate that reflects the duration characteristics of the liability. The upper-medium grade discount rate is determined by using observable market data, including published upper-medium grade discount curves. In situations where market data for an upper-medium grade discount curve is not available (e.g., in certain foreign jurisdictions), spreads are applied to adjust the available observable market data to an upper-medium grade discount curve. The last liquid point on the upper-medium grade discount curve for each jurisdiction grades to an ultimate forward rate, which is derived using assumptions of economic growth, inflation, and a long-term upper-medium grade spread.

The table below summarizes the market data and spreads applied to determine the upper-medium grade discount rate for products issued in key jurisdictions that are included in the disaggregated rollforwards in Note 4.

Disaggregated rollforwardsJurisdictionObservablebase curveSpread applied to derive upper-medium grade discount rate
RIS Annuities, Corporate & Other Long-term CareUnited StatesSingle A curveNo spread applied as there is an observable single A base discount curve.
Asia - Whole and Term Life & Endowments,Asia - Accident & HealthJapanJapanese government bond yieldA spread is applied based on local corporate bonds whose credit is deemed to approximate single A bonds. The spread is based on weighted average bond yields up to 10 years and held flat for years 10 to 30.
KoreaKorean government bond yieldA spread is applied based on local corporate bonds whose credit is deemed to approximate single A bonds. The spread is based on weighted average bond yields up to five years and held flat for years five to 30.
Latin America Fixed AnnuitiesChileChilean government bond yieldA blended spread is applied based on local corporate bonds whose credit is deemed to approximate single A bonds. The spread is based on weighted average bond yields up to 10 years and held flat for years 10 to 25.
MexicoMexican government bond yieldThere are few public corporate bonds denominated in Mexican pesos with a credit rating higher than sovereign bonds. Therefore, a spread is applied based on local corporate bond yields to approximate a single A equivalent bond.

The NPR and the change in FPB reflected in the statement of operations is calculated using a locked-in discount rate. For products issued prior to the LDTI Transition Date, a cohort level locked-in discount rate was developed that reflected the interest accretion rates that were locked in at inception of the underlying contracts (unless there was a historical premium deficiency event that resulted in updating the interest accretion rate prior to the LDTI Transition Date), or the acquisition date for contracts acquired through an assumed in-force reinsurance transaction or a business combination. For contracts issued subsequent to the LDTI Transition Date, the locked-in discount rate for each cohort represents the original upper-medium grade discount rate at the issue date of the underlying contracts. The FPB for all cohorts is remeasured to a current upper-medium grade discount rate at each reporting date through other comprehensive income (loss) (“OCI”).

For limited-payment long-duration contracts, the collection of premiums does not represent the completion of the earnings process, therefore, any gross premiums received in excess of net premiums is deferred and amortized as a deferred profit liability (“DPL”). The DPL is presented within FPBs and is amortized in proportion to either the present value of expected benefit payments or insurance in-force of each cohort to ensure that profits are recognized over the life of the underlying policies in that cohort. This amortization of the DPL is recorded through net income within policyholder benefits and claims. The DPL is also subject to retrospective remeasurement through net income, however, it is not remeasured for changes in discount rates.

When a cohort’s present value of future net premiums exceeds the present value of future benefits, a “flooring” adjustment is required. The flooring adjustment ensures that the liability for future policy benefits for each cohort is not less than zero, and is reported in net income to the extent that the flooring relates to the FPBs discounted at the locked-in discount rate or reported in OCI to the extent that it relates to changes in the current upper-medium grade discount rate.

Traditional Participating Products

The Company establishes FPBs for traditional participating contracts in the U.S., which include whole and term life participating contracts in both the open and closed block using a net premium approach, similar to traditional non-participating contracts. However, for participating contracts, the discount rate and actuarial assumptions are locked-in at inception, include a provision for adverse deviation, and all changes in the associated FPBs are reported within policyholder benefits and claims. See Note 10 for additional information on the closed block. For traditional participating contracts, the Company reviews its estimates of actuarial liabilities for future benefits and compares them with current best estimate assumptions. The Company revises estimates, to increase FPBs, if the Company determines that the liabilities previously established for future benefit payments less future expected net premiums in the aggregate for this line of business prove inadequate.

Additional Insurance Liabilities

Liabilities for universal, variable universal, and variable life policies with secondary guarantees (“ULSG”) and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments. The additional insurance liabilities are updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in future cash flow assumptions. The assumptions used in estimating the secondary and paid-up guarantee liabilities are investment income, mortality, lapse, and premium payment pattern and persistency. The assumptions of investment performance and volatility for variable products are consistent with historical experience of appropriate underlying equity and bond indices, such as the Standard & Poor’s Global Ratings (“S&P”) 500 Index. The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios. The resulting adjustments are recorded as policyholder liability remeasurement (gains) losses in the statement of operations reflecting the impact on the change in the ratio of benefits payable to total assessments over the life of the contract based on experience at the end of the quarter applied to the cumulative assessments received as of the beginning of the quarter.

For annuitization benefits, future benefits expected to be paid during the annuitization phase are discounted using an upper-medium grade discount rate to determine the excess benefit upon annuitization. The discount rate is not locked in for expected annuitization benefits, and is required to be updated quarterly, consistent with other components of the annuitization benefit cash flows. Changes in the discount rate applied to the future annuitization payments are reflected in policyholder benefits and claims within the statement of operations.

Premium Deficiency Reserves

Premium deficiency reserves may be established for short-duration contracts to provide for expected future losses and certain expenses that exceed unearned premiums. These reserves are based on actuarial estimates of the amount of loss inherent in that period, including losses incurred for which claims have not been reported. The provisions for unreported claims are calculated using studies that measure the historical length of time between the incurred date of a claim and its eventual reporting to the Company. For universal life-type and certain participating contracts, a premium deficiency reserve may be established when existing contract liabilities, together with the present value of future fees and/or premiums, are not sufficient to cover the present value of future benefits and settlement costs. Anticipated investment income is also considered in the calculations of premium deficiency reserves for short-duration contracts, as well as universal life-type and certain participating contracts.

Policyholder Account Balances

PABs represent the amount held by the Company on behalf of the policyholder at each reporting date. This amount includes deposits received from the policyholder and interest credited to the policyholder’s account balance, net of charges assessed against the account balance and any policyholder withdrawals. This balance also includes liabilities for certain structured settlement and institutional income annuities, and other contracts that do not contain significant insurance risk, as well as the estimated fair value of embedded derivatives associated with indexed annuity products.

Market Risk Benefits

Market risk benefits (“MRBs”) are contracts or contract features that guarantee benefits, such as guaranteed minimum benefits, in addition to an account balance, which expose insurance companies to other than nominal capital market risk (e.g., equity price, interest rate, and/or foreign currency exchange risk) and protect the contractholder from the same risk. Certain contracts may have multiple contract features that guarantee benefits. In these cases, each feature is separately evaluated to determine whether it meets the definition of an MRB at contract inception. If a contract includes multiple benefits that meet the definition of an MRB, those benefits are aggregated and measured as a single compound MRB.

All identified MRBs are required to be measured at estimated fair value, whether the contract or contract feature represents a direct, assumed or ceded capital market risk. All MRBs in an asset position are aggregated and presented as an asset, and all MRBs in a liability position are aggregated and presented as a liability. Changes in the estimated fair value of MRBs are recognized in net income, except for the portion of the fair value change attributable to the change in nonperformance risk of the Company which is recorded as a separate component of OCI. The Company generally uses an attributed fee approach to value MRBs, where the attributed fee is determined at contract inception by estimating the fair value of expected future benefits and the expected future fees. The attributed fee percentage is the portion of the expected future fees from contractholders deemed necessary at contract inception to fund all future expected benefits. This typically results in a zero fair value for the MRB at inception. The estimated fair value of the expected future benefits is estimated using a stochastically-generated set of risk-neutral scenarios. Once calculated, the attributed fee percentage is fixed and does not change over the life of the contract. All fees due from contractholders (or payable to reinsurers in the case of ceded MRBs) in excess of the attributed fees are reported in universal life and investment-type product policy fees. The valuation of these MRBs also includes an adjustment for the Company’s (or counterparty’s in the case of ceded MRBs) nonperformance risk and risk margins for non-capital market inputs.

Other Policy-Related Balances

Other policy-related balances include policy and contract claims, premiums received in advance, unearned revenue (“UREV”) liabilities, obligations assumed under structured settlement assignments, policyholder dividends due and unpaid, policyholder dividends left on deposit and negative value of business acquired (“VOBA”).

The liability for policy and contract claims generally relates to incurred but not reported (“IBNR”) death, disability, dental and vision claims. In addition, other policy-related balances include claims which have been reported but not yet settled for death, disability, dental and vision. The liability for these claims is based on the Company’s estimated ultimate cost of settling all claims. The Company derives estimates for the development of IBNR claims principally from analyses of historical patterns of claims by business line. The methods used to determine these estimates are continually reviewed. Adjustments resulting from this continuous review process and differences between estimates and payments for claims are recognized in policyholder benefits and claims expense in the period in which the estimates are changed or payments are made.

The Company accounts for the prepayment of premiums on its individual life, group life and health contracts as premiums received in advance. These amounts are then recognized in premiums when due.

The UREV liability relates to universal life and investment-type products and represents policy charges for services to be provided in future periods. The charges are deferred as UREV and amortized on a basis consistent with the methodologies and assumptions used for amortizing deferred policy acquisition costs (“DAC”) for the related contracts. Changes in the UREV liability for each period (representing deferrals less amortization) are reported in universal life and investment-type product policy fees.

See “— Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles” for a discussion of negative VOBA.

Recognition of Insurance Revenues and Deposits

Premiums related to long-duration whole and term life & endowment products, individual accident & health, disability, individual and group fixed annuities (including pension risk transfers, certain structured settlements, and certain income annuities), long-term care and participating products are recognized as revenues when due from policyholders. Policyholder benefits and expenses are provided to recognize profits over the estimated lives of the insurance policies. When premiums are due over a significantly shorter period than the period over which benefits are provided, any excess profit is deferred as a DPL and recognized into earnings in a constant relationship to insurance in-force or, for annuities, the present value of expected future policy benefit payments.

Premiums related to short-duration group term life, dental, disability, accident & health, vision and credit insurance contracts are recognized on a pro rata basis over the applicable contract term. Unearned premiums, representing the portion of premium written related to the unexpired coverage, are reflected as liabilities until earned.

Deposits related to universal life and investment-type products are credited to PABs. Revenues from such contracts consist of fees for mortality, policy administration and surrender charges and are recorded in universal life and investment-type product policy fees in the period in which services are provided. All fees due from contractholders (or payable to reinsurers in the case of ceded MRBs) in excess of the attributed fees on contracts with MRBs are reported in universal life and investment-type product policy fees. Amounts that are charged to earnings include interest credited and benefit claims incurred in excess of related PABs.

All revenues and expenses are presented net of ceded reinsurance, as applicable.

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles

The Company incurs significant costs in connection with acquiring new and renewal insurance business. Costs that are related directly to the successful acquisition or renewal of insurance contracts are capitalized as DAC. Such costs include:

incremental direct costs of contract acquisition, such as commissions;

the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed;

other essential direct costs that would not have been incurred had a policy not been acquired or renewed; and

the costs of direct-response advertising, the primary purpose of which is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits.

All other acquisition-related costs, including those related to general advertising and solicitation, market research, agent training, product development, unsuccessful sales and underwriting efforts, as well as all indirect costs, are expensed as incurred.

VOBA is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future policy and contract charges, premiums, mortality and morbidity, separate account performance, surrenders, operating expenses, investment returns, nonperformance risk adjustment and other factors. Actual experience with the purchased business may vary from these projections. VOBA is subject to periodic recoverability testing for traditional life and limited-payment contracts, as well as universal life type contracts.

DAC and VOBA for most long-duration products are amortized on a constant-level basis that approximates straight-line amortization on an individual contract basis. The DAC and VOBA related to RIS annuities are amortized over expected benefit payments, and for all other long-duration products are generally amortized in proportion to policy count. For short-duration products, DAC and VOBA are amortized in proportion to actual and expected future earned premiums.

DAC and VOBA are aggregated on the financial statements for reporting purposes. Amortization of DAC and VOBA is included in other expenses.

The Company generally has two different types of sales inducements which are included in other assets: (i) the policyholder receives a bonus whereby the policyholder’s initial account balance is increased by an amount equal to a specified percentage of the customer’s deposit; and (ii) the policyholder receives a higher interest rate using a dollar cost averaging method than would have been received based on the normal general account interest rate credited. The Company defers sales inducements and amortizes them over the life of the policy using the same methodologies and assumptions used to amortize DAC for the related contracts. The amortization of deferred sales inducements is included in policyholder benefits and claims.

Value of distribution agreements acquired (“VODA”) is reported in other assets and represents the present value of expected future profits associated with the expected future business derived from the distribution agreements acquired as part of a business combination. Value of customer relationships acquired (“VOCRA”) is also reported in other assets and represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. The VODA and VOCRA associated with past business combinations are amortized over the assets’ useful lives ranging from nine to 40 years and such amortization is included in other expenses. Each year, or more frequently if circumstances indicate a possible impairment exists, the Company reviews VODA and VOCRA to determine whether the asset is impaired.

For certain acquired blocks of business, the estimated fair value of the in-force contract obligations exceeded the book value of assumed in-force insurance policy liabilities, resulting in negative VOBA, which is presented separately from VOBA as a liability included in other policy-related balances. The estimated fair value of the in-force contract obligations is based on projections by each block of business. Negative VOBA is amortized on a basis consistent with the methodologies and assumptions used for amortizing DAC for the related contracts. Such amortization is recorded as an offset in other expenses.

Reinsurance

For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Cessions under reinsurance agreements do not discharge the Company’s obligations as the primary insurer. The Company reviews all contractual features, including those that may limit the amount of insurance risk to which the reinsurer is subject or features that delay the timely reimbursement of claims.

For reinsurance of existing in-force blocks of long-duration contracts that transfer significant insurance risk, the difference, if any, between the net consideration paid (received), and the liabilities ceded (assumed) related to the underlying reinsured contracts is generally considered the net cost of reinsurance at the inception of the reinsurance agreement. The net cost of reinsurance is amortized on a basis consistent with the methodologies and assumptions used for amortizing DAC related to the underlying reinsured contracts. Subsequent accounting for in-force blocks and new business assumed is the same as if the business was directly sold by the Company.

For prospective reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) are recorded as ceded (assumed) premiums and ceded (assumed) unearned premiums. Ceded (assumed) unearned premiums are reflected as a component of premiums, reinsurance and other receivables (future policy benefits). Such amounts are amortized through earned premiums over the remaining contract period in proportion to the amount of insurance protection provided. For retroactive reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) in excess of the related insurance liabilities ceded (assumed) are recognized immediately as a loss and are reported in policyholder benefits and claims. Any gain by the ceding entity on such retroactive agreement is deferred as a liability and is amortized over the estimated remaining settlement period.

The reinsurance recoverable for traditional non-participating and limited-payment contracts is generally measured using a net premium methodology to accrue the projected net gain or loss on reinsurance in proportion to the gross premiums of the underlying reinsured cohorts and is updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in cash flow assumptions. The locked-in discount rate used to measure changes in the reinsurance recoverable recorded in net income was established at the LDTI Transition Date, or at the inception of the reinsurance coverage for reinsurance agreements entered into subsequent to the LDTI Transition Date. The reinsurance recoverable is remeasured to an upper-medium grade discount rate through OCI at each reporting date, similar to the underlying reinsured contracts. The reinsurance recoverable for other long-duration contracts and associated contract features is measured using assumptions and methods generally consistent with the underlying direct policies, except that for reinsured MRBs, the entire change in fair value is recognized in net income each reporting period.

Amounts currently recoverable under reinsurance agreements are included in premiums, reinsurance and other receivables and amounts payable including funds withheld liabilities on coinsurance or modified coinsurance agreements are included in other liabilities. Assets and liabilities relating to reinsurance agreements with the same reinsurer may be recorded net on the balance sheet, if a right of offset exists within the reinsurance agreement. In the event that reinsurers do not meet their obligations to the Company under the terms of the reinsurance agreements, or when events or changes in circumstances indicate that its carrying amount may not be recoverable, reinsurance recoverable balances could become uncollectible. In such instances, reinsurance recoverable balances are stated net of an allowance for credit loss (“ACL”).

The funds withheld liability represents amounts withheld by the Company in accordance with the terms of certain reinsurance agreements. The Company withholds the funds rather than transferring the underlying investments and, as a result, records the funds withheld liability. The Company recognizes interest expense on funds withheld, included in other expenses, at a risk-free rate. Certain of these funds withheld liabilities have embedded derivatives that are carried at estimated fair value, with changes in estimated fair value reported in net derivative gains (losses).

Premiums, fees, policyholder liability remeasurement (gains) losses, policyholder benefits and claims, and market risk benefit remeasurement (gains) losses include amounts assumed under reinsurance agreements and are reported net of reinsurance ceded. Amounts received from reinsurers for policy administration are reported in other expenses.

If the Company determines that a reinsurance agreement does not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk, the Company records the agreement using the deposit method of accounting. Deposits received are included in other liabilities and deposits made are included within premiums, reinsurance and other receivables. As amounts are paid or received, consistent with the underlying contracts, the deposit assets or liabilities are adjusted. Interest on such deposits is recorded as other revenues or other expenses, as appropriate. Periodically, the Company evaluates the adequacy of the expected payments or recoveries and adjusts the deposit asset or liability through other revenues or other expenses, as appropriate.

Net Investment Income

Net investment income primarily includes interest income, including amortization of premium and accretion of discount, prepayment fees, dividend income, rental income and equity method income and is net of related investment expenses. Net investment income also includes: (i) realized gains (losses) on investments sold or disposed and (ii) unrealized gains (losses) recognized in earnings, representing changes in estimated fair value, primarily for Unit-linked investments (defined below) and FVO securities.

Net investment gains (losses) primarily include (i) realized gains (losses) from sales and other disposals of investments, which are determined by specific identification, (ii) intent-to-sell impairment losses on fixed maturity securities available-for-sale (“AFS”) and impairment losses on all other asset classes and, to a lesser extent, (iii) recognized gains (losses). Recognized gains (losses) are primarily comprised of the change in the ACL and unrealized gains (losses) for certain investments for which changes in estimated fair value are recognized in earnings. Changes in the ACL include both (i) provisions for credit loss on fixed maturity securities AFS, mortgage loans and certain leases, and (ii) subsequent changes in the ACL. Unrealized gains (losses), representing changes in estimated fair value recognized in earnings, primarily relate to equity securities and certain OLPI and REJV.

Net investment gains (losses) also include non-investment portfolio gains (losses) which do not relate to the performance of the investment portfolio, including gains (losses) from sales and divestitures of businesses and impairment of property, equipment, leasehold improvements and right-of-use (“ROU”) assets.

Accrued Investment Income

Accrued investment income is presented separately on the consolidated balance sheet and excluded from the carrying value of the related investments, primarily fixed maturity securities and mortgage loans.

Fixed Maturity Securities

The majority of the Company’s fixed maturity securities are classified as AFS and are reported at their estimated fair value. Changes in the estimated fair value of these securities not recognized in earnings representing unrecognized unrealized investment gains (losses) are recorded as a separate component of OCI, net of policy-related amounts and deferred income taxes. All security transactions are recorded on a trade date basis. Sales of securities are determined on a specific identification basis.

Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amortization of premium and accretion of discount, and is based on the estimated economic life of the securities, which for mortgage-backed and asset-backed securities considers the estimated timing and amount of prepayments of the underlying loans. See “— Fixed Maturity Securities AFS — Methodology for Amortization of Premium and Accretion of Discount on Structured Products” in Note 11. The amortization of premium and accretion of discount also take into consideration call and maturity dates. Generally, the accrual of income is ceased and accrued investment income that is considered uncollectible is recognized as a charge within net investment gains (losses) when securities are impaired.

The Company periodically evaluates these securities for impairment. The assessment of whether impairments have occurred is based on management’s case-by-case evaluation of the underlying reasons for the decline in estimated fair value as described in“— Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss” in Note 11.

For securities in an unrealized loss position, a credit loss is recognized in earnings within net investment gains (losses) when it is anticipated that the amortized cost, excluding accrued investment income, will not be recovered.

When either: (i) the Company has the intent to sell the security; or (ii) it is more likely than not that the Company will be required to sell the security before recovery, the reduction of amortized cost and the loss recognized in earnings is the entire difference between the security’s amortized cost and estimated fair value. If neither of these conditions exists, the difference between the amortized cost of the security and the present value of projected future cash flows expected to be collected is recognized in earnings as a credit loss by establishing an ACL with a corresponding charge recorded in net investment gains (losses). However, the ACL is limited by the amount that the fair value is less than the amortized cost. This limitation is known as the “fair value floor.” If the estimated fair value is less than the present value of projected future cash flows expected to be collected, this portion of the decline in value related to other-than-credit factors (“noncredit loss”) is recorded in OCI as an unrecognized loss.

For purchased credit deteriorated fixed maturity securities AFS and financing receivables, an ACL is established at acquisition, which is added to the purchase price to establish the initial amortized cost of the investment and is not recognized in earnings.

Equity Securities

Equity securities are reported at their estimated fair value, with unrealized gains (losses) representing changes in estimated fair value recognized in net investment gains (losses). Sales of securities are determined on a specific identification basis. Dividends are recognized in net investment income when declared.

Contractholder-Directed Equity Securities and Fair Value Option Securities

Contractholder-directed equity securities and FVO securities (collectively, “Unit-linked and FVO securities”) are investments for which the FVO has been elected, or which are otherwise required to be carried at estimated fair value, and include:

contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”) which do not qualify for presentation and reporting as separate account assets and liabilities. These investments are primarily equity securities and series mutual funds, which are generally VIEs. The investment returns on these investments inure to contractholders and are offset by a corresponding change in PABs through interest credited to PABs; and

fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products, investments in certain fund structures, and investments held by consolidated collateralized financing entities (“CFEs”).

Interest income and dividend income on these investments are included in net investment income. Realized gains (losses) on investments sold or disposed and unrealized gains (losses), representing changes in estimated fair value, are both recognized in net investment income for Unit-linked investments and certain FVO securities. Sales of these investments are determined on a specific identification basis. See Notes 11 and 13 for further information on VIEs and Unit-linked and FVO securities, respectively.

The Company may originate or acquire mortgage loans and in certain cases transfer an interest to third parties under participation agreements. The Company accounts for transfers of an interest in a mortgage loan as sales if the transfers meet both the conditions of a participating interest and the conditions for sale accounting. A mortgage transfer that does not meet these conditions is recognized as a secured borrowing with a pledge of collateral.

The Company disaggregates its mortgage loan investments into three portfolio segments: commercial, agricultural and residential. Also included in commercial mortgage loans are revolving line of credit loans collateralized by commercial properties. The accounting policies that are applicable to all portfolio segments are presented below and the accounting policies related to each of the portfolio segments are included in Note 11.

The Company recognizes an ACL in earnings within net investment gains (losses) at time of purchase or origination based on expected lifetime credit loss on mortgage loans, in an amount that represents the portion of the amortized cost basis of such mortgage loans that the Company does not expect to collect.

The Company ceases to accrue interest when the collection of interest is not considered probable, which is based on a current evaluation of the status of the borrower, including the number of days past due. When a loan is placed on non- accrual status, uncollected past due accrued interest income that is considered uncollectible is charged off against net investment income. Generally, the accrual of interest income resumes after all delinquent amounts are paid and management believes all future principal and interest payments will be collected. The Company records cash receipts on non-accruing loans in accordance with the loan agreement. The Company records charge-offs of mortgage loan balances not considered collectible upon the realization of a credit loss, for commercial, agricultural and residential mortgage loans, typically through foreclosure. The charge-off is recorded in net investment gains (losses), net of amounts recognized in ACL. Cash recoveries on principal amounts previously charged off are generally reported in net investment gains (losses). Upon foreclosure, the mortgage is de-recognized, the collateral received is recognized at fair value, and any difference between the net carrying value of the mortgage loan and the fair value of the collateral received is recognized within net investment gains (losses).

Mortgage loans are stated at unpaid principal balance, adjusted for any unamortized premium or discount, deferred fees or expenses, and are net of ACL. Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amortization of premium and deferred expenses and accretion of discount and deferred fees.

Also included in mortgage loans are residential mortgage loans for which the FVO was elected, and which are stated at estimated fair value. Changes in estimated fair value are recognized in net investment income.

Mortgage loans that are designated as held-for-sale are carried at the lower of amortized cost or estimated fair value.

Policy Loans

Policy loans are stated at unpaid principal balances. Interest income is recognized as earned using the contractual interest rate. Generally, accrued interest is capitalized on the policy’s anniversary date. Valuation allowances are not established for policy loans, as they are fully collateralized by the cash surrender value of the underlying insurance policies. Any unpaid principal and accrued interest are deducted from the cash surrender value or the death benefit prior to settlement of the insurance policy.

Real Estate

Real estate is stated at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis without any provision for salvage value, over the estimated useful life of the asset (typically up to 55 years). Rental income is recognized on a straight-line basis over the term of the respective leases. The Company periodically reviews its real estate for impairment and tests for recoverability when the carrying value of the real estate exceeds its estimated fair value and whenever events or changes in circumstances indicate the carrying value may not be recoverable. Properties whose carrying values are greater than their estimated undiscounted cash flows are written down to their estimated fair value.

Real estate for which the Company commits to a plan to sell within one year and actively markets that real estate in its current condition for a reasonable price in comparison to its estimated fair value is classified as held-for-sale. The Company ceases depreciation on real estate that is classified as held-for-sale. Real estate held-for-sale is stated at the lower of depreciated cost or estimated fair value less estimated disposition costs.

REJV and OLPI

The Company uses the equity method of accounting or the FVO for an investee when it has more than a minor ownership interest or more than a minor influence over the investee’s operations but does not hold a controlling financial interest, including when the Company is not deemed the primary beneficiary of a VIE. Under the equity method, the Company recognizes its share of the investee's earnings within net investment income. Contributions made by the Company increase carrying value and distributions received by the Company reduce carrying value. The Company generally recognizes its share of the investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.

The Company accounts for its interest in REJV and OLPI investments in which it has virtually no influence over the investee’s operations at estimated fair value. Unrealized gains (losses), representing changes in estimated fair value of these investments, are recognized in earnings within net investment gains (losses). Due to the nature and structure of these investments, they do not meet the characteristics of an equity security in accordance with applicable accounting guidance.

The Company consolidates REJV and OLPI investments when it holds a controlling financial interest, or it is deemed the primary beneficiary of an investee that is a VIE. Assets of certain consolidated REJV and OLPI are initially recorded at estimated fair value.

The Company elects the FVO for certain REJV that are managed on a total return basis. Unrealized gains (losses) representing changes in estimated fair value for REJV and OLPI investments recorded at estimated fair value are recognized in net investment income.

The Company routinely evaluates its equity method investments for impairment when the carrying value of the investment exceeds its fair value and when events or changes in circumstances indicate that the carrying amount may not be recoverable. When it is determined an equity method investment has had a loss in value that is other than temporary, an impairment is recognized and charged to net investment gains (losses).

Short-term Investments

Short-term investments include highly liquid securities and other investments with remaining maturities of one year or less, but greater than three months, at the time of purchase or acquisition. Securities included within short-term investments are stated at estimated fair value, while other investments included within short-term investments are stated at amortized cost less ACL, which approximates estimated fair value.

Other invested assets consist principally of the following:

Freestanding derivatives with positive estimated fair values, the accounting for which is described in “— Derivatives” below.

Company-owned life insurance policies (“COLI”) are carried at cash surrender value.

Net investment in direct financing leases is equal to the minimum lease payment receivables plus the unguaranteed residual value, less the unearned income, less ACL. Income is recognized by applying the pre-tax internal rate of return to the investment balance. The Company regularly reviews its minimum lease payment receivables for credit loss and residual value for impairments. Certain direct financing leases are linked to inflation.

Annuities funding structured settlement claims represent annuities funding claims assumed by the Company in its capacity as a structured settlements assignment company. The annuities are stated at their contract value, which represents the present value of the future periodic claim payments to be provided. The net investment income recognized reflects the amortization of discount of the annuity at its implied effective interest rate.

Investments in operating joint ventures that engage in insurance underwriting activities are accounted for under the equity method.

Investments in Federal Home Loan Bank of New York (“FHLBNY”) common stock are carried at redemption value and are considered restricted investments until redeemed by FHLBNY. Dividends are recognized in net investment income when declared.

Tax equity investments include low income housing tax credit partnerships and renewable energy investments, which derive a significant source of the investment returns in the form of income tax credits or other tax incentives. Beginning January 1, 2024, tax equity investments that meet certain criteria are accounted for using the proportional amortization method, where the initial cost of the investment is amortized in proportion to the tax credits received and recognized as a component of income tax expense (benefit). Tax equity investments which do not meet the qualification criteria for the proportional amortization method are accounted for using the equity method of accounting. See Note 22.

Funds withheld represent a receivable for amounts contractually withheld by ceding companies in accordance with reinsurance agreements. The Company recognizes interest on funds withheld at rates defined by the terms of the agreement which may be contractually specified or directly related to the underlying investments.

Net investment in leveraged leases is equal to the minimum lease payment receivables plus the unguaranteed residual value, less the unearned income, and is reported net of non-recourse debt. Income is recognized by applying the leveraged lease’s estimated rate of return to the net investment in the lease in those periods in which the net investment at the beginning of the period is positive. Leveraged leases derive investment returns in part from their income tax benefit. The Company regularly reviews its minimum lease payment receivables for credit loss and residual value for impairments.

Securities Lending Transactions and Repurchase Agreements

The Company accounts for securities lending transactions and repurchase agreements as financing arrangements and the associated liability is recorded at the amount of cash received. The securities loaned or sold under these agreements are included in invested assets. Income and expenses associated with securities lending transactions and repurchase agreements are recognized as investment income and investment expense, respectively, within net investment income.

Securities Lending Transactions

The Company enters into securities lending transactions, whereby securities are loaned to unaffiliated financial institutions. The Company obtains collateral at the inception of the loan, usually cash, in an amount generally equal to 102% of the estimated fair value of the securities loaned, and maintains it at a level greater than or equal to 100% for the duration of the loan. Securities loaned under such transactions may be sold or re-pledged by the transferee. The Company is liable to return to the counterparties the cash collateral received. Security collateral on deposit from counterparties in connection with securities lending transactions may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the Company’s consolidated financial statements. The Company monitors the ratio of the collateral held to the estimated fair value of the securities loaned on a daily basis and additional collateral is obtained as necessary throughout the duration of the loan.

Repurchase Agreements

The Company participates in short-term repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company sells securities and receives cash in an amount generally equal to 85% to 100% of the estimated fair value of the securities sold at the inception of the transaction, with a simultaneous agreement to repurchase such securities at a future date or on demand in an amount equal to the cash initially received plus interest. The Company monitors the ratio of the cash held to the estimated fair value of the securities sold throughout the duration of the transaction and additional cash or securities are obtained as necessary. Securities sold under such transactions may be sold or re-pledged by the transferee.

Freestanding derivatives are carried on the Company’s balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement.

Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivative’s carrying value in other invested assets or other liabilities.

If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows:

Statement of Operations Presentation:Derivative:
Net investment income• Derivatives held within Unit-linked investments
• Economic hedges of FVO securities which are linked to equity indices

Hedge Accounting

To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows:

Fair value hedge - a hedge of the estimated fair value of a recognized asset or liability - in the same line item as the earnings effect of the hedged item. The carrying value of the hedged recognized asset or liability is adjusted for changes in its estimated fair value due to the hedged risk.

Cash flow hedge - a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability in OCI and reclassified into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item.

Net investment in a foreign operation (“NIFO”) hedge - in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation.

The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item. Accruals on derivatives in net investment hedges are recognized in OCI.

In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument’s effectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income.

The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument.

When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. The changes in estimated fair value of derivatives related to discontinued cash flow hedges remain in OCI unless it is probable that the hedged forecasted transaction will not occur.

When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses). Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable of occurring are recognized immediately in net investment gains (losses).

In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses).

The Company issues certain products and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if:

the contract or contract feature does not meet the definition of a MRB;

the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;

the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and

a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.

Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are reported in net derivative gains (losses). If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation.

Fair Value

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. In most cases, the exit price and the transaction (or entry) price will be the same at initial recognition.

Subsequent to initial recognition, fair values are based on unadjusted quoted prices for identical assets or liabilities in active markets that are readily and regularly obtainable. When such unadjusted quoted prices are not available, estimated fair values are based on quoted prices in markets that are not active, quoted prices for similar but not identical assets or liabilities, or other observable inputs. If these inputs are not available, or observable inputs are not determinable, unobservable inputs and/or adjustments to observable inputs requiring significant management judgment are used to determine the estimated fair value of assets and liabilities. These unobservable inputs can be based on management’s judgment, assumptions or estimation and may not be observable in market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing the assets.

Acquisitions

The Company accounts for the purchase of a business using the acquisition method of accounting. The Company measures consideration transferred at estimated fair value which may include cash, equity issued, and liabilities incurred by the Company. The Company recognizes and measures tangible and intangible assets acquired and liabilities assumed based on their acquisition date fair values. The excess of the fair value of consideration transferred over the fair values of identifiable assets acquired and liabilities assumed is recorded as goodwill. The operating results of acquired businesses are included in the Company’s consolidated statements of operations from their acquisition date. Acquisition-related expenses and certain acquisition restructuring and other related charges are recognized separately from the business combination and are expensed as incurred.

The Company uses its best estimates of assumptions to value consideration transferred, assets acquired and liabilities assumed at the acquisition date. These estimates are inherently uncertain, and the Company may not be able to obtain all information necessary to complete its accounting during the period of acquisition. The Company will record adjustments to its initial accounting based on information obtained in subsequent periods which may affect the acquisition date estimated fair value of consideration transferred or assets acquired and liabilities assumed until the Company has obtained all information necessary to complete the initial accounting for the acquisition, not to exceed one year from the acquisition date. Contingent consideration is initially recorded at its estimated fair value at the acquisition date and is revalued at every financial reporting date until the contingency is resolved. Adjustments to contingent consideration liabilities after the completion of acquisition accounting are recorded in the consolidated statement of operations.

Goodwill

Goodwill represents the future economic benefits arising from net assets acquired in a business combination that are not individually identified and recognized. Goodwill is calculated as the excess of the cost of the acquired entity over the estimated fair value of such assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at least annually, or more frequently if events or circumstances indicate that there may be justification for conducting an interim test. The Company performs its annual goodwill impairment testing during the third quarter based upon data as of the close of the second quarter. Goodwill associated with a business acquisition is not tested for impairment during the year the business is acquired unless there is a significant identified impairment event.

The Company tests goodwill for impairment by performing a qualitative assessment and/or a quantitative test. The qualitative impairment assessment is an assessment of historical information and relevant current events and circumstances, including economic, industry and market considerations, to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company may elect not to perform the qualitative impairment assessment for some or all of its reporting units and perform a quantitative impairment test. In performing the quantitative impairment test, the Company may determine the fair values of its reporting units by applying a market multiple, discounted cash flow, and/or an actuarial-based valuation approach. The valuation methodologies utilized are subject to key judgments and assumptions that are sensitive to change.

The impairment test is performed at the reporting unit level, which is the operating segment or a business one level below the operating segment, if discrete financial information is prepared and regularly reviewed by management at that level. For purposes of goodwill impairment testing, if the carrying value of a reporting unit exceeds its estimated fair value, an impairment charge would be recognized for the amount by which the carrying value exceeds the reporting unit’s fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. Additionally, the Company will consider income tax effects from any tax deductible goodwill on the carrying value of the reporting unit when measuring the goodwill impairment loss, if applicable.

On an ongoing basis, the Company evaluates potential triggering events that may affect the estimated fair value of the Company’s reporting units to assess whether any goodwill impairment exists. Deteriorating or adverse economic, industry and market conditions for certain reporting units may have a significant impact on the estimated fair value of these reporting units and could result in future impairments of goodwill.

Employee Benefit Plans

Certain subsidiaries of MetLife, Inc. sponsor defined benefit pension plans and other postretirement benefit plans covering eligible employees. Measurement dates used for all of the subsidiaries’ defined benefit pension and other postretirement benefit plans correspond with the fiscal year ends of sponsoring subsidiaries, which is December 31 for U.S. and non-U.S. subsidiaries.

The Company recognizes the funded status of each of its defined benefit pension and other postretirement benefit plans, measured as the difference between the fair value of plan assets and the benefit obligation, which is the projected benefit obligation (“PBO”) for pension benefits and the accumulated postretirement benefit obligation (“APBO”) for other postretirement benefits in other assets or other liabilities.

Actuarial gains and losses result from differences between each plan’s actual experience and the assumed experience on plan assets or PBO/APBO during a particular period and are recorded in accumulated OCI (“AOCI”). To the extent such gains and losses exceed 10% of the greater of the PBO/APBO or the estimated fair value of plan assets, the excess is amortized into net periodic benefit costs, generally over the average projected future service years of the active employees. In addition, prior service costs (credit) are recognized in AOCI at the time of the amendment and then amortized to net periodic benefit costs over the average projected future service years of the active employees.

Net periodic benefit costs are determined using management’s estimates and actuarial assumptions and are comprised of service cost, interest cost, settlement and curtailment costs, expected return on plan assets, amortization of net actuarial (gains) losses, and amortization of prior service costs (credit). Fair value is used to determine the expected return on plan assets.

The subsidiaries also sponsor defined contribution plans for substantially all U.S. employees under which a portion of employee contributions is matched. Applicable matching contributions are made each payroll period. Accordingly, the Company recognizes compensation cost for current matching contributions. As all contributions are transferred currently as earned to the defined contribution plans, no liability for matching contributions is recognized on the balance sheets.

Income Tax

MetLife, Inc. and its includable life insurance and non-life insurance subsidiaries file a consolidated U.S. federal income tax return in accordance with the provisions of the Internal Revenue Code of 1986, as amended. Non-includable subsidiaries file either separate individual corporate tax returns or separate consolidated tax returns.

The Company’s accounting for income taxes represents management’s best estimate of various events and transactions.

Deferred tax assets and liabilities resulting from temporary differences between the financial reporting and tax bases of assets and liabilities are measured at the balance sheet date using enacted tax rates expected to apply to taxable income in the years the temporary differences are expected to reverse.

The realization of deferred tax assets depends upon the existence of sufficient taxable income within the carryback or carryforward periods under the tax law in the applicable tax jurisdiction. Valuation allowances are established against deferred tax assets when management determines, based on available information, that it is more likely than not that deferred income tax assets will not be realized. Significant judgment is required in determining whether valuation allowances should be established, as well as the amount of such allowances. When making such determination, the Company considers many factors, including:

the nature, frequency, and amount of cumulative financial reporting income and losses in recent years;

the jurisdiction in which the deferred tax asset was generated;

the length of time that carryforward can be utilized in the various taxing jurisdictions;

future taxable income exclusive of reversing temporary differences and carryforwards;

future reversals of existing taxable temporary differences;

taxable income in prior carryback years; and

tax planning strategies, including the intent and ability to hold certain AFS debt securities until they recover in value.

The Company may be required to change its provision for income taxes when estimates used in determining valuation allowances on deferred tax assets significantly change or when receipt of new information indicates the need for adjustment in valuation allowances. Additionally, the effect of changes in tax laws, tax regulations, or interpretations of such laws or regulations, is recognized in net income tax expense (benefit) in the period of change.

The Company determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded on the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon settlement. Unrecognized tax benefits due to tax uncertainties that do not meet the threshold are included within other liabilities and are charged to earnings in the period that such determination is made.

The Company classifies interest recognized as interest expense and penalties recognized as a component of income tax expense.

Litigation Contingencies

The Company is a defendant in a large number of litigation matters and is involved in a number of regulatory investigations. Liabilities are established when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Except as otherwise disclosed in Note 24, legal costs are recognized as incurred. On a quarterly and annual basis, the Company reviews relevant information with respect to liabilities for litigation, regulatory investigations and litigation-related contingencies to be reflected on the Company’s consolidated financial statements.

Other Accounting Policies

Stock-Based Compensation

The Company grants stock-based compensation awards to directors and certain employees. Director awards are fully vested at the grant date and employee awards are subject to vesting conditions. The Company recognizes compensation expense in an amount fixed at the grant date for equity-classified awards, or remeasured quarterly based on the fair value of the award for liability-classified awards, as described in Note 19. The Company takes an estimation of forfeitures into account and generally recognizes the expense over the vesting period. However, the Company truncates the expense period to the date the employee satisfies age-and-service requirements to exercise or receive payment for the award regardless of continued employment. In such a case, the Company does not accelerate award exercise or payment timing.

Cash and Cash Equivalents

The Company considers highly liquid securities and other investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Securities included within cash equivalents are stated at estimated fair value, while other investments included within cash equivalents are stated at amortized cost which approximates estimated fair value.

Property, Equipment, Leasehold Improvements and Computer Software

Property, equipment and leasehold improvements, which are included in other assets, are stated at cost, less accumulated depreciation and amortization. Included in property and equipment are capitalized costs related to purchased software, as well as certain internal and external costs incurred to develop internal-use computer software during the application development stage. Depreciation and amortization on property and equipment are determined using the straight-line method over the estimated useful lives of the assets, generally ranging from three to 40 years. Leasehold improvements are amortized over the shorter of the remaining lease term or useful life up to 20 years. The cost basis of the property, equipment and leasehold improvements was $7.8 billion and $7.7 billion at December 31, 2025 and 2024, respectively. Accumulated depreciation and amortization of property, equipment and leasehold improvements was $5.0 billion and $5.1 billion at December 31, 2025 and 2024, respectively. Related depreciation and amortization expense was $527 million, $469 million and $470 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Leases

The Company, as lessee, has entered into various lease and sublease agreements for office space and equipment. At contract inception, the Company determines that an arrangement contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. For contracts that contain a lease, the Company recognizes the ROU asset in other assets and the lease liability in other liabilities. The Company evaluates whether a ROU asset is impaired when events or changes in circumstances indicate that its carrying amount may not be recoverable. Leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease costs are recorded as an expense on a straight-line basis over the lease term.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are determined using the Company’s incremental borrowing rate based upon information available at commencement date to recognize the present value of lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs and prepaid or accrued lease payments, reduced by lease incentives received. Lease terms may include options to extend or terminate the lease and are included in the lease measurement when it is reasonably certain that the Company will exercise that option.

The Company has lease agreements with lease and non-lease components. The Company does not separate lease and non-lease components and accounts for these items as a single lease component for all asset classes.

The majority of the Company’s leases and subleases are operating leases related to office space. The Company recognizes lease expense for operating leases on a straight-line basis over the lease term.

Mezzanine Equity

Redeemable noncontrolling interests includes redeemable noncontrolling interests associated with certain consolidated entities. These redeemable noncontrolling interests are classified as mezzanine equity because their redemption is at the option of the holder and not within the control of the Company. Income (loss) attributable to redeemable noncontrolling interests is reported in net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests.

Notes issued by collateralized financing entities

Notes issued by CFEs represent notes issued by certain collateralized loan obligation (“CLO”) entities which the Company is required to consolidate as the primary beneficiary. The creditors of these consolidated VIEs do not have recourse to the Company in excess of the assets contained within the VIEs. For these notes, the Company has elected the FVO and has based the estimated fair value on the more observable of the notes or the corresponding assets. Changes in estimated fair value are reported in net investment gains (losses).

Other Revenues

Other revenues primarily include fees related to service contracts from customers for vision fee for service arrangements, prepaid legal plans, asset management fees, as further described below, administrative services-only (“ASO”) contracts, as well as recordkeeping and administrative services. Substantially all of the revenues from these services are recognized over time as the applicable services are provided or are made available to the customers. The revenues recognized include variable consideration to the extent it is probable that a significant reversal will not occur. In addition to the service fees, other revenues also include certain stable value fees and other miscellaneous revenues. These fees and miscellaneous revenues are recognized as earned.

Asset management fees are principally based on contractual rates applied to assets under management, or committed or invested capital, which are recognized over time as the applicable services are provided. In certain asset management fee arrangements, the Company is entitled to receive performance-based incentive fees or incentive allocations when the return on assets under management exceeds certain benchmark returns or other performance targets. The Company records (i) performance-based incentive fees and allocations revenues when the contractual terms of the asset management fee arrangement have been satisfied, and it is probable that a significant reversal in the amount of the fee will not occur, which is typically at, or near the end of the performance measurement period, and (ii) a liability for deferred performance-based incentive fees and allocations to the extent it receives cash related to the performance-based incentive fees and allocations revenues prior to meeting the revenue recognition criteria described above. In addition, asset management fee revenues include advisory service fees for non-discretionary investment advice, transaction fees and origination fees.

Policyholder Dividends

Policyholder dividends are approved annually by the insurance subsidiaries’ boards of directors. The aggregate amount of policyholder dividends is related to actual interest, mortality, morbidity and expense experience for the year, as well as management’s judgment as to the appropriate level of statutory surplus to be retained by the insurance subsidiaries.

Foreign Currency

Assets, liabilities and operations of foreign affiliates and subsidiaries, as well as investments accounted for under the equity method, are recorded based on the functional currency of each entity. The determination of the functional currency is made based on the appropriate economic and management indicators. For most of the Company’s foreign operations, the local currency is the functional currency. For certain other foreign operations, such as Japan, the local currency and one or more other currencies qualify as functional currencies. Assets and liabilities of foreign affiliates and subsidiaries are translated from the functional currency to U.S. dollars at the exchange rates in effect at each year-end and revenues and expenses are translated at the average exchange rates during the year. The resulting translation adjustments are charged or credited directly to OCI, net of applicable taxes. Gains and losses from foreign currency transactions, including the effect of re-measurement of monetary assets and liabilities to the appropriate functional currency, are reported as part of net investment gains (losses) in the period in which they occur.

Earnings Per Common Share

Basic earnings per common share are computed based on the weighted average number of common shares, or their equivalent, outstanding during the period. Diluted earnings per common share include the dilutive effect of the assumed exercise or issuance of stock-based awards using the treasury stock method. Under the treasury stock method, exercise or issuance of stock-based awards is assumed to occur with the proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.

Recent Accounting Pronouncements

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements.

Adopted Accounting Pronouncements

The table below describes the impacts of the ASUs recently adopted by the Company.

StandardDescriptionEffective Date andMethod of AdoptionImpact on Financial Statements
ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax DisclosuresAmong other things, the amendments require that public business entities, on an annual basis: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. In addition, the amendments require that all entities disclose on an annual basis the following information about income taxes paid: (i) the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes and (ii) the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received).Effective for annual periods beginning January 1, 2025, applied on a prospective basis.The Company has included the enhanced disclosures within Note 22.

Future Adoption of Accounting Pronouncements

ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of December 31, 2025 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below.

StandardDescriptionEffective Date andMethod of AdoptionImpact on Financial Statements
ASU 2025-08, Financial Instruments - Credit Losses (Topic 326): Purchased LoansThe key amendments include expanding the population of acquired financial assets that are accounted for using the gross-up approach by creating a new category of assets called purchased seasoned loans (“PSLs”), which will be accounted for using the gross-up approach. The day-1 expected credit losses on PSLs are now reflected as an adjustment to the amortized cost basis rather than an expense.Effective for annual and interim periods beginning January 1, 2027, to be applied prospectively (with early adoption permitted).The Company is evaluating the impact of the guidance on its consolidated financial statements.
ASU 2025-06, Intangibles—Goodwill and Other— Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use SoftwareThe key amendments remove all references to prescriptive and sequential software development project stages and require that an entity capitalize software costs when both: (i) management has authorized and committed to funding the software project; and (ii) it is probable that the project will be completed and the software will be used to perform the function intended.Effective for annual and interim periods beginning January 1, 2028, to be applied either prospectively, retrospectively, or using a modified transition approach (with early adoption permitted as of the beginning of an annual reporting period).The Company is evaluating the impact of the guidance on its consolidated financial statements.
ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as amended by ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying The Effective DateThe key amendments require disclosures in the notes to financial statements around employee compensation costs, depreciation, intangible asset amortization and certain other costs and expenses. Information on selling expenses is also required.Effective for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, to be applied prospectively with an option for retrospective application (with early adoption permitted).The Company is evaluating the impact of the guidance on its consolidated financial statements.
  1. Segment Information

In the fourth quarter of 2025, MetLife completed the Strategic Reorganization. As a result, MetLife is organized into the followingsix segments: Group Benefits; RIS; Asia; Latin America; EMEA; and MIM. See Note 1. Also, in conjunction with the Strategic Reorganization, effective January 1, 2025, the Company amended agreements between MIM and other MetLife entities to manage general account investments at current market rate fees, a change from 2024 and 2023.

The Group Benefits segment, based in the U.S., offers a broad range of products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include term, variable and universal life insurance, dental, group and individual disability, accident & health insurance and vision.

RIS

The RIS segment, based in the U.S., offers a broad range of life and annuity-based insurance and investment products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include stable value and pension risk transfer products, institutional income annuities, structured settlements, longevity reinsurance solutions, benefit funding solutions, funded reinsurance solutions and capital markets investment products.

Asia

The Asia segment offers a broad range of products and services to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, accident & health insurance and retirement and savings.

The Latin America segment offers a broad range of products to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance.

EMEA

The EMEA segment offers products to individuals, corporations, other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance.

MIM

MIM provides asset management and advisory services to institutional investors worldwide in public and private fixed income, real estate, equity, alternatives, multi-asset solutions and insurance solutions. MIM also manages investments for the Company’s general account.

Financial Measure and Segment Accounting Policies

Adjusted earnings is used by the Company’s chief operating decision maker, its Chief Executive Officer, to evaluate performance and allocate resources. Adjusted earnings and related measures based on adjusted earnings are also the measures by which senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and related measures based on adjusted earnings allow analysis of the Company’s performance relative to its business plan and facilitate comparisons to industry results.

Consistent with GAAP guidance for segment reporting, adjusted earnings is the Company’s GAAP measure of segment performance and is reported below. The Company believes the presentation of adjusted earnings enhances its investors’ understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.

Adjusted earnings focuses on the Company’s primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, (iii) revenues and costs related to divested businesses, and (iv) other adjustments. Also, adjusted earnings excludes results of discontinued operations under GAAP.

Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), MRB remeasurement gains (losses) and goodwill impairments. Further, net investment income is adjusted to exclude similar items relating to joint ventures accounted for under the equity method, and policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.

Asymmetrical and non-economic accounting adjustments are made in calculating adjusted earnings:

Universal life and investment-type product policy fees exclude asymmetrical accounting associated with in-force reinsurance.

Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment.

Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.

Policyholder benefits and claims excludes (i) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (ii) asymmetrical accounting associated with in-force reinsurance, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.

Policyholder liability remeasurement gains (losses) excludes asymmetrical accounting associated with in-force reinsurance.

Interest credited to PABs excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.

“Divested businesses” are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.

Other adjustments are made in calculating adjusted earnings:

Beginning in the fourth quarter of 2025, net investment income excludes depreciation of wholly-owned real estate and REJVs.

Net investment income and interest credited to PABs exclude certain amounts related to contractholder-directed equity securities.

Net investment income and other expenses exclude Reinsurance activity (as defined below).

Net investment income and interest expense on debt exclude amounts related to CFEs that are consolidated VIEs.

Other revenues include fee revenue on synthetic guaranteed interest contracts (“GICs”) accounted for as freestanding derivatives.

Other expenses exclude (i) amortization and impairment of asset management intangible assets, (ii) implementation of new insurance regulatory requirements and other costs, and (iii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests and redeemable noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.

“Reinsurance activity” relates to amounts subject to ceded reinsurance arrangements with third parties and joint ventures, including (i) the related investment returns and expenses which are passed through to the reinsurers and (ii) the corresponding invested assets and cash and cash equivalents.

Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

The Company’s segment accounting policies are the same as those used to prepare the Company’s consolidated financial statements. In addition, segment accounting policies include the method of capital allocation described below.

Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business.

The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.

Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings.

Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Expenses are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.

Corporate & Other contains various run-off and developing businesses. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities not allocated to the segments (including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions and enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, and the elimination of intersegment amounts (which generally relate to asset management fees and loans bearing interest rates commensurate with related borrowings).

The run-off businesses principally consist of operations relating to products and businesses that the Company no longer actively markets in the U.S. and were reported in the Company’s former MetLife Holdings segment. These products include: (i) variable, universal and term life insurance, (ii) whole life insurance, (iii) fixed and variable annuities, as well as the related guarantees, (iv) in-force block of assumed variable annuity guarantees from a third party, and (v) long-term care insurance, which offers protection against the potentially high costs of long-term health care services.

The financial measure and accounting policies used to prepare the Company’s segment results are the same as those used to prepare results for Corporate & Other. See “— Financial Measure and Segment Accounting Policies.”

Set forth in the tables below is certain financial information with respect to the Company’s segments for the years ended December 31, 2025, 2024 and 2023.

Year Ended December 31, 2025GroupBenefitsRISAsiaLatinAmericaEMEAMIM
(In millions)
Revenues
Premiums$22,858$11,569$5,050$5,155$2,525$—
Universal life and investment-type product policy fees9364091,6401,447342—
Net investment income (1)1,4128,7745,1871,6982536
Other revenues1,67528478434932
Expenses
Policyholder benefits and claims and policyholder dividends20,21514,8304,1724,8451,253—
Policyholder liability remeasurement (gains) losses(34)(2)(158)(7)6—
Interest credited to PABs2893,5523,09737383—
Other expenses:
Amortization of DAC, VOBA and negative VOBA2681854571367—
Interest expense on debt314—15——
Direct and allocated expenses2,0723651,216576451638
Other segment expenses (2)2,16811737484551333
Provision for income tax expense (benefit)45040869828811467
Adjusted earnings$1,692$1,671$1,702$798$367$200
Year Ended December 31, 2024GroupBenefitsRISAsiaLatinAmericaEMEAMIM
(In millions)
Revenues
Premiums$22,427$8,034$4,991$4,476$2,202$—
Universal life and investment-type product policy fees9093141,6901,419314—
Net investment income (1)1,2528,4824,6581,6502227
Other revenues1,534246764132718
Expenses
Policyholder benefits and claims and policyholder dividends19,82411,2464,0834,1271,100—
Policyholder liability remeasurement (gains) losses(1)(170)(35)(9)7—
Interest credited to PABs1913,3712,69543870—
Other expenses:
Amortization of DAC, VOBA and negative VOBA2666832503355—
Interest expense on debt215—15——
Direct and allocated expenses2,0003091,176560426615
Other segment expenses (2)2,04913941374345737
Provision for income tax expense (benefit)4254336303287218
Adjusted earnings$1,606$1,667$1,621$881$283$55
Year Ended December 31, 2023GroupBenefitsRISAsiaLatinAmericaEMEAMIM
(In millions)
Revenues
Premiums$21,558$8,248$5,251$4,287$2,016$—
Universal life and investment-type product policy fees8783131,6321,398298—
Net investment income (1)1,3017,8033,9571,6441973
Other revenues1,493271864232719
Expenses
Policyholder benefits and claims and policyholder dividends19,16411,2694,3334,094984—
Policyholder liability remeasurement (gains) losses(28)(131)105(25)(3)—
Interest credited to PABs1932,8872,30142672—
Other expenses:
Amortization of DAC, VOBA and negative VOBA2649772468344—
Interest expense on debt214—11——
Direct and allocated expenses1,8962751,172578404591
Other segment expenses (2)1,88011440368239938
Provision for income tax expense (benefit)4424505582977823
Adjusted earnings$1,655$1,708$1,282$840$265$70

(1)The percentage of net investment income from equity method invested assets by segment was as follows:

Years Ended December 31,
202520242023
Group Benefits1%—%—%
RIS6%3%1%
Asia13%12%4%
Latin America—%1%1%
EMEA1%—%—%

(2)Includes pension, postretirement and postemployment benefit costs; premium taxes, other taxes, and licenses & fees, as well as commissions and other variable expenses. This line item is net of capitalization of DAC.

The Company does not report total assets by segment, as this metric is not used to allocate resources or evaluate segment performance.

The following table presents the reconciliation of certain financial measures used in calculating segment results to those used in calculating consolidated Company results:

Years Ended December 31,
202520242023
(In millions)
Total segment adjusted earnings$6,430$6,113$5,820
Corporate & Other(293)(117)(97)
Total consolidated adjusted earnings6,1375,9965,723
Net investment gains (losses)(1,145)(1,184)(2,824)
Net derivative gains (losses)(1,939)(1,623)(2,140)
MRB remeasurement gains (losses)5081,109994
Investment hedge adjustments(410)(604)(1,012)
Depreciation of wholly-owned real estate and REJVs(72)
Other(307)63(173)
Provision for income tax (expense) benefit6316871,034
Net income (loss)$3,403$4,444$1,602
Segment revenues:
Group$26,881$26,122$25,230
RIS21,03617,07616,635
Asia11,95511,41510,926
Latin America8,3047,5867,371
EMEA3,1542,7702,543
MIM (1)938725722
Total segment revenues72,26865,69463,427
Net investment gains (losses)(1,145)(1,184)(2,824)
Net derivative gains (losses)(1,939)(1,623)(2,140)
Investment hedge adjustments(410)(604)(1,012)
Unit-linked investment income1,2171,0911,183
Reinsurance activity48931—
Revenues attributed to business activities within Corporate & Other6,5727,3578,288
Other32224(17)
Total consolidated revenues$77,084$70,986$66,905

(1)Includes intersegment asset management fees of$563 million, $417 million and $403 million for the years ended December 31, 2025, 2024 and 2023, respectively, earned in connection with management of general account investments of the Company and reflecting a change to current market rate fees in 2025.

The following table presents total premiums, universal life and investment-type product policy fees and other revenues by major product groups of the Company’s segments, as well as Corporate & Other:

Years Ended December 31,
202520242023
(In millions)
Life insurance$22,519$22,250$22,111
Accident & health insurance18,93518,35618,014
Annuities14,00210,12110,193
Other2,1531,7931,643
Total$57,609$52,520$51,961

The following table presents total premiums, universal life and investment-type product policy fees and other revenues associated with the Company’s U.S. and foreign operations:

Years Ended December 31,
202520242023
(In millions)
U.S.$41,234$37,266$36,869
Japan4,6494,7025,020
Other11,72610,55210,072
Total$57,609$52,520$51,961

Revenues derived from any single customer did not exceed 10% of consolidated premiums, universal life and investment-type product policy fees and other revenues for the years ended December 31, 2025, 2024 or 2023.

  1. Acquisition

Acquisition of PineBridge Investments

On December 30, 2025, the Company completed the acquisition of PineBridge Investments (“PineBridge”), a global asset manager. The acquisition of PineBridge further enhances the existing scale of the Company’s institutional asset management business, MIM. The preliminary purchase consideration paid in cash at closing was $885 million, comprised of purchase consideration of $800 million plus $85 million for the excess of cash and investments acquired over liabilities assumed. The preliminary purchase consideration is subject to change from any post-closing adjustments to the estimated amounts utilized at closing for cash and investments acquired, working capital, transaction expenses, liabilities assumed, net deferred tax liability and final acquisition date estimated fair value of consolidated VIEs, which will be determined after closing. The purchase consideration and the purchase price allocation, described below, are preliminary and are subject to adjustment during the measurement period, which is up to one year from the acquisition date.

The PineBridge acquisition was accounted for as a business combination using the acquisition method of accounting. Accordingly, the purchase price consideration was allocated to the assets acquired, including separately identified intangible assets, tangible assets and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of the estimated fair value of consideration transferred over the estimated fair value of identifiable intangible assets acquired, tangible assets acquired and liabilities assumed was recorded as goodwill. Asset management agreements and asset advisory agreements identifiable intangible assets were determined using the multi-period excess earnings method.

Of the preliminary purchase price, $486 million, $264 million and $15 million were preliminarily allocated to the estimated fair value of tangible assets acquired, liabilities assumed and noncontrolling interests assumed, respectively. The noncontrolling interests, which are less than 2% of the preliminary purchase consideration, represent the interests of shareholders, other than the Company, in an acquired entity. The tangible assets acquired primarily include CLO fund investments (“CLO Investments”) of $150 million, reported in FVO securities; accrued revenue and accounts receivable of $100 million, reported in premiums, reinsurance and other receivables; cash and cash equivalents of $100 million; other operating assets of $81 million, reported primarily in other assets; and FVO securities of $55 million. The liabilities assumed primarily include accounts payable, accrued compensation and benefits and other accrued expenses of $189 million, reported

  1. Acquisition (continued)

in other liabilities; and investment-related debt of $75 million, reported in long-term debt. In addition, certain fund investments, reported in contractholder-directed equity securities, and related redeemable noncontrolling interests, each in the amount of $241 million, at estimated fair value, were recorded.

The CLO Investments acquired are comprised of non-consolidated and consolidated investments. The non-consolidated CLO Investments were comprised of FVO securities with an estimated fair value of $91 million at December 31, 2025. The consolidated CLO Investments, along with certain investment fund general partner entities, represent consolidated VIEs of which the Company is the primary beneficiary. Accordingly, the Company has consolidated these VIEs. See “– Variable Interest Entities – Consolidated VIEs” in Note 11 for further information. The consolidated CLO Investments were comprised primarily of FVO securities and operating assets, including cash, of $1.4 billion, and related notes issued by CFEs for which the Company has elected the FVO, and operating liabilities of $1.4 billion, both at estimated fair value.

Additionally, of the preliminary purchase price, $543 million was allocated to goodwill which is included in the MIM segment and $147 million was allocated to identified intangible assets for asset management agreements and asset advisory agreements, reported in other assets. The goodwill recognized in connection with the acquisition includes future benefits for the MIM segment as a result of the increase in scale, broadening of existing capabilities, addition of new capabilities and extension of the global footprint, assembled workforce and expected synergies from the combined operations. The purchase price allocated to these identified intangible assets reflects the estimated fair value of the expected future earnings associated with asset management agreements acquired related to open-ended funds, closed-ended funds and separately managed accounts, as well as to asset advisory agreements acquired. Finite-lived intangible assets, including closed-end funds and separately managed accounts asset management agreements and asset advisory agreements, totaling $78 million are amortized over the assets’ useful lives ranging fromone to 16 years with a weighted average remaining useful life of 14 years as of the acquisition date. The indefinite-lived intangible asset, relating to open-ended funds asset management agreements acquired, of $69 million is not being amortized and will be tested for impairment at least annually. In addition, operating lease ROU assets acquired, reported in other assets, and operating lease liabilities assumed, reported in other liabilities, were each recorded at their estimated fair values of $76 million.

The preliminary purchase accounting also included a net deferred income tax liability of $12 million, which was attributable to the identified intangible assets and assumed liabilities, excluding goodwill, established at the acquisition date. The amount of the goodwill expected to be deductible for tax purposes was approximately $200 million.

Total revenues of PineBridge represented less than 1% of pro forma total revenues of MetLife for each of the years ended December 31, 2025, and 2024, when evaluated as though the acquisition had occurred on January 1, 2024.

  1. Future Policy Benefits

The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated DPLs, additional insurance liabilities, participating life and short-duration contracts.

The Company’s FPBs on the consolidated balance sheets were as follows at:

December 31,
20252024
(In millions)
Traditional and Limited-Payment Contracts:
RIS - Annuities$79,523$66,262
Asia:
Whole and term life & endowments10,14011,167
Accident & health7,9139,406
Latin America - Fixed annuities12,3369,600
Corporate & Other - Long-term care (1)15,22414,537
Deferred Profit Liabilities:
RIS - Annuities3,8553,780
Asia:
Whole and term life & endowments919759
Accident & health993849
Latin America - Fixed annuities562498
Additional Insurance Liabilities:
Asia:
Variable life1,0741,108
Universal and variable universal life330355
Corporate & Other - Universal and variable universal life (1)2,7132,496
Corporate & Other - Participating life (1)47,35948,485
Other long-duration (2)11,14810,712
Short-duration and other14,76613,632
Total$208,855$193,646

(1) See Note 1 for information on the Strategic Reorganization.

(2) This balance represents liabilities for various smaller product lines across multiple segments, as well as Corporate & Other.

Rollforwards - Traditional and Limited-Payment Contracts

The following information about the direct and assumed liability for FPBs includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers, except with respect to ending net liability for FPB balances where applicable. See Note 9 for further information regarding the impact of reinsurance on the consolidated balance sheets and the consolidated statements of operations.

RIS - Annuities

The RIS segment’s annuity products include pension risk transfers (including assumed pension risk transfers from the United Kingdom (“U.K.”)), certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. The Company reinsures portions of certain pension risk transfers and structured settlements on a modified coinsurance basis. Information regarding these products was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Present Value of Expected Net Premiums
Balance at January 1, at current discount rate at balance sheet date$—$—$—
Balance at January 1, at original discount rate$—$—$—
Effect of changes in cash flow assumptions (1)———
Effect of actual variances from expected experience (2)(71)(48)(106)
Adjusted balance(71)(48)(106)
Issuances14,8157,9856,572
Net premiums collected(14,744)(7,937)(6,466)
Balance at December 31, at original discount rate———
Balance at December 31, at current discount rate at balance sheet date$—$—$—
Present Value of Expected FPBs
Balance at January 1, at current discount rate at balance sheet date$66,621$64,515$58,695
Balance at January 1, at original discount rate$69,643$64,737$61,426
Effect of changes in cash flow assumptions (1)(79)(195)(284)
Effect of actual variances from expected experience (2)(91)(121)(270)
Adjusted balance69,47364,42160,872
Issuances15,2758,1296,588
Interest accrual3,4273,1462,897
Benefit payments(6,699)(6,050)(5,620)
Effect of foreign currency translation22(3)—
Balance at December 31, at original discount rate81,49869,64364,737
Effect of changes in discount rate assumptions(1,656)(3,022)(222)
Balance at December 31, at current discount rate at balance sheet date79,84266,62164,515
Cumulative amount of fair value hedging adjustments(319)(359)(191)
Net liability for FPBs79,52366,26264,324
Less: Reinsurance recoverables12,5061,919269
Net liability for FPBs, net of reinsurance$67,017$64,343$64,055
Undiscounted - Expected future benefit payments$144,721$126,735$130,878
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)$79,842$66,621$64,515
Weighted-average duration of the liability8 years8 years9 years
Weighted-average interest accretion (original locked-in) rate4.6%4.8%4.7%
Weighted-average current discount rate at balance sheet date5.4%5.6%5.1%

(1)For the year ended December 31, 2025, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $65 million. For the year ended December 31, 2024, the net effect of changes in cash flow assumptions was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $62 million. For the year ended December 31, 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $211 million.

(2) For the year ended December 31, 2025, the net effect of actual variances from expected experience was more than offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $31 million. For the year ended December 31, 2024, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $35 million. For the year ended December 31, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $118 million.

For each of the years ended December 31, 2025, 2024 and 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to mortality.

For the year ended December 31, 2023, the net effect of actual variances from expected experience was primarily driven by favorable mortality and model refinements.

When single premium annuity contracts are issued, the FPB reserve is required to be measured at an upper-medium grade discount rate. Due to differences between the upper-medium grade discount rate and pricing assumptions used to determine the contractual premium, the initial FPB reserve at issue for a particular cohort may be greater than the contractual premium received, and the difference must be recognized as an immediate loss at issue. On these cohorts, future experience that differs from expected experience and changes in cash flow assumptions result in the recognition of remeasurement gains and losses with net remeasurement gains limited to the amount of the original loss at issue, after which any favorable experience is deferred and recorded within the DPL. For the year ended December 31, 2025, the Company incurred a loss at issue of $451 million. The loss at issue was partially offset by a deferred gain on ceded reinsurance which will be amortized over the life of the reinsurance agreement. For the year ended December 31, 2024, the Company incurred a loss at issue of $147 million. The loss at issue was largely offset by a deferred gain on ceded reinsurance which will be amortized over the life of the reinsurance agreement. Additionally, for the year ended December 31, 2024, the Company recognized a net remeasurement gain related to the net effect of changes in cash flow assumptions.

The principal inputs used in the establishment of the FPB for the RIS segment’s annuity products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate mortality assumptions.

Asia

Whole and Term Life & Endowments

The Asia segment’s whole and term life & endowment products in Japan and Korea offer various life insurance coverages to customers. Information regarding these products was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Present Value of Expected Net Premiums
Balance at January 1, at current discount rate at balance sheet date$4,023$4,561$4,682
Balance at January 1, at original discount rate$4,286$4,793$4,943
Effect of changes in cash flow assumptions (1)265811
Effect of actual variances from expected experience (2)(108)(98)(62)
Adjusted balance4,2044,7534,892
Issuances630558730
Interest accrual827059
Net premiums collected(624)(604)(611)
Effect of foreign currency translation45(491)(277)
Balance at December 31, at original discount rate4,3374,2864,793
Effect of changes in discount rate assumptions(433)(288)(242)
Effect of foreign currency translation on the effect of changes in discount rate assumptions62510
Balance at December 31, at current discount rate at balance sheet date$3,910$4,023$4,561
Present Value of Expected FPBs
Balance at January 1, at current discount rate at balance sheet date$15,190$17,435$17,463
Balance at January 1, at original discount rate$15,252$17,198$18,209
Effect of changes in cash flow assumptions (1)283658
Effect of actual variances from expected experience (2)(108)(135)(30)
Adjusted balance15,17217,09918,237
Issuances630558729
Interest accrual383368370
Benefit payments(970)(958)(1,174)
Effect of foreign currency translation143(1,815)(964)
Balance at December 31, at original discount rate15,35815,25217,198
Effect of changes in discount rate assumptions(1,390)11224
Effect of foreign currency translation on the effect of changes in discount rate assumptions82(73)13
Balance at December 31, at current discount rate at balance sheet date14,05015,19017,435
Net liability for FPBs10,14011,16712,874
Less: Amount due to reinsurer(2)(2)(1)
Net liability for FPBs, net of reinsurance$10,142$11,169$12,875
Undiscounted:
Expected future gross premiums$9,138$8,678$9,331
Expected future benefit payments$26,455$25,422$28,130
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums$7,363$7,316$8,067
Expected future benefit payments$14,050$15,190$17,435
Weighted-average duration of the liability16 years17 years17 years
Weighted -average interest accretion (original locked-in) rate2.8%2.6%2.5%
Weighted-average current discount rate at balance sheet date3.6%2.8%2.6%

(1)For the year ended December 31, 2024, the net effect of changes in cash flow assumptions was more than offset by the corresponding impact in DPL associated with the Asia segment’s whole and term life & endowment products of $28 million. For the year ended December 31, 2023, the net effect of changes in cash flow assumptions was not offset by the corresponding impact in DPL associated with the Asia segment’s whole and term life & endowment products due to the diversification and the underlying characteristics of the products.

(2) For the year ended December 31, 2023, the net effect of actual variances from expected experience was not offset by the corresponding impact in DPL associated with the Asia segment’s whole and term life & endowment product due to the diversification and the underlying characteristics of the products.

The principal inputs used in the establishment of the FPB reserve for the Asia segment’s whole and term life & endowment products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, and morbidity.

Accident & Health

The Asia segment’s accident & health products in Japan and Korea offer various hospitalization, cancer, critical illness, disability, income protection and personal accident coverage. Information regarding these products was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Present Value of Expected Net Premiums
Balance at January 1, at current discount rate at balance sheet date$17,203$19,835$21,181
Balance at January 1, at original discount rate$18,820$21,232$22,594
Effect of changes in cash flow assumptions (1)(95)439867
Effect of actual variances from expected experience (2)(326)(205)(158)
Adjusted balance18,39921,46623,303
Issuances1,1581,0321,030
Interest accrual223223236
Net premiums collected(1,829)(1,843)(2,016)
Effect of foreign currency translation and other - net292(2,058)(1,321)
Balance at December 31, at original discount rate18,24318,82021,232
Effect of changes in discount rate assumptions(2,895)(1,772)(1,449)
Effect of foreign currency translation on the effect of changes in discount rate assumptions4115552
Balance at December 31, at current discount rate at balance sheet date$15,389$17,203$19,835
Present Value of Expected FPBs
Balance at January 1, at current discount rate at balance sheet date$26,565$30,480$30,879
Balance at January 1, at original discount rate$32,838$36,010$37,189
Effect of changes in cash flow assumptions (1)(186)439898
Effect of actual variances from expected experience (2)(362)(203)(180)
Adjusted balance32,29036,24637,907
Issuances1,1561,0301,028
Interest accrual476470485
Benefit payments(1,326)(1,268)(1,279)
Effect of foreign currency translation and other - net346(3,640)(2,131)
Balance at December 31, at original discount rate32,94232,83836,010
Effect of changes in discount rate assumptions(9,946)(6,890)(5,793)
Effect of foreign currency translation on the effect of changes in discount rate assumptions157617263
Balance at December 31, at current discount rate at balance sheet date23,15326,56530,480
Cumulative impact of flooring the future policyholder benefits reserve1494467
Net liability for FPBs7,9139,40610,712
Less: Reinsurance recoverables111142142
Net liability for FPBs, net of reinsurance$7,802$9,264$10,570
Undiscounted:
Expected future gross premiums$36,643$36,908$41,734
Expected future benefit payments$43,479$43,016$47,046
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums$26,671$29,436$34,356
Expected future benefit payments$23,153$26,565$30,480
Weighted-average duration of the liability19 years23 years25 years
Weighted-average interest accretion (original locked-in) rate1.8%1.7%1.7%
Weighted-average current discount rate at balance sheet date3.8%2.8%2.5%

(1) For the year ended December 31, 2023, the net effect of changes in cash flow assumptions was partially offset by the corresponding impact in DPL associated with the Asia segment’s accident & health products of ($10) million.

(2) For the year ended December 31, 2023, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the Asia segment’s accident & health products of $4 million.

For the year ended December 31, 2025, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to morbidity, partially offset by mortality. For the year ended December 31, 2024, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to morbidity, substantially offset by policyholder behavior assumptions related to lapses. For the year ended December 31, 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior assumptions related to lapses, partially offset by updates in assumptions related to mortality and morbidity.

The principal inputs used in the establishment of the FPB reserve for the Asia segment’s accident & health products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, thecurrent upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse and morbidity.

Latin America - Fixed Annuities

The Latin America segment’s fixed annuity products in Chile and Mexico include fixed income annuities that provide for asset distribution needs. Information regarding these products was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Present Value of Expected Net Premiums
Balance at January 1, at current discount rate at balance sheet date$—$—$—
Balance at January 1, at original discount rate$—$—$—
Effect of changes in cash flow assumptions (1)———
Effect of actual variances from expected experience (2)———
Adjusted balance———
Issuances1,4611,0201,045
Interest accrual312129
Net premiums collected(1,492)(1,041)(1,074)
Balance at December 31, at original discount rate———
Balance at December 31, at current discount rate at balance sheet date$—$—$—
Present Value of Expected FPBs
Balance at January 1, at current discount rate at balance sheet date$9,600$9,637$9,265
Balance at January 1, at original discount rate$9,133$9,249$8,240
Effect of changes in cash flow assumptions (1)5(4)(5)
Effect of actual variances from expected experience (2)(25)(2)(31)
Adjusted balance9,1139,2438,204
Issuances1,5421,0651,153
Interest accrual373339341
Benefit payments(813)(701)(671)
Inflation adjustment343391415
Effect of foreign currency translation1,030(1,204)(193)
Balance at December 31, at original discount rate11,5889,1339,249
Effect of changes in discount rate assumptions687536391
Effect of foreign currency translation on the effect of changes in discount rate assumptions61(69)(3)
Balance at December 31, at current discount rate at balance sheet date12,3369,6009,637
Net liability for FPBs$12,336$9,600$9,637
Undiscounted - Expected future benefit payments$17,146$13,660$13,994
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)$12,336$9,600$9,637
Weighted-average duration of the liability11 years11 years11 years
Weighted-average interest accretion (original locked-in) rate3.4%3.5%3.6%
Weighted-average current discount rate at balance sheet date2.9%3.1%3.3%

(1)For the years ended December 31,2024 and 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products of $3 million and $4 million, respectively.

(2)For the years ended December 31, 2024 and 2023, the net effect of actual variances from expected experience was not offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products primarily due to the variance coming from cohorts with no DPL.

The principal inputs used in the establishment of the FPB reserve for the Latin America segment’s fixed annuity products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate mortality assumptions.

Corporate & Other - Long-term Care

Corporate & Other’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Present Value of Expected Net Premiums
Balance at January 1, at current discount rate at balance sheet date$5,475$5,687$5,775
Balance at January 1, at original discount rate$5,568$5,566$5,807
Effect of changes in cash flow assumptions68212(152)
Effect of actual variances from expected experience15974199
Adjusted balance5,7955,8525,854
Interest accrual284285294
Net premiums collected(564)(569)(582)
Balance at December 31, at original discount rate5,5155,5685,566
Effect of changes in discount rate assumptions33(93)121
Balance at December 31, at current discount rate at balance sheet date$5,548$5,475$5,687
Present Value of Expected FPBs
Balance at January 1, at current discount rate at balance sheet date$20,012$20,927$19,619
Balance at January 1, at original discount rate$21,024$20,494$20,165
Effect of changes in cash flow assumptions66205(190)
Effect of actual variances from expected experience21384223
Adjusted balance21,30320,78320,198
Interest accrual1,1151,0891,070
Benefit payments(928)(848)(774)
Balance at December 31, at original discount rate21,49021,02420,494
Effect of changes in discount rate assumptions(718)(1,012)433
Balance at December 31, at current discount rate at balance sheet date20,77220,01220,927
Net liability for FPBs$15,224$14,537$15,240
Undiscounted:
Expected future gross premiums$10,382$10,644$10,603
Expected future benefit payments$44,696$44,981$45,016
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums$7,001$6,966$7,139
Expected future benefit payments$20,772$20,012$20,927
Weighted-average duration of the liability13 years14 years15 years
Weighted-average interest accretion (original locked-in) rate5.4%5.4%5.4%
Weighted-average current discount rate at balance sheet date5.8%5.8%5.2%

For the year ended December 31, 2025, the net effect of changes in cash flow assumptions was primarily driven by updates in operational assumptions related to future premium rate increases, substantially offset by unfavorable morbidity and policyholder behavior related to lapses. For the year ended December 31, 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior assumptions related to claim utilization experience, which lowered the expected cost of care. This was partially offset by updates in assumptions associated with an increase in incidence rates.

For the year ended December 31, 2025, the net effect of actual variances from expected experience was primarily driven by unfavorable morbidity and mortality, partially offset by the expected premium rate increases.

The principal inputs used in the establishment of the FPB reserve for long-term care products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, incidence, claim utilization, claim cost inflation, claim continuance, and premium rate increases.

Rollforwards - Additional Insurance Liabilities

The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for variable life, universal life, and variable universal life contract features whereby the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met.

The following information about the direct liability for additional insurance liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in these rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers. See Note 9 for further information regarding the impact of reinsurance on the consolidated balance sheets and the consolidated statements of operations.

Asia - Variable Life and Universal and Variable Universal Life

The Asia segment’s variable life, universal life, and variable universal life products in Japan offer a contract feature whereby the Company guarantees to the contractholder a secondary guarantee. Information regarding these additional insurance liabilities was as follows:

Years Ended December 31,
202520242023202520242023
Variable Life · Universal and Variable Universal Life
(Dollars in millions)
Balance, at January 1,$1,108$1,258$1,381$355$424$455
Less: AOCI adjustment———10(14)(33)
Balance, at January 1, before AOCI adjustment1,1081,2581,381345438488
Effect of changes in cash flow assumptions(3)17(4)(46)(23)(2)
Effect of actual variances from expected experience(16)(12)(10)(6)(34)(24)
Adjusted balance1,0891,2631,367293381462
Assessments accrual(4)(4)(3)(4)——
Interest accrual171719567
Excess benefits paid(33)(38)(36)———
Effect of foreign currency translation and other, net5(130)(89)4(42)(31)
Balance, at December 31, before AOCI adjustment1,0741,1081,258298345438
Add: AOCI adjustment———3210(14)
Balance, at December 31,$1,074$1,108$1,258$330$355$424
Weighted-average duration of the liability16 years16 years16 years42 years42 years42 years
Weighted-average interest accretion rate1.6%1.5%1.5%1.6%1.4%1.4%

The principal inputs used in the establishment of the additional insurance liability for the Asia segment’s variable life products include historical actual fees and benefits, in-force data, the locked-in discount rate, the stochastic fund return scenario assumption, and best estimate lapse and mortality assumptions.

The stochastic fund return scenario assumption includes the long-term average return and volatility for each fund, and the correlation matrix for each fund. For newer products, the discount rate is determined based on the weighting and return of each fund.

The principal inputs used in the establishment of the additional insurance liability for the Asia segment’s universal and variable universal life products include historical actual fees and benefits, in-force data, the locked-in discount rate, the stochastic fund return scenario assumption, and best estimate lapse and mortality assumptions.

The stochastic fund return scenario assumption includes the foreign currency exchange long-term average trend, foreign currency exchange volatility, long-term U.S. swap and treasury yield, U.S. swap volatility and the correlation between foreign currency exchange and U.S. swap rates.

The locked-in discount rate used for these products is based on the earned rate and foreign currency exchange rates at acquisition.

Corporate & Other - Universal and Variable Universal Life

Corporate & Other’s universal life and variable universal life products provide a contract feature whereby the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows:

Years Ended December 31,
202520242023
Universal and Variable Universal Life
(Dollars in millions)
Balance, at January 1$2,496$2,362$2,156
Less: AOCI adjustment(17)(14)(63)
Balance, at January 1, before AOCI adjustment2,5132,3762,219
Effect of changes in cash flow assumptions(8)(2)38
Effect of actual variances from expected experience12053—
Adjusted balance2,6252,4272,257
Assessments accrual107104105
Interest accrual139132124
Excess benefits paid(145)(150)(110)
Balance, at December 31, before AOCI adjustment2,7262,5132,376
Add: AOCI adjustment(13)(17)(14)
Balance, at December 312,7132,4962,362
Less: Reinsurance recoverables2,3672,1742,055
Balance, at December 31, net of reinsurance$346$322$307
Weighted-average duration of the liability14 years15 years15 years
Weighted-average interest accretion rate5.5%5.5%5.5%

Liabilities for ULSG and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments.

The guaranteed benefits are estimated over a range of scenarios. The significant assumptions used in estimating the ULSG and paid-up guarantee liabilities are investment income, mortality, lapses, and premium payment pattern and persistency. In addition, projected earned rate and crediting rates are used to project the account values and excess death benefits and assessments. The discount rate is equal to the crediting rate for each annual cohort and is locked-in at inception.

The Company’s gross premiums or assessments and interest expense recognized in the consolidated statements of operations for long-duration contracts, excluding Corporate & Other’s participating life contracts, were as follows:

Years Ended December 31,
202520242023
Gross Premiums orAssessments (1)Interest Expense (2)Gross Premiums orAssessments (1)Interest Expense (2)Gross Premiums orAssessments (1)Interest Expense (2)
(In millions)
Traditional and Limited-Payment Contracts:
RIS - Annuities$14,901$3,427$8,084$3,146$6,660$2,897
Asia:
Whole and term life & endowments1,2033011,1302981,124311
Accident & health3,0522533,0662473,364249
Latin America - Fixed annuities1,4923421,0413181,074312
Corporate & Other - Long-term care720831724804731776
Deferred Profit Liabilities:
RIS - AnnuitiesN/A184N/A178N/A167
Asia:
Whole and term life & endowmentsN/A44N/A36N/A31
Accident & healthN/A23N/A20N/A18
Latin America - Fixed annuitiesN/A20N/A20N/A22
Additional Insurance Liabilities:
Asia:
Variable life16017117178919
Universal and variable universal life295(35)6(31)7
Corporate & Other - Universal and variable universal life615139642132730124
Other long-duration5,5474874,7174734,516460
Total$27,719$6,073$19,486$5,695$18,257$5,393

(1)Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income.

(2)Interest expense is included in policyholder benefits and claims.

Participating Business

Participating business represented 2% of the Company’s life insurance in-force at both December 31, 2025 and 2024. Participating policies represented 9%,9% and 10% of gross traditional life insurance premiums for the years ended December 31, 2025, 2024 and 2023, respectively.

Liabilities for Unpaid Claims and Claim Expenses

The following is information about incurred and paid claims development by segment at December 31, 2025. Such amounts are presented net of reinsurance, and are not discounted. The tables present claims development and cumulative claim payments by incurral year. The development tables are only presented for significant short-duration product liabilities within each segment. In order to eliminate potential fluctuations related to foreign exchange rates, liabilities and payments denominated in a foreign currency have been translated using the 2025 year-end spot rates for all periods presented. The information about incurred and paid claims development prior to 2025 is presented as supplementary information.

Group Life - Term

Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance · At December 31, 2025
Years Ended December 31, · Total IBNRLiabilities PlusExpectedDevelopment onReported Claims · CumulativeNumber ofReportedClaims
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(Dollars in millions)
2016$7,125$7,085$7,095$7,104$7,105$7,104$7,107$7,109$7,110$7,113$2221,367
20177,4327,4187,4257,4277,4287,4287,4327,4347,4384263,945
20187,7577,6557,6467,6507,6517,6527,6597,6645251,712
20197,9357,9007,9077,9177,9147,9217,9277253,430
20208,9139,3679,3899,3849,3889,39812298,095
202110,55510,79510,77710,78310,80425308,345
20229,6409,6539,6629,68938259,225
20239,5849,4719,47524246,008
20249,9099,68855238,104
20259,8551,185203,552
Total89,051
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance(85,850)
All outstanding liabilities for incurral years prior to 2016, net of reinsurance15
Total unpaid claims and claim adjustment expenses, net of reinsurance$3,216
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
Years Ended December 31,
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(In millions)
2016$5,582$6,980$7,034$7,053$7,086$7,096$7,100$7,106$7,109$7,109
20175,7617,2927,3557,3747,4007,4147,4277,4317,433
20186,0087,5217,5787,5957,6297,6467,6527,656
20196,1787,7567,8207,8537,8987,9087,916
20206,8629,1039,2429,2969,3539,375
20218,00810,47610,64010,68910,757
20227,1019,3999,5369,573
20236,9299,2259,346
20247,2829,435
20257,250
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance$85,850
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
Years12345678910
Group Life - Term75.5%21.9%1.1%0.4%0.5%0.2%0.1%0.1%—%—%

Group Long-term Disability

Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance · At December 31, 2025
Years Ended December 31, · Total IBNRLiabilities PlusExpectedDevelopment onReported Claims · CumulativeNumber ofReportedClaims
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(Dollars in millions)
2016$1,131$1,139$1,159$1,162$1,139$1,124$1,123$1,086$1,108$1,104$—17,974
20171,2441,2021,2031,1951,1651,1811,1011,1351,131—16,330
20181,2401,1751,1631,1471,1701,1021,1501,146—15,217
20191,2771,2121,1691,1771,1031,1661,161—15,427
20201,2531,2231,1551,1001,1581,161—15,820
20211,5521,6081,4771,5861,591—19,664
20221,6411,7321,5781,557—18,408
20231,7251,7221,719720,301
20241,8901,9413718,460
20252,05784112,601
Total14,568
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance(7,440)
All outstanding liabilities for incurral years prior to 2016, net of reinsurance1,463
Total unpaid claims and claim adjustment expenses, net of reinsurance$8,591
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
Years Ended December 31,
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(In millions)
2016$49$267$433$548$628$696$750$769$839$871
201756290476579655719718812848
201854314497594666663775817
201957342522620621764811
202059355535560706763
2021955056209021,002
202276609721838
202384520775
202498561
2025154
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance$7,440
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
Years12345678910
Group Long-term Disability5.2%24.7%13.5%9.1%6.5%5.8%4.7%4.6%4.8%2.9%

Group Life - Term and Group Long-term Disability incurred but not paid (“IBNP”) liabilities are developed using a combination of loss ratio and development methods. Claims in the course of settlement are then subtracted from the IBNP liabilities, resulting in the IBNR liabilities. The loss ratio method is used in the period in which the claims are neither sufficient nor credible. In developing the loss ratios, any material rate increases that could change the underlying premium without affecting the estimated incurred losses are taken into account. For periods where sufficient and credible claim data exists, the development method is used based on the claim triangles which categorize claims according to both the period in which they were incurred and the period in which they were paid, adjudicated or reported. The end result is a triangle of known data that is used to develop known completion ratios and factors. Claims paid are then subtracted from the estimated ultimate incurred claims to calculate the IBNP liability.

An expense liability is held for the future expenses associated with the payment of IBNP claims (IBNR and pending). This is expressed as a percentage of the underlying claims liability and is based on past experience and the anticipated future expense structure.

For Group Life - Term, first year incurred claims and allocated loss adjustment expenses decreased in 2025 compared to the 2024 incurral year due to lower claim volume. For Group Long-term Disability, first year incurred claims and allocated loss adjustment expenses increased in 2025 compared to the 2024 incurral year due to the growth in the size of the business.

The assumptions used in calculating the unpaid claims and claim adjustment expenses for Group Life - Term and Group Long-term Disability are updated annually to reflect emerging trends in claim experience.

Certain of the Group Life - Term customers have experience-rated contracts, whereby the group sponsor participates in the favorable and/or adverse claim experience, including favorable and/or adverse prior year development. Claim experience adjustments on these contracts are not reflected in the foregoing incurred and paid claim development tables, but are instead reflected as an increase (adverse experience) or decrease (favorable experience) to premiums on the consolidated statements of operations.

Liabilities for Group Life - Term unpaid claims and claim adjustment expenses are not discounted.

The liabilities for Group Long-term Disability unpaid claims and claim adjustment expenses were $7.2 billion and $6.8 billion at December 31, 2025 and 2024, respectively. Using interest rates ranging from 2% to 8%, based on the incurral year, the total discount applied to these liabilities was $1.7 billion and $1.5 billion at December 31, 2025 and 2024, respectively. The amount of interest accretion recognized was $618 million, $464 million and $516 million for the years ended December 31, 2025, 2024 and 2023, respectively. These amounts were reflected in policyholder benefits and claims.

For Group Life - Term, claims were based upon individual death claims. For Group Long-term Disability, claim frequency was determined by the number of reported claims as identified by a unique claim number assigned to individual claimants. Claim counts initially include claims that do not ultimately result in a liability. These claims are omitted from the claim counts once it is determined that there is no liability.

The incurred and paid claims disclosed for the Group Life - Term product includes activity related to the product’s continued protection feature; however, the associated actuarial reserve for future benefit obligations under this feature is excluded from the liability for unpaid claims.

The Group Long-term Disability IBNR, included in the development tables above, was developed using discounted cash flows, and is presented on a discounted basis.

Asia

Group Disability & Group Life

Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance · At December 31, 2025
Years Ended December 31, · Total IBNRLiabilities PlusExpectedDevelopment onReported Claims · CumulativeNumber ofReportedClaims
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(Dollars in millions)
2016$199$203$191$204$206$211$213$212$204$204$84,922
2017259240247265273267269256253105,917
2018315288300310304311294293266,414
2019341319334330338317308256,618
2020379353325333302284375,886
2021361376394373373877,413
20224804444054441218,876
20234433703691268,047
20244994572518,452
20254183573,360
Total3,403
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance(2,356)
All outstanding liabilities for incurral years prior to 2016, net of reinsurance15
Total unpaid claims and claim adjustment expenses, net of reinsurance$1,062
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
Years Ended December 31,
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(In millions)
2016$56$115$131$164$178$187$194$199$194$197
201775136180220236238248240243
201883152205239248269262267
201991167217252282277283
202084150200231236246
202176168244268287
202287219286323
202392181243
202487206
202561
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance$2,356
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
Years12345678910
Group Disability & Group Life24.3%25.4%16.2%11.5%5.5%2.9%1.7%0.3%(0.6)%1.5%

For Group Life, the IBNR liability is determined by using the Bornhuetter-Ferguson Method, with factors derived by examining the experience of historical claims. A pending liability is also calculated for claims that have been reported but have not been paid. A claim eligibility ratio based on past experience is applied to the face amount of individual claims.

For Group Disability, the IBNR liability is calculated by applying a percentage to premiums in-force based on the expected delay as evidenced by the experience in the portfolio. The IBNR liability is then allocated back into different incurral years based on historical run-off patterns. As the benefit for this class of business is a regular series of payments, an additional reserve is required for the liability for ongoing benefit payments - claims in course of payment (“CICP”). The assumptions employed in the calculation of the CICP are adjusted for the Company’s own experience.

An expense liability is held for the future expenses associated with the payment of incurred but not yet paid claims. This is expressed as a percentage of the underlying claims liability and is based on past experience and the future expense structure.

The assumptions used in calculating the unpaid claims and claim adjustment expenses for Group Disability and Group Life are updated annually to reflect emerging trends in claim experience.

No additional premiums or return premiums have been accrued as a result of the prior year development.

The liabilities for unpaid claims and claim adjustment expenses were $1.5 billion and $1.2 billion at December 31, 2025 and 2024, respectively. These amounts were discounted using interest rates ranging from 1% to 7%, based on the incurral year. The total discount applied to these liabilities was $217 million and $166 million at December 31, 2025 and 2024, respectively. The amount of interest accretion recognized was $53 million, $44 million and $37 million for the years ended December 31, 2025, 2024 and 2023, respectively. These amounts were reflected in policyholder benefits and claims.

The Company tracks claim frequency by the number of reported claims as identified by a unique claim number assigned to individual claimants. Claim counts include claims that do not ultimately result in a liability. A liability is only established for those claims that are expected to result in a liability, based on historical factors.

Protection Life

Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance · At December 31, 2025
Years Ended December 31, · Total IBNRLiabilities PlusExpectedDevelopment onReported Claims · CumulativeNumber ofReportedClaims
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(Dollars in millions)
2016$337$444$456$464$465$466$456$455$460$461$—39,029
2017348338339337338328328331331—31,094
2018323312310312310310313313—30,073
2019348318321319320319318—32,699
2020529529534538536534—43,554
2021667581581577578253,455
2022460434431432541,764
20234474144171041,300
20245174702842,923
202546918638,798
Total4,323
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance(3,904)
All outstanding liabilities for incurral years prior to 2016, net of reinsurance11
Total unpaid claims and claim adjustment expenses, net of reinsurance$430
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
Years Ended December 31,
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(In millions)
2016$240$430$450$458$461$464$457$457$458$459
2017206309326330333325326328329
2018162276288294291292294294
2019181274296294297298299
2020228457470478482487
2021343480500536543
2022284381404413
2023293401412
2024275433
2025235
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance$3,904
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
Years12345678910
Protection Life57.0%31.8%4.3%2.0%0.6%—%(0.1)%0.2%0.3%0.2%

Protection Health

Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance · At December 31, 2025
Years Ended December 31, · Total IBNRLiabilities PlusExpectedDevelopment onReported Claims · CumulativeNumber ofReportedClaims
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(Dollars in millions)
2016$288$331$329$329$329$328$329$330$330$332$—107,342
2017417388389388388388389390391—122,644
2018447469445443443443444445—145,846
2019149194187187187188189—134,352
2020539529527527528529—152,170
20216926946916926911174,683
20227537447467464204,780
202395294094113223,268
20241,0701,07126229,219
20251,226116174,440
Total6,561
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance(6,301)
All outstanding liabilities for incurral years prior to 2016, net of reinsurance2
Total unpaid claims and claim adjustment expenses, net of reinsurance$262
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
Years Ended December 31,
(Unaudited)
Incurral Year · 2016 · 2017 · 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
(In millions)
2016$271$324$327$327$328$328$329$329$330$331
2017340383385386387388389390390
2018381435438439441441442443
2019125176180183185186188
2020455515520522525527
2021611676682686688
2022639726735740
2023808914926
20249081,035
20251,033
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance$6,301
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
Years12345678910
Protection Health83.5%13.5%1.1%0.5%0.5%0.2%0.5%0.2%0.2%0.3%

The Latin America segment establishes liabilities for unpaid losses, which are equal to the accumulation of unpaid reported claims, plus an estimate for IBNR claims.

In general terms, for both the Protection Life and Protection Health products, the methodology for IBNR is the Bornhuetter-Ferguson Method, with factors derived by examining the experience of historical claims. In the more recent incurral months, the credibility is higher on expected loss ratios and lower on claims calculated using the experience-derived factors. The credibility grows for the factors as incurral months become older.

For Protection Health products, claim duration can be very long due to the multiple incidences that may occur over time for a single claim. Depending on the characteristics of the product, the number of claims reported per year may or may not be based on the original claim occurrence date for each individual claim. For Protection Life products, claims are based upon individual death claims.

The assumptions used in calculating the unpaid claims and claim adjustment expenses for Protection Life and Protection Health are updated annually to reflect emerging trends in claim experience.

Certain of the Protection Life customers have experience-rated contracts, whereby the group sponsor participates in the favorable and/or adverse claim experience, including favorable and/or adverse prior year development. Claim experience adjustments on these contracts are not reflected in the foregoing incurred and paid claim development tables, but are instead reflected as an increase (adverse experience) or decrease (favorable experience) to premiums on the consolidated statements of operations.

Liabilities for unpaid claims and claim adjustment expenses were not discounted.

For Protection Life and Protection Health products, claim counts initially include claims that do not ultimately result in a liability. These claims are omitted from the claim counts once it is determined that there is no liability.

Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Liability for Unpaid Claims and Claim Adjustment Expenses

The reconciliation of the net incurred and paid claims development tables to the liability for unpaid claims and claims adjustment expenses on the consolidated balance sheet was as follows at:

(In millions)
Short-Duration:
Unpaid claims and allocated claims adjustment expenses, net of reinsurance:
Group Benefits:
Group Life - Term$3,216
Group Long-term Disability8,591
Total$11,807
Asia - Group Disability & Group Life1,062
Latin America:
Protection Life430
Protection Health262
Total692
Other insurance lines1,684
Total unpaid claims and allocated claims adjustment expenses, net of reinsurance15,245
Reinsurance recoverables on unpaid claims:
Group Benefits:
Group Life - Term6
Group Long-term Disability295
Total301
Asia - Group Disability & Group Life580
Latin America:
Protection Life18
Protection Health23
Total41
Other insurance lines262
Total reinsurance recoverable on unpaid claims1,184
Total unpaid claims and allocated claims adjustment expense16,429
Unallocated claims adjustment expenses—
Discounting(1,933)
Liability for unpaid claims and claim adjustment liabilities - short-duration14,496
Liability for unpaid claims and claim adjustment liabilities - all long-duration lines2,634
Total liability for unpaid claims and claim adjustment expense (includes $8.3 billion of FPBs and $8.8 billion of other policy-related balances)$17,130

Rollforward of Claims and Claim Adjustment Expenses

Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:

Years Ended December 31,
202520242023
(In millions)
Balance at January 1,$16,118$16,468$16,098
Less: Reinsurance recoverables2,7902,5922,452
Net balance at January 1,13,32813,87613,646
Incurred related to:
Current year29,19326,62627,080
Prior years (1)26657374
Total incurred29,45926,68327,454
Paid related to:
Current year(21,880)(20,607)(20,220)
Prior years(6,683)(6,624)(7,004)
Total paid(28,563)(27,231)(27,224)
Net balance at December 31,14,22413,32813,876
Add: Reinsurance recoverables2,9062,7902,592
Balance at December 31,$17,130$16,118$16,468

(1)For the years ended December 31, 2025, 2024 and 2023, incurred claims and claim adjustment expenses associated with prior years increased due to events incurred in prior years but reported in the current year.

  1. Policyholder Account Balances

The Company establishes liabilities for PABs, which are generally equal to the account value, and which include accrued interest credited, but exclude the impact of any applicable charge that may be incurred upon surrender.

The Company’s PABs on the consolidated balance sheets were as follows at:

December 31, 2025December 31, 2024
(In millions)
Group Benefits - Life$11,005$7,632
RIS:
Capital markets investment products and stable value GICs65,59263,715
Annuities and risk solutions26,40620,699
Asia:
Universal and variable universal life54,37450,801
Fixed annuities43,18838,421
Corporate & Other: (1)
Annuities6,38310,142
Life and other7,10911,132
Other (2)22,80018,903
Total$236,857$221,445

(2)Includes EMEA variable annuity PABs of $2.3 billion at December 31, 2024, which was previously disclosed as a separate disaggregated rollforward.

The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance.

Life

The Group Benefits segment’s life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account portion of variable life insurance products. Information regarding this liability was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$7,632$7,692$8,028
Transfer, January 1 (1)3,773——
Deposits3,8813,7203,311
Policy charges(669)(658)(635)
Surrenders and withdrawals(3,885)(3,296)(3,192)
Benefit payments(9)(13)(12)
Net transfers from (to) separate accounts1(3)—
Interest credited281190192
Balance at December 31,$11,005$7,632$7,692
Weighted-average annual crediting rate2.5 %2.5 %2.5 %
At period end:
Cash surrender value$10,936$7,569$7,630
Net amount at risk, excluding offsets from reinsurance:
In the event of death (2)$265,192$263,198$250,033

(1)A product previously reported within the former MetLife Holdings segment was moved to the Group Benefits segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(2)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

The Group Benefits segment’s life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50%above GMCREqual to orgreater than0.50% but lessthan 1.50% above GMCREqual to orgreater than1.50% aboveGMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$503$77$758$4,154$5,492
Equal to or greater than 2% but less than 4%4,5369984—4,719
Equal to or greater than 4%67925353760
Products with either a fixed rate or no GMCRN/AN/AN/AN/A34
Total$5,718$201$845$4,207$11,005
Equal to or greater than 0% but less than 2%$456$72$816$4,086$5,430
Equal to or greater than 2% but less than 4%1,2471006111,409
Equal to or greater than 4%682—3937758
Products with either a fixed rate or no GMCRN/AN/AN/AN/A35
Total$2,385$172$916$4,124$7,632
Equal to or greater than 0% but less than 2%$—$86$863$4,558$5,507
Equal to or greater than 2% but less than 4%1,19696221,269
Equal to or greater than 4%72714334805
Products with either a fixed rate or no GMCRN/AN/AN/AN/A111
Total$1,923$96$968$4,594$7,692

RIS

Capital Markets Investment Products and Stable Value GICs

The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements.

In addition, certain subsidiaries of the Company have entered into funding agreements with FHLBNY and a subsidiary of the Federal Agricultural Mortgage Corporation, a federally chartered instrumentality of the U.S. (“Farmer Mac”). The PAB balances for FHLBNY funding agreements were $14.2 billion at both December 31, 2025 and 2024. These advances are collateralized by residential mortgage-backed securities (“RMBS”) with an estimated fair value of $18.2 billion and $18.4 billion at December 31, 2025 and 2024, respectively. The applicable subsidiary of the Company is permitted to withdraw any portion of the collateral in the custody of FHLBNY as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. Upon any event of default by such subsidiary, FHLBNY’s recovery on the collateral is limited to the amount of such subsidiary’s liability to FHLBNY. The PAB balances for the Farmer Mac funding agreements were $2.1 billion at both December 31, 2025 and 2024. The obligations under the Farmer Mac funding agreements are secured by a pledge of certain eligible agricultural mortgage loans and may, under certain circumstances, be secured by other qualified collateral. The carrying value of such collateral was $2.2 billion at both December 31, 2025 and 2024.

Information regarding the RIS segment’s capital markets investment products and stable value GICs in PABs was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$63,715$64,140$63,723
Deposits80,37173,10369,229
Surrenders and withdrawals(82,551)(74,974)(71,938)
Interest credited2,4082,4242,091
Effect of foreign currency translation and other, net1,649(978)1,035
Balance at December 31,$65,592$63,715$64,140
Weighted-average annual crediting rate3.8 %3.9 %3.3 %
Cash surrender value at period end$1,379$1,936$2,126

The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50%above GMCREqual to orgreater than0.50% but lessthan 1.50% above GMCREqual to orgreater than1.50% aboveGMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$—$—$—$2,435$2,435
Products with either a fixed rate or no GMCRN/AN/AN/AN/A63,157
Total$—$—$—$2,435$65,592
Equal to or greater than 0% but less than 2%$—$—$—$2,675$2,675
Products with either a fixed rate or no GMCRN/AN/AN/AN/A61,040
Total$—$—$—$2,675$63,715
Equal to or greater than 0% but less than 2%$—$—$1$2,621$2,622
Products with either a fixed rate or no GMCRN/AN/AN/AN/A61,518
Total$—$—$1$2,621$64,140

Annuities and Risk Solutions

The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, group fixed deferred annuities, the fixed account portion of group variable deferred annuities, registered index-linked annuities and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$20,699$17,711$15,549
Transfer, January 1 (1)3,109——
Deposits3,8763,7472,734
Policy charges(153)(138)(178)
Surrenders and withdrawals(1,090)(527)(210)
Benefit payments(1,176)(961)(812)
Net transfers from (to) separate accounts66353
Interest credited1,016761637
Other59103(62)
Balance at December 31,$26,406$20,699$17,711
Weighted-average annual crediting rate4.1 %4.0 %3.9 %
At period end:
Cash surrender value$13,633$9,396$7,912
Net amount at risk, excluding offsets from reinsurance:
In the event of death (2)$45,467$43,786$40,397
At annuitization or exercise of other living benefits (3)$17N/AN/A

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(2)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

(3)For benefits that are payable in the event of annuitization or exercise of other living benefits, the net amount at risk is generally defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates or to provide other living benefits. This amount represents the Company’s potential economic exposure in the event all contractholders were to annuitize or to exercise other living benefits at the balance sheet date.

The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50%above GMCREqual to orgreater than0.50% but lessthan 1.50% above GMCREqual to orgreater than1.50% aboveGMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$—$—$8$3,135$3,143
Equal to or greater than 2% but less than 4%4042,2695711,2424,486
Equal to or greater than 4%4,411—43464,851
Products with either a fixed rate or no GMCRN/AN/AN/AN/A13,926
Total$4,815$2,269$1,013$4,383$26,406
Equal to or greater than 0% but less than 2%$—$—$11$2,446$2,457
Equal to or greater than 2% but less than 4%195324566611,344
Equal to or greater than 4%4,333—29464,633
Products with either a fixed rate or no GMCRN/AN/AN/AN/A12,265
Total$4,528$32$761$3,113$20,699
Equal to or greater than 0% but less than 2%$—$—$20$1,651$1,671
Equal to or greater than 2% but less than 4%24934105432820
Equal to or greater than 4%4,346—28254,633
Products with either a fixed rate or no GMCRN/AN/AN/AN/A10,587
Total$4,595$34$407$2,088$17,711

Asia

Universal and Variable Universal Life

The Asia segment’s universal and variable universal life PABs in Japan primarily include interest sensitive whole life products. Information regarding this liability was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$50,801$49,739$46,417
Deposits6,4785,8857,595
Policy charges(994)(1,046)(1,210)
Surrenders and withdrawals(3,157)(3,171)(2,959)
Benefit payments(536)(451)(508)
Interest credited1,6621,5171,408
Effect of foreign currency translation and other, net120(1,672)(1,004)
Balance at December 31,$54,374$50,801$49,739
Weighted-average annual crediting rate3.2 %3.1 %3.0 %
At period end:
Cash surrender value$47,525$44,685$42,577
Net amount at risk, excluding offsets from reinsurance:
In the event of death (1)$82,387$86,683$93,172

(1)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

The Asia segment’s universal and variable universal life account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50%above GMCREqual to orgreater than0.50% but lessthan 1.50% above GMCREqual to orgreater than1.50% aboveGMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$9,822$26$257$1,989$12,094
Equal to or greater than 2% but less than 4%7,06215,9384,95511,76639,721
Equal to or greater than 4%228———228
Products with either a fixed rate or no GMCRN/AN/AN/AN/A2,331
Total$17,112$15,964$5,212$13,755$54,374
Equal to or greater than 0% but less than 2%$9,789$15$240$1,574$11,618
Equal to or greater than 2% but less than 4%7,38715,8075,21210,05838,464
Equal to or greater than 4%239———239
Products with either a fixed rate or no GMCRN/AN/AN/AN/A480
Total$17,415$15,822$5,452$11,632$50,801
Equal to or greater than 0% but less than 2%$10,640$24$231$1,001$11,896
Equal to or greater than 2% but less than 4%5,93215,6347,8017,66937,036
Equal to or greater than 4%250———250
Products with either a fixed rate or no GMCRN/AN/AN/AN/A557
Total$16,822$15,658$8,032$8,670$49,739

Fixed Annuities

Information regarding the Asia segment’s fixed annuity PAB liability in Japan was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$38,421$36,863$32,454
Deposits6,8896,2218,115
Policy charges(4)(2)(2)
Surrenders and withdrawals(2,003)(2,760)(2,344)
Benefit payments(1,836)(2,208)(2,156)
Interest credited1,2901,070866
Effect of foreign currency translation and other, net431(763)(70)
Balance at December 31,$43,188$38,421$36,863
Weighted-average annual crediting rate3.2 %2.9 %2.5 %
At period end:
Cash surrender value$38,891$34,105$31,936
Net amount at risk, excluding offsets from reinsurance:
In the event of death (1)$2$1$73

(1)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

The Asia segment’s fixed annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50%above GMCREqual to orgreater than0.50% but lessthan 1.50% above GMCREqual to orgreater than1.50% aboveGMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$275$395$3,918$37,517$42,105
Equal to or greater than 2% but less than 4%—4——4
Products with either a fixed rate or no GMCRN/AN/AN/AN/A1,079
Total$275$399$3,918$37,517$43,188
Equal to or greater than 0% but less than 2%$328$534$4,808$31,572$37,242
Equal to or greater than 2% but less than 4%—4——4
Products with either a fixed rate or no GMCRN/AN/AN/AN/A1,175
Total$328$538$4,808$31,572$38,421
Equal to or greater than 0% but less than 2%$322$584$6,274$28,343$35,523
Equal to or greater than 2% but less than 4%—5——5
Products with either a fixed rate or no GMCRN/AN/AN/AN/A1,335
Total$322$589$6,274$28,343$36,863

Annuities

Corporate & Other’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$10,142$11,537$13,286
Transfer, January 1 (1)(3,109)——
Deposits113167176
Policy charges(9)(13)(15)
Surrenders and withdrawals(944)(1,688)(1,981)
Benefit payments(307)(390)(420)
Net transfers from (to) separate accounts28014672
Interest credited213349396
Other43423
Balance at December 31,$6,383$10,142$11,537
Weighted-average annual crediting rate3.2 %3.3 %3.3 %
At period end:
Cash surrender value$5,872$9,555$10,904
Net amount at risk, excluding offsets from reinsurance (2):
In the event of death (3)$2,240$2,540$2,821
At annuitization or exercise of other living benefits (4)$702$750$688

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(2)Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “Corporate & Other – Annuities” in Note 6.

(3)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

(4)For benefits that are payable in the event of annuitization or exercise of other living benefits, the net amount at risk is generally defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates or to provide other living benefits. This amount represents the Company’s potential economic exposure in the event all contractholders were to annuitize or to exercise other living benefits at the balance sheet date.

Corporate & Other’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50% above GMCREqual to or greater than 0.50% but less than 1.50% above GMCREqual to or greater than 1.50% above GMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$50$1$483$174$708
Equal to or greater than 2% but less than 4%2,5471,600267624,476
Equal to or greater than 4%4344096—849
Products with either a fixed rate or no GMCRN/AN/AN/AN/A350
Total$3,031$2,010$756$236$6,383
Equal to or greater than 0% but less than 2%$2$140$441$75$658
Equal to or greater than 2% but less than 4%1,6395,6755251077,946
Equal to or greater than 4%72839912—1,139
Products with either a fixed rate or no GMCRN/AN/AN/AN/A399
Total$2,369$6,214$978$182$10,142
Equal to or greater than 0% but less than 2%$36$307$378$252$973
Equal to or greater than 2% but less than 4%1,0337,2054592028,899
Equal to or greater than 4%78841132—1,231
Products with either a fixed rate or no GMCRN/AN/AN/AN/A434
Total$1,857$7,923$869$454$11,537

Life and Other

Corporate & Other’s life and other PABs include retained asset accounts, universal life products, the fixed account portion of variable life insurance products and funding agreements. Information regarding this liability was as follows:

Years Ended December 31,
202520242023
(Dollars in millions)
Balance at January 1,$11,132$11,641$12,402
Transfer, January 1 (1)(3,773)——
Deposits565784783
Policy charges(667)(690)(702)
Surrenders and withdrawals(322)(1,053)(1,171)
Benefit payments(161)(151)(152)
Net transfers from (to) separate accounts435135
Interest credited288421445
Other41291
Balance at December 31,$7,109$11,132$11,641
Weighted-average annual crediting rate4.1 %3.8 %3.8 %
At period end:
Cash surrender value$6,575$10,576$11,177
Net amount at risk, excluding offsets from reinsurance (2):
In the event of death (3)$60,701$64,031$67,786

(1)A product previously reported within the former MetLife Holdings segment was moved to the Group Benefits segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(2)Including offsets from reinsurance, the net amount at risk for each of the years ended December 31, 2025, 2024 and 2023, as presented in the above table, would be reduced by 99%.

(3)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

Corporate & Other’s life and other products account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than 0% but less than 0.50% above GMCREqual to or greater than 0.50% but less than 1.50% above GMCREqual to or greater than 1.50% above GMCRTotal Account Value
(In millions)
Equal to or greater than 0% but less than 2%$—$—$—$—$—
Equal to or greater than 2% but less than 4%3641686131401,285
Equal to or greater than 4%4,7703881195,178
Products with either a fixed rate or no GMCRN/AN/AN/AN/A646
Total$5,134$556$614$159$7,109
Equal to or greater than 0% but less than 2%$—$—$14$50$64
Equal to or greater than 2% but less than 4%4,0621752605315,028
Equal to or greater than 4%4,860122403225,407
Products with either a fixed rate or no GMCRN/AN/AN/AN/A633
Total$8,922$297$677$603$11,132
Equal to or greater than 0% but less than 2%$—$—$16$55$71
Equal to or greater than 2% but less than 4%4,4531712805495,453
Equal to or greater than 4%5,066124413135,616
Products with either a fixed rate or no GMCRN/AN/AN/AN/A501
Total$9,519$295$709$617$11,641
  1. Market Risk Benefits

The Company establishes assets and liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit, less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets.

The Company’s MRB assets and MRB liabilities on the consolidated balance sheets were as follows at:

December 31,
20252024
AssetLiabilityNet Liability (Asset)AssetLiabilityNet Liability (Asset)
(In millions)
Corporate & Other - Annuities (1)$258$2,043$1,785$231$2,300$2,069
Other (2)200363163141281140
Total$458$2,406$1,948$372$2,581$2,209

(2)Includes an Asia retirement assurance MRB liability and a net liability of $178 million at December 31, 2024, which was previously disclosed as a separate disaggregated rollforward.

The following information about the direct and assumed liabilities (assets) for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.

Corporate & Other’s variable annuity products offer contract features whereby the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantee contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Corporate & Other’s variable annuity products also include an in-force block of assumed variable annuity guarantees from a third party. Information regarding Corporate & Other’s variable annuity products (including assumed reinsurance) was as follows:

Years Ended December 31,
202520242023
(In millions)
Balance at January 1, (1)$2,069$2,722$3,225
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$1,992$2,772$3,360
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)(191)——
Attributed fees collected314352377
Benefit payments(93)(90)(58)
Effect of changes in interest rates(221)(736)(161)
Effect of changes in capital markets(497)(514)(900)
Effect of changes in equity index volatility—40(135)
Actual policyholder behavior different from expected behavior237220144
Effect of changes in future expected policyholder behavior and other assumptions(15)129
Effect of foreign currency translation and other, net (2)160(4)152
Effect of changes in risk margin(21)(60)(16)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk1,6651,9922,772
Cumulative effect of changes in the instrument-specific credit risk12178(54)
Effect of foreign currency translation on the cumulative instrument-specific credit risk(1)(1)4
Net balance at December 31,1,7852,0692,722
Less: Reinsurance recoverable285——
Balance at December 31,$1,500$2,069$2,722
At period end:
Net amount at risk, excluding offsets from hedging (3):
In the event of death (4)$2,242$2,543$2,828
At annuitization or exercise of other living benefits (5)$669$718$675
Weighted-average attained age of contractholders:
In the event of death (4)72 years71 years70 years
At annuitization or exercise of other living benefits (5)71 years70 years70 years

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was ($165) million. See Note 1 for further information on the Strategic Reorganization.

(2) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility.

(3) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs, which are disclosed in “Corporate & Other – Annuities” in Note 5.

(4) For those guarantees of benefits that are payable in the event of death, the net amount at risk is generally defined as the current guaranteed minimum death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

(5) For benefits that are payable in the event of annuitization or exercise of other living benefits, the net amount at risk is generally defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates or to provide other living benefits. This amount represents the Company’s potential economic exposure in the event all contractholders were to annuitize or to exercise other living benefits at the balance sheet date.

The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI.

The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates.

Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 13 for additional information on significant unobservable inputs.

The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.

Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees.

These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI.

Other

In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features across various segments. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 13 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities (assets) was as follows:

Years Ended December 31,
202520242023
(In millions)
Balance at January 1, (1)$140$171$258
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$126$155$257
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)191——
Attributed fees collected615237
Benefit payments(18)(18)(40)
Effect of changes in interest rates(104)(53)(2)
Effect of changes in capital markets(83)(3)(41)
Effect of changes in equity index volatility1—(6)
Actual policyholder behavior different from expected behavior113(23)
Effect of changes in future expected policyholder behavior and other assumptions(4)(2)1
Effect of foreign currency translation and other, net(17)(7)(27)
Effect of changes in risk margin(4)(1)(1)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk160126155
Cumulative effect of changes in the instrument-specific credit risk21515
Effect of foreign currency translation on the cumulative instrument-specific credit risk1(1)1
Net balance at December 31,163140171
Less: Reinsurance recoverable81218
Balance at December 31,$155$128$153

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was $165 million. See Note 1 for further information on the Strategic Reorganization.

  1. Separate Accounts

Separate account assets consist of investment accounts established and maintained by the Company. The investment objectives of these assets are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities.

Separate account assets and liabilities include two categories of account types: pass-through separate accounts totaling $128.7 billion and $113.6 billion at December 31, 2025 and 2024, respectively, for which the contractholder assumes all investment risk, and separate accounts for which the Company contractually guarantees either a minimum return or account value to the contractholder which totaled $23.3 billion and $25.9 billion at December 31, 2025 and 2024, respectively. The latter category consisted primarily of GICs. The average interest rate credited on these contracts was 2.5% and 2.6% at December 31, 2025 and 2024, respectively.

Separate Account Liabilities

The Company’s separate account liabilities on the consolidated balance sheets were as follows at:

December 31, 2025December 31, 2024
(In millions)
RIS:
Stable Value and Risk Solutions$38,925$40,319
Annuities18,09911,001
Latin America - Pensions48,54938,765
Corporate & Other - Annuities (1)19,62127,829
Other26,73921,590
Total$151,933$139,504

The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.

The separate account liabilities are primarily comprised of the following: RIS stable value and risk solutions contracts, RIS annuity participating and non-participating group contracts and group variable deferred annuities, Latin America savings-oriented pension product in Chile within the country’s mandatory individual capitalization pension system, and Corporate & Other variable annuities.

The balances of and changes in separate account liabilities were as follows:

RIS Stable Value and Risk SolutionsRISAnnuitiesLatin AmericaPensionsCorporate & OtherAnnuities
(In millions)
Balance, January 1, 2023$48,265$11,694$39,428$28,499
Premiums and deposits2,2031757,936256
Policy charges(285)(21)(287)(609)
Surrenders and withdrawals(11,123)(944)(5,781)(2,948)
Benefit payments(99)—(1,702)(464)
Investment performance2,5957742,8144,561
Net transfers from (to) general account(56)3—(74)
Effect of foreign currency translation and other, net(157)(22)(1,088)3
Balance, December 31, 2023$41,343$11,659$41,320$29,224
Premiums and deposits3,0651456,779235
Policy charges(273)(21)(264)(603)
Surrenders and withdrawals(5,423)(918)(5,147)(3,794)
Benefit payments(99)—(1,679)(491)
Investment performance1,755832,9813,411
Net transfers from (to) general account(4)——(147)
Effect of foreign currency translation and other, net(45)53(5,225)(6)
Balance, December 31, 2024$40,319$11,001$38,765$27,829
Transfer, January 1 (1)—6,926—(6,926)
Premiums and deposits4,6572466,97266
Policy charges(285)(107)(271)(467)
Surrenders and withdrawals(6,804)(1,579)(5,422)(2,593)
Benefit payments(154)(41)(1,924)(420)
Investment performance2,8481,7836,0902,415
Net transfers from (to) general account15(81)—(281)
Effect of foreign currency translation and other, net (2)(1,671)(49)4,339(2)
Balance, December 31, 2025$38,925$18,099$48,549$19,621
Cash surrender value at December 31, 2023 (3)$35,950N/A$41,320$29,078
Cash surrender value at December 31, 2024 (3)$34,949N/A$38,765$27,703
Cash surrender value at December 31, 2025 (1), (3)$35,333$6,960$48,549$19,532

(1)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

(2)The effect of foreign currency translation and other, net, for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities.

(3)Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges.

Separate Account Assets

The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at:

GroupBenefitsRISAsiaLatinAmericaEMEACorporate & Other (1)Total
(In millions)
Fixed maturity securities:
Bonds:
Government and agency$—$9,257$1,128$12,336$4,326$—$27,047
Public utilities—1,077173———1,250
Municipals—30717———324
Corporate bonds—8,0787338,749461—18,021
Total bonds—18,7192,05121,0854,787—46,642
Mortgage-backed securities—8,306————8,306
Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)—2,388————2,388
Redeemable preferred stock—8138———146
Total fixed maturity securities—29,4212,18921,0854,787—57,482
Equity securities—2,8893,6984,2611,953—12,801
Mutual funds (2):
Bond funds871,2701915,657442,0419,290
Equity funds1,1566,5613,36613,49516913,78238,529
Balanced funds8089———2171
Other11510,673336—6811,09722,289
Total mutual funds1,43818,5933,89319,15228126,92270,279
Other invested assets—1,1983123,753118—5,381
Total investments1,43852,10110,09248,2517,13926,922145,943
Other assets—5,02764029825—5,990
Total$1,438$57,128$10,732$48,549$7,164$26,922$151,933
GroupBenefitsRISAsiaLatinAmericaEMEACorporate & Other (1)Total
(In millions)
Fixed maturity securities:
Bonds:
Government and agency$—$9,950$1,115$10,545$3,017$15$24,642
Public utilities—1,090188——71,285
Municipals—25018——12280
Corporate bonds—8,6827237,7203205217,497
Total bonds—19,9722,04418,2653,3378643,704
Mortgage-backed securities—9,021———389,059
ABS & CLO—2,145———172,162
Redeemable preferred stock—8————8
Total fixed maturity securities—31,1462,04418,2653,33714154,933
Equity securities—2,8302,3242,3531,200—8,707
Mutual funds (2):
Bond funds868471863,228412,6036,991
Equity funds1,0471,5212,63611,0675518,58734,913
Balanced funds681———70139
Other1187,666276—3313,49121,584
Total mutual funds1,31910,0353,09814,29512934,75163,627
Other invested assets—1,3983122,55743—4,310
Total investments1,31945,4097,77837,4704,70934,892131,577
Other assets—6,0114531,29516627,927
Total$1,319$51,420$8,231$38,765$4,875$34,894$139,504

(2)Mutual fund balances are presented by fund type. Prior year amounts, previously presented in the aggregate, have been reclassified to conform to the current year presentation.

  1. Deferred Policy Acquisition Costs, Value of Business Acquired, Unearned Revenue and Other Intangibles

DAC and VOBA

Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at:

GroupBenefitsRISAsia (1)LatinAmerica (2)EMEA (2)Corporate& Other (3)Total
(In millions)
DAC:
Balance at January 1, 2023$264$267$10,270$1,542$1,480$3,821$17,644
Capitalizations201761,583651457302,917
Amortization(26)(46)(705)(418)(332)(264)(1,791)
Effect of foreign currency translation and other, net (4)——(284)17513(286)(382)
Balance at December 31, 202325839710,8641,9501,6183,30118,388
Capitalizations182181,380704486272,833
Amortization(26)(63)(782)(461)(345)(235)(1,912)
Effect of foreign currency translation and other, net——(677)(357)(95)(2)(1,131)
Balance at December 31, 202425055210,7851,8361,6643,09118,178
Transfer, January 1 (5)—98———(98)—
Capitalizations262131,617770568253,219
Amortization(26)(78)(811)(530)(360)(213)(2,018)
Effect of foreign currency translation and other, net (4)——52267149(114)354
Balance at December, 31, 2025$250$785$11,643$2,343$2,021$2,691$19,733
VOBA:
Balance at January 1, 2023$—$19$1,290$545$127$28$2,009
Amortization—(3)(89)(50)(16)(3)(161)
Effect of foreign currency translation and other, net (4)——(82)22(7)(85)
Balance at December 31, 2023—161,119497113181,763
Amortization—(3)(71)(42)(14)(4)(134)
Effect of foreign currency translation and other, net——(113)(62)(5)—(180)
Balance at December 31, 2024—1393539394141,449
Amortization—(3)(64)(41)(11)(2)(121)
Effect of foreign currency translation and other, net (4)——4418(7)46
Balance at December 31, 2025$—$10$875$393$91$5$1,374
Total DAC and VOBA:
Balance at December 31, 2023$20,151
Balance at December 31, 2024$19,627
Balance at December 31, 2025$21,107

(1)Includes DAC balances primarily related to accident & health, universal and variable universal life, variable life and fixed annuity products and VOBA balances primarily related to accident & health products.

  1. Deferred Policy Acquisition Costs, Value of Business Acquired, Unearned Revenue and Other Intangibles (continued)

(2)Includes DAC balances primarily related to universal life, variable universal life, ordinary life and accident & health products.

(3)Includes DAC balances primarily related to whole life, variable annuities, term life, universal life and long-term care products. See Note 1 for further information on the Strategic Reorganization.

(4)Corporate & Other includes activity for total DAC and total VOBA ceded at the date of inception related to a reinsurance agreement.

(5)A product previously reported within the former MetLife Holdings segment was moved to the RIS segment as part of the Strategic Reorganization. Accordingly, the reported balances for the year ended December 31, 2025 have been updated to reflect this change. See Note 1 for further information on the Strategic Reorganization.

The Company amortizes DAC and VOBA related to long-duration contracts over the estimated lives of the contracts in proportion to benefits in-force for RIS annuities and policy count for all other products. The amortization amount is calculated using the same cohorts as the corresponding liabilities on a quarterly basis, using an amortization rate that includes current period reporting experience and end of period persistency and longevity assumptions that are consistent with those used to measure the corresponding liabilities.

The Company amortizes DAC for credit insurance and other short-duration contracts, which is primarily comprised of commissions and certain underwriting expenses, in proportion to actual and future earned premium over the applicable contract term.

Information regarding other intangibles was as follows:

Years Ended December 31,
202520242023
(In millions)
VODA and VOCRA:
Balance at January 1,$710$794$876
Amortization(83)(85)(88)
Effect of foreign currency translation and other916
Balance at December 31,$636$710$794
Accumulated amortization$923$840$755
Negative VOBA:
Balance at January 1,$369$427$473
Amortization(25)(25)(26)
Effect of foreign currency translation and other6(33)(20)
Balance at December 31,$350$369$427
Accumulated amortization$3,448$3,423$3,398

The estimated future amortization expense (credit) to be reported in other expenses for the next five years is as follows:

VOBA · VODA and VOCRA · Negative VOBA
(In millions)
2026$117$80$(22)
2027$110$78$(21)
2028$100$75$(20)
2029$92$73$(19)
2030$82$66$(18)
  1. Deferred Policy Acquisition Costs, Value of Business Acquired, Unearned Revenue and Other Intangibles (continued)

Unearned Revenue

Information regarding the Company’s UREV primarily related to interest sensitive whole life, variable life and universal life products by segment, as well as Corporate & Other, included in other policy-related balances was as follows:

RISAsiaLatin AmericaEMEACorporate & Other (1)Total
(In millions)
Balance at January 1, 2023$36$2,382$848$559$281$4,106
Deferrals26671479548959
Amortization(7)(181)(116)(63)(18)(385)
Effect of foreign currency translation and other - net (2)—(18)11017(252)(143)
Balance at December 31, 2023312,850989608594,537
Deferrals25341469815795
Amortization(6)(228)(115)(68)(5)(422)
Effect of foreign currency translation and other - net—(80)(179)(16)—(275)
Balance at December 31, 2024273,076841622694,635
Deferrals249614312412777
Amortization(6)(238)(115)(69)(5)(433)
Effect of foreign currency translation and other - net (2)—1212846(3)183
Balance at December 31, 2025$23$3,346$997$723$73$5,162

(2)Corporate & Other includes activity for total UREV ceded at the date of inception related to a reinsurance agreement.

UREV is amortized similarly to DAC and VOBA, see “— DAC and VOBA.”

  1. Reinsurance

The Company enters into reinsurance agreements both as a purchaser of reinsurance for its various insurance products and also as a provider of reinsurance for pension, annuity and insurance products issued by third parties. The Company purchases reinsurance in order to limit losses, minimize exposure to significant risks and provide additional capacity for future growth.

Under the terms of the reinsurance agreements, the reinsurer agrees to reimburse the Company for the ceded amount in the event a claim is paid. Cessions under reinsurance agreements do not discharge the Company’s obligation as the primary insurer. In the event that reinsurers do not meet their obligations under the terms of the reinsurance agreements, reinsurance recoverable balances could become uncollectible.

Accounting for reinsurance requires extensive use of assumptions and estimates, particularly related to the future performance of the underlying business and the potential impact of counterparty credit risks. The Company periodically reviews actual and anticipated experience compared to the aforementioned assumptions used to establish assets and liabilities relating to ceded and assumed reinsurance and evaluates the financial strength of counterparties to its reinsurance agreements using criteria similar to that evaluated in the security impairment process discussed in “ — Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss” in Note 11.

For its Group Benefits segment, the Company generally retains most of the risk, with the exception of its Group Term Life business and certain client arrangements.

The Company reinsures a 90% quota share of its non-participating Group Term Life business and a 50% quota share of its Group Dental business for capital management purposes. The majority of the Company’s other reinsurance activity within this segment relates to client agreements for employer sponsored captive programs, risk-sharing agreements and multinational pooling. The risks ceded under these agreements are generally quota shares of group life and disability policies. The cessions vary and the Company may cede up to 100% of all the risks of the policies.

RIS

For its RIS segment, the Company reinsures longevity risks for certain pension products issued by unaffiliated providers located in the U.K. The Company also reinsures certain registered indexed annuities. The Company cedes risk on certain pension products and certain structured settlement annuities.

Asia, Latin America and EMEA

For selected large corporate clients, the Company reinsures group employee benefits or credit insurance business with various client-affiliated reinsurance companies, covering policies issued to the employees or customers of the clients. Additionally, the Company cedes and assumes risk with other insurance companies when either company requires a business partner with the appropriate local licensing to issue certain types of policies in certain jurisdictions. In these cases, the assuming company typically underwrites the risks, develops the products and assumes most or all of the risk. The Company also has reinsurance agreements in-force that reinsure a portion of the living and death benefit guarantees issued in connection with variable annuity products. Under these agreements, the Company pays reinsurance fees associated with the guarantees collected from policyholders and receives reimbursement for benefits paid or accrued in excess of account values, subject to certain limitations. The Company may also reinsure certain risks with external reinsurers depending upon the nature of the risk and local regulatory requirements.

For its life products, the Company has historically reinsured the mortality risk primarily on an excess of retention basis or on a quota share basis. In addition to reinsuring mortality risk as described above, the Company reinsures other risks, as well as specific coverages. Placement of reinsurance is done primarily on an automatic basis and also on a facultative basis for risks with specified characteristics. The Company assumes the risk associated with certain whole life policies, certain term life policies and universal life policies with secondary death benefit guarantees. The Company also ceded (i) an in-force block of universal life, variable universal life, universal life with secondary guarantees and fixed annuities on a 100% quota share basis and (ii) certain participating whole life business and certain variable annuities.

For its other products, the Company has a reinsurance agreement in-force to assume the living and death benefit guarantees issued in connection with certain variable annuity guarantees from a third party in Japan. Under this agreement, the Company receives reinsurance fees associated with the guarantees collected from policyholders, and provides reimbursement for benefits paid or accrued in excess of account values, subject to certain limitations.

Catastrophe Coverage

The Company has exposure to catastrophes which could contribute to significant fluctuations in the Company’s results of operations. For the Group Benefits and EMEA segments, the Company purchases catastrophe coverage to reinsure risks issued within territories that the Company believes are subject to the greatest catastrophic risks. For its other segments, the Company uses excess of retention and quota share reinsurance agreements to provide greater diversification of risk and minimize exposure to larger risks. Excess of retention reinsurance agreements provide for a portion of a risk to remain with the direct writing company and quota share reinsurance agreements provide for the direct writing company to transfer a fixed percentage of all risks of a class of policies.

Reinsurance Recoverables

The Company reinsures its business through a diversified group of well-capitalized reinsurers. The Company analyzes recent trends in arbitration and litigation outcomes in disputes, if any, with its reinsurers. The Company monitors ratings and evaluates the financial strength of its reinsurers by analyzing their financial statements. In addition, the reinsurance recoverable balance due from each reinsurer is evaluated as part of the overall monitoring process. Recoverability of reinsurance recoverable balances is evaluated based on these analyses. The Company generally secures large reinsurance recoverable balances with various forms of collateral, including secured trusts, funds withheld accounts and irrevocable letters of credit. These reinsurance recoverable balances are stated net of allowances for uncollectible reinsurance, which at December 31, 2025 and 2024, were not significant. A U.S. life insurance subsidiary of the Company also secured collateral from its counterparties to mitigate counterparty default risk related to its longevity reinsurance agreements.

The Company has secured certain reinsurance recoverable balances with various forms of collateral, including secured trusts, funds withheld accounts and irrevocable letters of credit. The Company had$4.8 billion and $4.2 billion of unsecured reinsurance recoverable balances at December 31, 2025 and 2024, respectively.

At December 31, 2025, the Company had $35.1 billion of net ceded reinsurance recoverables. Of this total, $30.6 billion, or 87%, were with the Company’s five largest ceded reinsurers, including $1.7 billion of net ceded reins urance recoverables which were unsecured. At December 31, 2025, the top three reinsurers including Chariot Re, and two other third-party reinsurers accounted for 27%,26% and 24%, respectively, of the net ceded reinsurance recoverables. At December 31, 2024, the Company had $17.6 billion of net ceded reinsurance recoverables. Of this total, $14.7 billion, or 84%, were with the Company’s five largest ceded reinsurers, including $2.4 billion of net ceded reinsurance recoverables which were unsecured. At December 31, 2024, the largest reinsurer accounted for 55% of the net ceded reinsurance recoverables.

The Company reinsured, with an unaffiliated third-party reinsurer,59% of the closed block through a modified coinsurance agreement. In October 2025, the Company recaptured this agreement. The Company accounted for this agreement under the deposit method of accounting. The Company, having the right of offset, offset the modified coinsurance deposit liability with the deposit recoverable.

The amounts on the consolidated statements of operations include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows:

Years Ended December 31,
202520242023
(In millions)
Premiums
Direct premiums$53,375$45,153$43,359
Reinsurance assumed4,4993,7883,112
Reinsurance ceded(8,095)(3,996)(2,188)
Net premiums$49,779$44,945$44,283
Universal life and investment-type product policy fees
Direct universal life and investment-type product policy fees$5,925$5,914$5,787
Reinsurance assumed4(3)(19)
Reinsurance ceded(926)(937)(616)
Net universal life and investment-type product policy fees$5,003$4,974$5,152
Policyholder benefits and claims
Direct policyholder benefits and claims$54,464$45,662$44,155
Reinsurance assumed4,2023,6142,904
Reinsurance ceded(8,948)(4,548)(2,469)
Net policyholder benefits and claims$49,718$44,728$44,590
Policyholder liability remeasurement (gains) losses
Direct policyholder liability remeasurement (gains) losses$(21)$(169)$(54)
Reinsurance assumed—(13)(20)
Reinsurance ceded(129)(24)29
Net policyholder liability remeasurement (gains) losses$(150)$(206)$(45)
MRB remeasurement (gains) losses
Direct MRB (gains) losses$(490)$(992)$(785)
Reinsurance assumed(89)(123)(214)
Reinsurance ceded7165
Net MRB (gains) losses$(508)$(1,109)$(994)
Other expenses
Direct other expenses$13,618$13,054$12,760
Reinsurance assumed222202235
Reinsurance ceded20(239)(285)
Net other expenses$13,860$13,017$12,710

The amounts on the consolidated balance sheets include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows at:

December 31,
20252024
DirectAssumedCededTotalBalanceSheetDirectAssumedCededTotalBalanceSheet
(In millions)
Assets
Premiums, reinsurance and other receivables (1)$7,612$1,594$39,853$49,059$6,496$1,432$21,833$29,761
MRBs40454—4583657—372
DAC and VOBA21,353355(601)21,10719,753352(478)19,627
Total assets$29,369$2,003$39,252$70,624$26,614$1,791$21,355$49,760
Liabilities
FPBs$204,122$4,733$—$208,855$189,328$4,318$—$193,646
PABs (2)236,487370—236,857221,268177—221,445
MRBs2,38026—2,4062,56615—2,581
Other policy-related balances19,0821,297(309)20,07018,1381,052(291)18,899
Other liabilities27,6271,70028,25557,58226,7221,8638,25836,843
Total liabilities$489,698$8,126$27,946$525,770$458,022$7,425$7,967$473,414

(1)Includes ceded PABs, FPBs and MRBs.

(2)Prior year PABs have been presented to conform to the current year presentation.

Reinsurance agreements that do not expose the Company to a reasonable possibility of a significant loss from insurance risk are recorded using the deposit method of accounting. Included in premiums, reinsurance and other receivables in the table above are deposit assets on reinsurance of$8.1 billion and $4.6 billion at December 31, 2025 and 2024, respectively. Included in other liabilities in the table above are deposit liabilities on reinsurance of$1.2 billion at both December 31, 2025 and 2024.

In December 2025, the Company entered into a reinsurance agreement with Talcott Resolution Life Insurance Company to cede certain variable annuity contracts and rider reserves on a funds withheld basis. The Company recorded premiums, reinsurance and other receivables of $2.0 billion and a funds withheld liability of $2.0 billion within other liabilities at December 31, 2025. The Company retained $8.3 billion of separate account assets on a funds withheld basis at December 31, 2025.

In November 2025, the Company entered into a reinsurance agreement to cede certain group annuity contracts issued in connection with a qualifying pension risk transfer on a funds withheld basis. The Company recorded cash and cash equivalents of $624 million, premiums, reinsurance and other receivables of $5.3 billion and a funds withheld liability of $5.7 billion within other liabilities at December 31, 2025. The Company also recorded premiums of ($4.5) billion, net derivative gains of $37 million, policyholder benefits and claims of ($4.6) billion and other expenses of $24 million for the year ended December 31, 2025.

Also in 2025, the Company entered into two reinsurance agreements with Chariot Reinsurance, Ltd. (“Chariot Re”): one to cede certain structured settlement annuity contracts and group annuity contracts associated with pension risk transfers on a funds withheld basis and another to cede certain participating whole life business on a funds withheld basis. For both transactions, the Company recorded cash and cash equivalents of $977 million, premiums, reinsurance and other receivables of $9.8 billion and a funds withheld liability of $10.5 billion within other liabilities at December 31, 2025. The Company also recorded net derivative losses of $167 million, other revenues of $66 million, policyholder benefits and claims of ($146) million and other expenses of $184 million for the year ended December 31, 2025. See Note 25 for additional related party transactions.

  1. Closed Block

On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC. Assets have been allocated to the closed block in an amount that has been determined to produce cash flows which, together with anticipated revenues from the policies included in the closed block, are reasonably expected to be sufficient to support obligations and liabilities relating to these policies, including, but not limited to, provisions for the payment of claims and certain expenses and taxes, and to provide for the continuation of policyholder dividend scales in effect for 1999, if the experience underlying such dividend scales continues, and for appropriate adjustments in such scales if the experience changes. At least annually, the Company compares actual and projected experience against the experience assumed in the then-current dividend scales. Dividend scales are adjusted periodically to give effect to changes in experience.

The closed block assets, the cash flows generated by the closed block assets and the anticipated revenues from the policies in the closed block will benefit only the holders of the policies in the closed block. To the extent that, over time, cash flows from the assets allocated to the closed block and claims and other experience related to the closed block are, in the aggregate, more or less favorable than what was assumed when the closed block was established, total dividends paid to closed block policyholders in the future may be greater than or less than the total dividends that would have been paid to these policyholders if the policyholder dividend scales in effect for 1999 had been continued. Any cash flows in excess of amounts assumed will be available for distribution over time to closed block policyholders and will not be available to stockholders. If the closed block has insufficient funds to make guaranteed policy benefit payments, such payments will be made from assets outside of the closed block. The closed block will continue in effect as long as any policy in the closed block remains in-force. The expected life of the closed block is over 100 years from the Demutualization Date.

The Company uses the same accounting principles to account for the participating policies included in the closed block as it used prior to the Demutualization Date. However, the Company establishes a policyholder dividend obligation for earnings that will be paid to policyholders as additional dividends as described below. The excess of closed block liabilities over closed block assets at the Demutualization Date (adjusted to eliminate the impact of related amounts in AOCI) represents the estimated maximum future earnings from the closed block expected to result from operations, attributed net of income tax, to the closed block. Earnings of the closed block are recognized in income over the period the policies and contracts in the closed block remain in-force.

If, over the period the closed block remains in existence, the actual cumulative earnings of the closed block are greater than the expected cumulative earnings of the closed block, the Company will pay the excess to closed block policyholders as additional policyholder dividends unless offset by future unfavorable experience of the closed block and, accordingly, will recognize only the expected cumulative earnings in income with the excess recorded as a policyholder dividend obligation. If over such period, the actual cumulative earnings of the closed block are less than the expected cumulative earnings of the closed block, the Company will recognize only the actual earnings in income. However, the Company may change policyholder dividend scales in the future, which would be intended to increase future actual earnings until the actual cumulative earnings equal the expected cumulative earnings.

At least annually, management performs a premium deficiency test using best estimate assumptions to determine whether the projected future earnings of the closed block are sufficient to support the payment of future closed block contractual benefits. The most recent deficiency test demonstrated that the projected future earnings of the closed block are sufficient to support the payment of future closed block contractual benefits.

Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block.

Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.

  1. Closed Block (continued)

Information regarding the liabilities and assets designated to the closed block was as follows at:

December 31,
20252024
(In millions)
Closed Block Liabilities
FPBs$33,846$35,015
Other policy-related balances281315
Policyholder dividends payable140174
Policyholder dividend obligation——
Current income tax payable26
Other liabilities1,137854
Total closed block liabilities35,40636,364
Assets Designated to the Closed Block
Investments:
Fixed maturity securities AFS, at estimated fair value19,03218,958
Equity securities, at estimated fair value511
Mortgage loans5,3725,720
Policy loans3,6473,829
Real estate and REJV668659
Other invested assets351512
Total investments29,07529,689
Cash and cash equivalents1,286930
Accrued investment income355367
Premiums, reinsurance and other receivables5945
Deferred income tax asset340470
Total assets designated to the closed block31,11531,501
Excess of closed block liabilities over assets designated to the closed block4,2914,863
AOCI:
Unrealized investment gains (losses), net of income tax(684)(1,256)
Unrealized gains (losses) on derivatives, net of income tax49183
Total amounts included in AOCI(635)(1,073)
Maximum future earnings to be recognized from closed block assets and liabilities$3,656$3,790
  1. Closed Block (continued)

Information regarding the closed block revenues and expenses was as follows:

Years Ended December 31,
202520242023
(In millions)
Revenues
Premiums$830$874$922
Net investment income1,3321,3621,362
Net investment gains (losses)(64)(28)7
Net derivative gains (losses)(3)15—
Total revenues2,0952,2232,291
Expenses
Policyholder benefits and claims1,5321,6211,706
Policyholder dividends316354366
Other expenses768286
Total expenses1,9242,0572,158
Revenues, net of expenses before provision for income tax expense (benefit)171166133
Provision for income tax expense (benefit)373628
Revenues, net of expenses and provision for income tax expense (benefit)$134$130$105

MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

  1. Investments

See Note 13 for information about the fair value hierarchy for investments and the related valuation methodologies.

Investment Risks and Uncertainties

Investments are exposed to the following primary sources of risk: credit, interest rate, liquidity, market valuation, currency and real estate risk. The financial statement risks, stemming from such investment risks, are those associated with the determination of estimated fair values, the diminished ability to sell certain investments in times of strained market conditions, the recognition of ACL and impairments, the recognition of income on certain investments and the potential consolidation of VIEs. The use of different methodologies, assumptions and inputs relating to these financial statement risks may have a material effect on the amounts presented within the consolidated financial statements.

The determination of ACL and impairments is highly subjective and is based upon quarterly evaluations and assessments of known and inherent risks associated with the respective asset class. Such evaluations and assessments are revised as conditions change and new information becomes available.

The recognition of income on certain investments (e.g. structured securities, including mortgage-backed securities, ABS & CLO, certain structured investment transactions and FVO securities) is dependent upon certain factors such as prepayments and defaults, and changes in such factors could result in changes in amounts to be earned.

Fixed Maturity Securities AFS

Fixed Maturity Securities AFS by Sector

The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. RMBS includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans, broadly syndicated bank loans, and other assets. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.”

December 31,
2025 · 2024
Gross Unrealized · EstimatedFairValue · AmortizedCost · Gross Unrealized · EstimatedFairValue
Sector · AmortizedCost · ACL · Gains · Losses · ACL · Gains · Losses
(In millions)
U.S. corporate$92,855$(138)$1,899$6,657$87,959$86,315$(59)$1,331$8,213$79,374
Foreign corporate62,606(7)2,4434,45360,58958,646(18)1,4786,34753,759
RMBS46,567(1)8221,97045,41837,085(1)3142,97734,421
Foreign government47,037(57)1,0687,30040,74844,377(57)1,2565,32640,250
U.S. government and agency42,877—3035,65837,52238,963—1795,71433,428
ABS & CLO23,028(6)24637122,89720,973(9)15352620,591
Municipals12,195—2251,35611,06411,205—1661,4989,873
CMBS10,036(40)1313939,7349,857(16)1045989,347
Total fixed maturity securities AFS$337,201$(249)$7,137$28,158$315,931$307,421$(160)$4,981$31,199$281,043

Methodology for Amortization of Premium and Accretion of Discount on Structured Products

Amortization of premium and accretion of discount on Structured Products consider the estimated timing and amount of prepayments of the underlying loans. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the originally anticipated and the actual prepayments received and currently anticipated. Prepayment assumptions for Structured Products are estimated using inputs obtained from third-party specialists and based on management’s knowledge of the current market. For credit-sensitive and certain prepayment-sensitive Structured Products, the effective yield is recalculated on a prospective basis. For all other Structured Products, the effective yield is recalculated on a retrospective basis.

Maturities of Fixed Maturity Securities AFS

The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at December 31, 2025:

Due in OneYear or LessDue After One Year ThroughFive YearsDue After Five YearsThrough Ten YearsDue After Ten YearsStructuredProductsTotal FixedMaturitySecurities AFS
(In millions)
Amortized cost, net of ACL$14,492$49,369$57,472$136,035$79,584$336,952
Estimated fair value$14,635$49,826$57,315$116,106$78,049$315,931

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity.

Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position.

December 31,
2025 · 2024
Less than 12 Months · Equal to or Greater than 12 Months · Less than 12 Months · Equal to or Greater than 12 Months
Sector & Credit Quality · EstimatedFair Value · GrossUnrealizedLosses · EstimatedFair Value · GrossUnrealizedLosses · EstimatedFair Value · GrossUnrealizedLosses · EstimatedFair Value · GrossUnrealizedLosses
(Dollars in millions)
U.S. corporate$8,564$527$37,884$6,092$17,222$1,586$35,940$6,599
Foreign corporate5,31419922,6874,25110,51670924,4545,625
Foreign government9,71665216,2146,6466,46258116,3384,740
RMBS3,8486912,9831,90210,15235813,9222,619
U.S. government and agency8,54418116,3415,4779,33768714,0825,027
ABS & CLO5,349494,0003222,840885,831436
Municipals1,000795,1471,2772,0122264,6211,272
CMBS1,164363,6603551,272394,788559
Total fixed maturity securities AFS$43,499$1,792$118,916$26,322$59,813$4,274$119,976$26,877
Investment grade$41,743$1,707$116,021$26,002$56,946$4,132$116,072$26,325
Below investment grade1,756852,8953202,8671423,904552
Total fixed maturity securities AFS$43,499$1,792$118,916$26,322$59,813$4,274$119,976$26,877
Total number of securities in an unrealized loss position5,4899,8507,22010,468

Evaluation of Fixed Maturity Securities AFS for Credit Loss

Evaluation and Measurement Methodologies

Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell, including transfers in connection with reinsurance transactions, a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators.

The methodology and significant inputs used to determine the amount of credit loss are as follows:

The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities.

When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security, the likelihood that the issuer can service the interest and principal payments, the quality and amount of any credit enhancements, the security’s position within the capital structure of the issuer, possible corporate restructurings or asset sales by the issuer, any private and public sector programs to restructure foreign government securities and municipals, and changes to the rating of the security or the issuer by rating agencies.

Additional considerations are made when assessing the features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security.

With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments.

In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL may not be reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security.

Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position

Gross unrealized losses on securities without an ACL decreased $3.0 billion for the year ended December 31, 2025 to $28.1 billion primarily due to a decrease in interest rates.

As shown in the table above, most of the gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater at December 31, 2025 relate to investment grade securities. These unrealized losses are principally due to narrowing credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase.

As of December 31, 2025, $320 million of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater on below investment grade securities were concentrated in the consumer, transportation, and communications sectors within corporate securities and in foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty and, with respect to fixed-rate securities, rising interest rates since purchase.

At December 31, 2025, the Company did not intend to sell its securities in an unrealized loss position without an ACL, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Therefore, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at December 31, 2025.

Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation.

Rollforward of ACL for Fixed Maturity Securities AFS By Sector

The rollforward of ACL for fixed maturity securities AFS by sector is as follows:

U.S. CorporateForeignCorporateForeignGovernmentRMBSABS & CLOCMBSTotal
(In millions)
Balance at January 1, 2024$68$2$88$1$7$18$184
ACL not previously recorded4119————60
Changes for securities with previously recorded ACL9—(6)—249
Securities sold or exchanged(59)(3)(25)——(6)(93)
Balance at December 31, 20245918571916160
ACL not previously recorded1137—1110132
Changes for securities with previously recorded ACL44(2)——(1)1455
Securities sold or exchanged(78)(16)—(1)(3)—(98)
Balance at December 31, 2025$138$7$57$1$6$40$249

Equity Securities

The following table presents equity securities by security type:

December 31,
20252024
Security TypeCostNet UnrealizedGains (Losses) (1)EstimatedFair ValueCostNet UnrealizedGains (Losses) (1)EstimatedFair Value
(In millions)
Common stock (2)$498$246$744$451$167$618
Non-redeemable preferred stock106811493194
Total$604$254$858$544$168$712

(1)Represents cumulative changes in estimated fair value, recognized in earnings.

(2)Includes common stock, exchange traded funds, certain mutual funds and certain real estate investment trusts.

Contractholder-Directed Equity Securities and FVO Securities

The following table presents these investments by asset type:

December 31,
20252024
Asset TypeCost orAmortizedCostNet UnrealizedGains (Losses) (1)EstimatedFair ValueCost orAmortizedCostNet UnrealizedGains (Losses) (1)EstimatedFair Value
(In millions)
Contractholder-directed equity securities: (2)
Equity securities$3,164$855$4,019$2,928$595$3,523
Series mutual funds and other securities5,0891,6406,7294,4701,1045,574
Total contractholder-directed equity securities$8,253$2,495$10,748$7,398$1,699$9,097
FVO securities: (2)
Securities held by CFEs$1,283$—$1,283$—$—$—
General account and other securities1,1497791,9288866891,575
Total FVO securities:$2,432$779$3,211$886$689$1,575
Total$10,685$3,274$13,959$8,284$2,388$10,672

(1)Represents cumulative changes in estimated fair value, recognized in earnings.

(2)Amounts presented by asset type. Prior year amounts previously presented in the aggregate have been reclassified to conform to the current year presentation.

Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:

December 31,
20252024
Portfolio SegmentCarryingValue (1)% ofTotalCarryingValue (1)% ofTotal
(Dollars in millions)
Commercial$49,40058.4%$56,31063.3%
Agricultural19,55123.119,31321.7
Residential16,80019.914,18915.9
Total amortized cost85,751101.489,812100.9
ACL(1,193)(1.4)(800)(0.9)
Total mortgage loans held-for-investment84,558100.089,012100.0
Mortgage loans held-for-sale35———
Total mortgage loans$84,593100.0%$89,012100.0%

(1)Includes certain mortgage loans originated for third parties of $6.5 billion and $7.5 billion at amortized cost with the corresponding mortgage loan secured financing liability of $6.5 billion and $7.5 billion included in other liabilities on the consolidated balance sheet at December 31, 2025 and 2024, respectively.

The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($789) million and ($879) million at December 31, 2025 and 2024, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at December 31, 2025 was $172 million, $206 million and $140 million, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at December 31, 2024 was $249 million, $199 million and $117 million, respectively. The accrued interest income related to mortgage loans is included in accrued investment income on the consolidated balance sheets.

Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $4.1 billion, $2.2 billion and $1.5 billion for the years ended December 31, 2025, 2024 and 2023, respectively.

Sales of mortgage loans, consisting primarily of commercial mortgage loans, were $41 million, $168 million and $254 million for the years ended December 31, 2025, 2024 and 2023, respectively.

For the year ended December 31, 2025, the Company exchanged, as part of loan restructurings, commercial mortgage loans with an amortized cost of $175 million for equity interests in REJVs.

For the years ended December 31, 2025, 2024 and 2023, the Company contributed commercial mortgage loans with an amortized cost of $179 million, $218 million and $15 million, respectively, to REJVs which subsequently completed foreclosure on those mortgage loans.

For the year ended December 31, 2024, the Company acquired wholly-owned real estate by completing foreclosures on commercial mortgage loans with an amortized cost of $61 million.

Rollforward of ACL for Mortgage Loans by Portfolio Segment

The rollforward of ACL for mortgage loans, by portfolio segment, was as follows:

Years Ended December 31,
202520242023
CommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotal
(In millions)
Balance at January 1,$537$84$179$800$367$172$182$721$218$119$190$527
Provision (release)480399561419834(3)22916889(8)249
Charge-offs, net of recoveries(210)(8)(3)(221)(28)(122)—(150)(19)(36)—(55)
Balance at December 31,$807$115$271$1,193$537$84$179$800$367$172$182$721

The gross charge-offs of mortgage loans by origination year and portfolio segment for the year ended December 31, 2025 was as follows:

Portfolio Segment20252024202320222021PriorTotal
(In millions)
Commercial$—$—$—$—$—$210$210
Agricultural—————88
Residential——11—13
Total$—$—$1$1$—$219$221

ACL Methodology

The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses).

Commercial and Agricultural Mortgage Loan Portfolio Segments

Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. In its evaluation, the Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for such loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans.

Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans.

For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio.

For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated.

After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly.

Residential Mortgage Loan Portfolio Segment

The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year.

For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss.

Modifications to Borrowers Experiencing Financial Difficulty

The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications, in materially impacted mortgage segments, where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means: principal forgiveness, interest rate reduction, other-than- insignificant payment delay or maturity extension. The amount, timing and extent of modifications granted and subsequent performance are considered in determining any ACL recorded. All loans modified to borrowers experiencing financial difficulties are evaluated individually for credit loss as collateral dependent loans.

These mortgage loan modifications are summarized as follows:

Amortized Cost · Affected Loans (in Years)
Portfolio Segment · MaturityExtension · PaymentDelay · Total · Weighted Average Life Increase · Average YearsPayment Deferral · % of BookValue
(Dollars in millions)
Commercial$1,170$—$1,1704 Years—2.4%
Agricultural—186186—2 years<1%
Total$1,170$186$1,356
Amortized Cost · Affected Loans (in Years)
Portfolio SegmentMaturityExtension (1)PaymentDelayTotalWeighted Average Life Increase% of BookValue
(Dollars in millions)
Commercial$641$—$6412 years1.1%

(1)Includes commercial mortgage loans with an amortized cost of $206 million that received interest rate reductions from 7.6% to 6.5% in addition to maturity extensions.

For the years ended December 31, 2025 and 2024, all commercial mortgage loans modified to borrowers experiencing financial difficulties and still outstanding were current. For the year ended December 31, 2024, commercial mortgage loans with an amortized cost of $182 million, which were previously extended, became delinquent and foreclosed within 12 months of modification.

Credit Quality of Mortgage Loans by Portfolio Segment

The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2025:

Credit Quality Indicator20252024202320222021PriorRevolvingLoansTotal% ofTotal
(Dollars in millions)
LTV ratios:
Less than 65%$2,636$3,453$1,965$2,367$2,639$12,273$1,578$26,91154.5%
65% to 75%4025666482,2821,3162,461—7,67515.5
76% to 80%97—633622702,358—3,1506.4
Greater than 80%1871841057831,5338,872—11,66423.6
Total$3,322$4,203$2,781$5,794$5,758$25,964$1,578$49,400100.0%
DSCR:
> 1.20x$2,716$3,832$2,045$5,004$5,015$21,492$1,578$41,68284.4%
1.00x - 1.20x318114861604882,582—4,0458.2
<1.00x2883602506302551,890—3,6737.4
Total$3,322$4,203$2,781$5,794$5,758$25,964$1,578$49,400100.0%

The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2025:

Credit Quality Indicator20252024202320222021PriorRevolvingLoansTotal% ofTotal
(Dollars in millions)
LTV ratios:
Less than 65%$1,340$698$1,199$2,198$2,327$8,683$1,422$17,86791.4%
65% to 75%854777285258575731,4007.2
76% to 80%———223034590.3
Greater than 80%—12—148—51142251.1
Total$1,425$757$1,276$2,653$2,615$9,312$1,513$19,551100.0%

The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2025:

Credit Quality Indicator20252024202320222021PriorRevolvingLoansTotal% ofTotal
(Dollars in millions)
Performance indicators:
Performing$2,575$2,253$777$2,182$1,791$6,699$—$16,27796.9%
Nonperforming (1)956539040275—5233.1
Total$2,584$2,309$830$2,272$1,831$6,974$—$16,800100.0%

(1)Includes residential mortgage loans in process of foreclosure with an amortized cost of $186 million and $140 million at December 31, 2025 and 2024, respectively.

Past Due and Nonaccrual Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 98% of all mortgage loans classified as performing at both December 31, 2025 and 2024. The Company defines delinquency in a manner consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL by portfolio segment, were as follows:

December 31,
202520242025202420252024
Portfolio Segment · Past Due · Past Due and Still Accruing Interest · Nonaccrual
(In millions)
Commercial$682$773$3$—$1,915$1,123
Agricultural2523416626222589
Residential5234642318500446
Total$1,457$1,578$92$280$2,640$1,658

Real Estate and REJV

The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method REJV. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated:

December 31, · Years Ended December 31,
20252024202520242023
Income Type · Carrying Value · Income
(In millions)
Wholly-owned real estate:
Leased real estate$4,174$4,283$358$341$366
Other real estate710650364291297
REJV8,5568,409125(192)(225)
Total real estate and REJV$13,440$13,342$847$440$438

Depreciation expense on real estate investments was $117 million, $124 million and $112 million for the years ended December 31, 2025, 2024 and 2023, respectively. Real estate investments were net of accumulated depreciation of $1.1 billion and $1.0 billion at December 31, 2025 and 2024, respectively.

Leases

Leased Real Estate Investments - Operating Leases

The Company, as lessor, leases investment real estate, principally commercial real estate for office and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification, and geographic diversification. Leased real estate investments and income earned, by property type, were as follows at and for the periods indicated:

December 31, · Years Ended December 31,
20252024202520242023
Property Type · Carrying Value · Income
(In millions)
Leased real estate investments:
Office$2,271$2,138$222$206$228
Retail622766454547
Apartment511596474647
Land488522252424
Industrial199190141515
Hotel8371555
Total leased real estate investments$4,174$4,283$358$341$366

Future contractual receipts under operating leases at December 31, 2025 were $265 million in 2026, $213 million in 2027, $184 million in 2028, $157 million in 2029, $130 million in 2030, $883 million thereafter and, in total, were $1.8 billion.

Other invested assets is comprised primarily of freestanding derivatives with positive estimated fair values (see Note 12), COLI (see Note 1), direct financing and leveraged leases (see Note 1), annuities funding structured settlement claims (see Note 1), operating joint ventures (see Notes 1 and 25), FHLBNY common stock (see “— Invested Assets on Deposit, Held in Trust and Pledged as Collateral”) and tax credit and renewable energy partnerships (see Note 1).

Tax Equity Investments

The Company invests in certain tax equity investments, including low income housing tax credit partnerships and renewable energy partnerships. The carrying value of tax equity investments, reported in other invested assets on the consolidated balance sheets, was$676 million and $714 million at December 31, 2025 and 2024, respectively. For the years ended December 31, 2025 and 2024, income tax credits and other income tax benefits of$130 million and $149 million, respectively, and amortized expense of$117 million and $134 million, respectively, were recognized net as a component of income tax expense in the Company’s consolidated statement of operations.

Cash Equivalents

Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $11.5 billion and $11.9 billion, at estimated fair value, at December 31, 2025 and 2024, respectively.

Concentrations of Credit Risk

Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, were in fixed income securities of the following foreign governments and their agencies:

December 31,
20252024
(In millions)
Japan$16,265$18,886
South Korea$5,971$6,078
Mexico$4,190$3,468

Securities Lending Transactions and Repurchase Agreements

Securities, Collateral and Reinvestment Portfolio

Transactions and agreements accounted for as secured borrowings were as follows:

December 31,
2025 · 2024
Securities (1)Securities (1)
Agreement TypeEstimatedFair ValueCashCollateralReceived fromCounterparties (2)ReinvestmentPortfolio atEstimatedFair ValueEstimatedFair ValueCashCollateralReceived fromCounterparties (2)ReinvestmentPortfolio atEstimatedFair Value
(In millions)
Securities lending$11,866$12,198$12,082$11,119$11,404$11,202
Repurchase agreements$3,002$2,975$2,948$3,019$2,975$2,925

(1)These securities were included within fixed maturity securities AFS, short-term investments and cash equivalentsat December 31, 2025 and within fixed maturity securities AFS at December 31, 2024. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge these securities.

(2)The liability for cash collateral is included within payables for collateral under securities loaned and other transactions.

Contractual Maturities

Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows:

December 31,
2025 · 2024
Remaining MaturitiesRemaining Maturities
Cash collateral liability by security type:Open (1)1 Monthor LessOver 1 Month to 6 MonthsOver 6 Months to 1 YearTotalOpen (1)1 Monthor LessOver 1 Month to 6 MonthsOver 6 Months to 1 YearTotal
(In millions)
Securities lending:
U.S. government and agency$1,986$3,911$4,880$—$10,777$2,987$4,986$2,089$—$10,062
Foreign government—755355—1,110—677493—1,170
Agency RMBS—311——311—10864—172
Total$1,986$4,977$5,235$—$12,198$2,987$5,771$2,646$—$11,404
Repurchase agreements:
U.S. government and agency$—$2,975$—$—$2,975$—$2,975$—$—$2,975

(1)The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both.

The securities lending and repurchase agreement reinvestment portfolios consist principally of high quality, liquid, publicly traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities in the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential cash demands when securities are put back by the counterparty.

Invested Assets on Deposit, Held in Trust and Pledged as Collateral

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value and were as follows at:

December 31,
20252024
(In millions)
Invested assets on deposit (regulatory deposits)$1,396$1,515
Invested assets held in trust (external reinsurance agreements) (1)1,7751,255
Invested assets pledged as collateral (2)27,66327,125
Total invested assets on deposit, held in trust and pledged as collateral$30,834$29,895

(1)Represents assets held in trust related to assumed third-party reinsurance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $1.8 billion and $1.9 billion at December 31, 2025 and 2024, respectively.

(2)The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Note 5), derivative transactions (see Note 12), secured debt and short-term debt related to repurchase agreements (see Note 16), and a collateral financing arrangement (see Note 17).

See “— Securities Lending Transactions and Repurchase Agreements” for information regarding securities supporting securities lending transactions and repurchase agreements and Note 10 for information regarding investments designated to the closed block. In addition, the Company’s investment in FHLBNY common stock, included within other invested assets, which is considered restricted until redeemed by the issuer, was $700 million and $699 million, at redemption value, at December 31, 2025 and 2024, respectively.

At December 31, 2025, the Company maintained invested assets and cash and cash equivalents that are subject to ceded reinsurance arrangements with third parties and joint ventures of $22.4 billion, which included cash and cash equivalents of $1.2 billion.

Collectively Significant Equity Method Investments

The Company held equity method investments of $24.7 billion at December 31, 2025, comprised primarily of OLPI, REJV and real estate funds, tax equity and renewable energy partnerships and operating joint ventures. The Company’s maximum exposure to loss related to these equity method investments was limited to the carrying value of these investments plus $6.9 billion of unfunded commitments at December 31, 2025.

As described in Note 1, the Company generally recognizes its share of earnings in its equity method investments within net investment income using a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Aggregate net investment income from these equity method investments exceeded 10% of the Company’s consolidated pre-tax income (loss) for two of the three most recent annual periods: 2025 and 2024.

The following aggregated summarized financial data reflects the latest available financial information and does not represent the Company’s proportionate share of the assets, liabilities, or earnings of such entities. Aggregate total assets of these entities totaled $1.4 trillion and $1.3 trillion at December 31, 2025 and 2024, respectively. Aggregate total liabilities of these entities totaled $164.0 billion and $154.1 billion at December 31, 2025 and 2024, respectively. Aggregate net income (loss) of these entities totaled $99.4 billion, $63.7 billion and $32.8 billion for the years ended December 31, 2025, 2024 and 2023, respectively. Aggregate net income (loss) from the underlying entities in which the Company invests is primarily comprised of investment income, including recurring investment income (loss) and realized and unrealized investment gains (losses).

Variable Interest Entities

The Company has invested in legal entities that are VIEs. Legal entities are determined to be VIEs if (1) the equity investors lack (i) the ability to control the entity, (ii) the obligation to absorb losses or (iii) the rights to receive returns of the entity, or (2) the entity lacks sufficient equity to finance its activities without subordinated financial support provided by parties which are not equity holders.

For VIEs, the Company determines whether it is the primary beneficiary, which involves an evaluation of the purpose and design of the entity and whether, based on the design of the entity, the Company has both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE. Significant judgment is required in the primary beneficiary determination, which includes an evaluation of the substance of contractual arrangements and voting agreements, the rights of other investors in an entity and potential financial results of the entity.

The Company continuously assesses if facts or circumstances indicate that a potential change in the primary beneficiary has occurred. This could include new contractual arrangements of an entity or changes in the investors of an entity. As a result of changes in circumstances, the Company may consolidate or deconsolidate a VIE.

Consolidated VIEs

The Company is the asset manager of certain asset-backed securitization entities, primarily CLOs, for which the Company earns asset management fees. The Company may invest in securities issued by these entities. The Company is also the asset manager of certain investment fund structures in which the Company also invests.

The Company has analyzed its relationships with the CLOs and investment fund structures and determined that it is the primary beneficiary of these entities. This analysis includes a review of the rights and responsibilities as the asset manager, the rights of the investors in the entity, and the exposure of the Company to the potential losses and returns of the entity.

The assets of the VIEs may only be used to satisfy the liabilities of VIE. The Company is not required to, and has not provided material financial support, other than its investment in these VIEs.

The Company is also the primary beneficiary of certain investment funds and partnership entities in which the Company has invested but is not the asset manager.

The table below reflects the carrying amount and balance sheet classification in which the assets and liabilities of consolidated VIEs are reported. The liabilities primarily comprise debt instruments issued by the VIEs. The creditors of these VIEs do not have recourse to the Company in excess of the assets contained within the respective VIEs.

December 31,
2025202420252024
Asset Type · Consolidated VIEs for which the Company is the Asset Manager · Other Consolidated VIEs
(In millions)
FVO securities primarily held by CFEs$1,300$—$—$—
Contractholder-directed equity securities451———
Real estate and REJVs81—221183
Investment funds (1)490375——
Renewable energy partnership (1)——4549
Leases (1)25———
Cash and cash equivalents90368
Other2193465
Total assets of consolidated VIEs$2,458$387$306$305
Short-term debt$—$—$117$133
Long-term debt28———
Notes issued by CFEs1,206———
Other liabilities158397
Total liabilities of consolidated VIEs$1,392$3$126$140

(1)Included in other invested assets.

Unconsolidated VIEs

The Company has determined that it is not the primary beneficiary of certain VIEs because the Company does not have both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE.

The Company invests in structured products issued by CFEs or securitization entities that are VIEs which typically do not have substantial equity. Its investments in these structured products are fixed maturity securities investments and include mortgage-backed securities, and ABS & CLOs. The Company’s exposure to losses of these entities is limited to the amount of its investment, See“— Fixed Maturity Securities AFS”for details regarding amounts and classification of these assets.

The Company also invests in or provides loans to other legal entities that are VIEs. These primarily include hedge funds, private equity funds and similar entities that are classified within OLPIs, REJVs, other invested assets, fixed maturity securities, FVO securities and mortgage loans. The Company’s maximum exposure to loss for these VIEs is limited to the carrying value of the equity investment plus any unfunded capital commitments. The carrying value of these investments was $24.6 billion and $20.4 billion at December 31, 2025 and 2024, respectively, and the Company’s unfunded commitments were $6.2 billion and $4.7 billion at December 31, 2025 and 2024, respectively.

In connection with a certain reinsurance agreement, collateral securing the reinsurance agreement was transferred to trusts that do not have substantial equity. For managing these assets, MIM will recognize asset management fees which represent a variable interest. The Company’s maximum exposure to loss is limited to the asset management fee revenue that has been earned but not yet received.

The Company did not provide financial or other support that it was not contractually obligated to provide to entities designated as VIEs for the years ended December 31, 2025 or 2024.

Net Investment Income

The composition of net investment income by asset type was as follows:

Years Ended December 31,
Asset Type202520242023
(In millions)
Fixed maturity securities AFS (1)$14,559$13,598$12,990
Equity securities232332
FVO securities225205188
Mortgage loans (1)4,4664,7344,761
Policy loans449453471
Real estate and REJV847440438
OLPI (1)1,197965454
Cash, cash equivalents and short-term investments (1)9931,1221,011
Operating joint ventures17817538
Other505715604
Subtotal investment income23,44222,43020,987
Less: Investment expenses2,1002,2482,262
Subtotal, net21,34220,18218,725
Unit-linked investments1,2171,0911,183
Net investment income$22,559$21,273$19,908
Net Investment Income Information
Net realized and unrealized gains (losses) recognized in net investment income:
Net realized gains (losses) from sales and disposals (primarily FVO securities and Unit-linked investments)$357$270$207
Net unrealized gains (losses) from changes in estimated fair value (primarily FVO securities and Unit-linked investments)7839311,168
Net realized and unrealized gains (losses) recognized in net investment income$1,140$1,201$1,375
Changes in estimated fair value subsequent to purchase of FVO securities and Unit-linked investments still held at the end of the respective periods and recognized in net investment income$1,036$925$1,119
Equity method investments net investment income (primarily REJV, OLPI, tax credit and renewable energy partnerships and operating joint ventures)$1,554$988$151

(1)Includes net investment income related to invested assets and cash and cash equivalents that are subject to ceded reinsurance with third parties.

Net Investment Gains (Losses) by Asset Type and Transaction Type

The composition of net investment gains (losses) by asset type and transaction type was as follows:

Years Ended December 31,
Asset Type202520242023
(In millions)
Fixed maturity securities AFS (1)$(631)$(731)$(2,471)
Equity securities65(18)81
Mortgage loans (1)(676)(289)(270)
Real estate and REJV (excluding changes in estimated fair value)5924569
OLPI (excluding changes in estimated fair value) (2)24(55)12
Other gains (losses)(10)(3)(158)
Subtotal(1,169)(851)(2,737)
Change in estimated fair value of OLPI and REJV—4(6)
Non-investment portfolio gains (losses)24(337)(81)
Subtotal24(333)(87)
Net investment gains (losses)$(1,145)$(1,184)$(2,824)
Transaction Type
Realized gains (losses) on investments sold or disposed (1), (2)$(371)$(436)$(1,028)
Impairment (losses) (1)(180)(101)(1,498)
Recognized gains (losses):
Change in ACL recognized in earnings(708)(248)(271)
Unrealized net gains (losses) recognized in earnings90(62)54
Total recognized gains (losses)(618)(310)(217)
Non-investment portfolio gains (losses)24(337)(81)
Net investment gains (losses)$(1,145)$(1,184)$(2,824)
Net Investment Gains (Losses) Information
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)$62$(39)$22
Other gains (losses) include:
Gains (losses) on disposed investments which were previously in a qualified cash flow hedge relationship$(20)$(3)$(7)
Gains (losses) on leveraged leases and renewable energy partnerships$9$12$24
Foreign currency gains (losses)$156$(79)$52
Net Realized Investment Gains (Losses) From Sales and Disposals of Investments
Recognized in net investment gains (losses)$(371)$(436)$(1,028)
Recognized in net investment income357270207
Net realized investment gains (losses) from sales and disposals of investments$(14)$(166)$(821)

(1)Includes a net loss of $1.2 billion during the year ended December 31, 2023 for investments disposed of in connection with a reinsurance transaction. The net loss was comprised of ($1.3) billion of impairments and $95 million of realized gains on disposal for fixed maturity securities AFS, ($56) million of adjustments to mortgage loans, reflected as impairments (calculated at lower of amortized cost or estimated fair value), and ($2) million of realized losses on disposal for mortgage loans.

(2)Includes a net loss of $2 million and $46 million during the years ended December 31, 2025 and 2024, respectively, for private equity investments sold. For the years ended December 31, 2025 and 2024, the Company sold $43 million and $798 million, respectively, in portfolios of investments to a fund for proceeds of $41 million and $752 million, respectively, in cash and receivables secured by the value of the fund. The Company has entered into an agreement to serve as the asset manager of the fund for which it will receive a management fee.

Fixed Maturity Securities AFS and Equity Securities – Composition of Net Investment Gains (Losses)

The composition of net investment gains (losses) for these securities is as follows:

Years Ended December 31,
Fixed Maturity Securities AFS202520242023
(In millions)
Proceeds$29,702$28,690$40,625
Gross investment gains$413$489$563
Gross investment (losses)(950)(1,178)(1,732)
Realized gains (losses) on sales and disposals(537)(689)(1,169)
Net credit loss (provision) release (change in ACL recognized in earnings)(89)23(2)
Impairment (losses)(5)(65)(1,300)
Net credit loss (provision) release and impairment (losses)(94)(42)(1,302)
Net investment gains (losses)$(631)$(731)$(2,471)
Equity Securities
Realized gains (losses) on sales and disposals$(24)$47$21
Unrealized net gains (losses) recognized in earnings89(65)60
Net investment gains (losses)$65$(18)$81
  1. Derivatives

Accounting for Derivatives

See Note 1 for a description of the Company’s accounting policies for derivatives and Note 13 for information about the fair value hierarchy for derivatives.

Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives.

Derivatives are financial instruments with values derived from interest rates, foreign currency exchange rates, credit spreads and/or other financial indices. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The types of derivatives the Company uses include swaps, forwards, futures and option contracts. To a lesser extent, the Company uses credit default swaps and structured interest rate swaps to synthetically replicate investment risks and returns which are not readily available in the cash markets.

Interest Rate Derivatives

The Company uses a variety of interest rate derivatives to reduce its exposure to changes in interest rates, including interest rate swaps, interest rate total return swaps, caps, floors, swaptions, futures and forwards.

Interest rate swaps are used by the Company primarily to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). In an interest rate swap, the Company agrees with another party to exchange, at specified intervals, the difference between fixed rate and floating rate interest amounts as calculated by reference to an agreed notional amount. The Company utilizes interest rate swaps in fair value, cash flow and nonqualifying hedging relationships.

The Company uses structured interest rate swaps to synthetically create investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and a cash instrument such as a U.S. government and agency, or other fixed maturity securities AFS. Structured interest rate swaps are included in interest rate swaps and are not designated as hedging instruments.

Interest rate total return swaps are swaps whereby the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and a benchmark interest rate, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. These transactions are entered into pursuant to master agreements that provide for a single net payment to be made by the counterparty at each due date. Interest rate total return swaps are used by the Company to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). The Company utilizes interest rate total return swaps in nonqualifying hedging relationships.

The Company purchases interest rate caps primarily to protect its floating rate liabilities against rises in interest rates above a specified level, and against interest rate exposure arising from mismatches between assets and liabilities, and interest rate floors primarily to protect its minimum rate guarantee liabilities against declines in interest rates below a specified level. In certain instances, the Company locks in the economic impact of existing purchased caps and floors by entering into offsetting written caps and floors. The Company utilizes interest rate caps and floors in nonqualifying hedging relationships.

In exchange-traded interest rate (Treasury and swap) futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of interest rate securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded interest rate (Treasury and swap) futures are used primarily to hedge (i) mismatches between the duration of assets in a portfolio and the duration of liabilities supported by those assets, (ii) against changes in value of securities the Company owns or anticipates acquiring, (iii) against changes in interest rates on anticipated liability issuances by replicating Treasury or swap curve performance, and (iv) minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded interest rate futures in nonqualifying hedging relationships.

Swaptions are used by the Company to hedge interest rate risk associated with the Company’s long-term liabilities and invested assets. A swaption is an option to enter into a swap with a forward starting effective date. In certain instances, the Company locks in the economic impact of existing purchased swaptions by entering into offsetting written swaptions. The Company pays a premium for purchased swaptions and receives a premium for written swaptions. In certain instances, the Company may enter into a combination of transactions to hedge changes in interest rates within a pre-determined range through the purchase and sale of options. The Company utilizes swaptions in nonqualifying hedging relationships. Swaptions are included in interest rate options.

The Company enters into interest rate forwards to buy and sell securities. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. The Company utilizes interest rate forwards in cash flow and nonqualifying hedging relationships.

Synthetic GICs are contracts that simulate the performance of traditional GICs through the use of financial instruments. The contractholder owns the underlying assets, and the Company provides a guarantee (or “wrap”) on the participant funds for an annual risk charge. The Company’s maximum exposure to loss on synthetic GICs is the notional amount, in the event the values of all of the underlying assets were reduced to zero. The Company’s risk is substantially lower due to contractual provisions that limit the portfolio to high quality assets, which are pre-approved and monitored for compliance, as well as the collection of risk charges. In addition, the crediting rates reset periodically to amortize market value gains and losses over a period equal to the duration of the wrapped portfolio, subject to a 0% floor. While plan participants may transact at book value, contractholder withdrawals may only occur immediately at market value, or at book value paid over a period of time per contract provisions. Synthetic GICs are not designated as hedging instruments.

Foreign Currency Exchange Rate Derivatives

The Company uses foreign currency exchange rate derivatives, including foreign currency swaps, foreign currency forwards, currency options and exchange-traded currency futures, to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets and liabilities denominated in foreign currencies. The Company also uses foreign currency derivatives to hedge the foreign currency exchange rate risk associated with certain of its net investments in foreign operations.

In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company utilizes foreign currency swaps in fair value, cash flow and nonqualifying hedging relationships.

In a foreign currency forward transaction, the Company agrees with another party to deliver a specified amount of an identified currency at a specified future date. The price is agreed upon at the time of the contract and payment for such a contract is made at the specified future date. The Company utilizes foreign currency forwards in fair value, NIFO hedges and nonqualifying hedging relationships.

The Company enters into currency options that give it the right, but not the obligation, to sell the foreign currency amount in exchange for a functional currency amount within a limited time at a contracted price. The contracts may also be net settled in cash, based on differentials in the foreign currency exchange rate and the strike price. The Company uses currency options to hedge against the foreign currency exposure inherent in certain of its variable annuity products. The Company also uses currency options as an economic hedge of foreign currency exposure related to the Company’s non-U.S. subsidiaries. The Company utilizes currency options in NIFO hedges.

To a lesser extent, the Company uses exchange-traded currency futures to hedge currency mismatches between assets and liabilities, and to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded currency futures in nonqualifying hedging relationships.

Credit Derivatives

The Company enters into purchased credit default swaps to hedge against credit-related changes in the value of its investments. In a credit default swap transaction, the Company agrees with another party to pay, at specified intervals, a premium to hedge credit risk. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the delivery of par quantities of the referenced investment equal to the specified swap notional amount in exchange for the payment of cash amounts by the counterparty equal to the par value of the investment surrendered. Credit events vary by type of issuer but typically include bankruptcy, failure to pay debt obligations and involuntary restructuring for corporate obligors, as well as repudiation, moratorium or governmental intervention for sovereign obligors. In each case, payout on a credit default swap is triggered only after the relevant third party, Credit Derivatives Determinations Committee determines that a credit event has occurred. The Company utilizes credit default swaps in nonqualifying hedging relationships.

The Company enters into written credit default swaps to synthetically create credit investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and one or more cash instruments, such as U.S. government and agency, or other fixed maturity securities AFS. These credit default swaps are not designated as hedging instruments.

The Company enters into forwards to lock in the price to be paid for forward purchases of certain securities. The price is agreed upon at the time of the contract and payment for the contract is made at a specified future date. When the primary purpose of entering into these transactions is to hedge against the risk of changes in purchase price due to changes in credit spreads, the Company designates these transactions as credit forwards. The Company utilizes credit forwards in cash flow hedging relationships.

Equity Derivatives

The Company uses a variety of equity derivatives to reduce its exposure to equity market risk, including equity index options, equity variance swaps, exchange-traded equity futures and equity total return swaps.

Equity index options are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. To hedge against changes in equity indices, the Company enters into contracts to sell the underlying equity index within a limited time at a contracted price. The contracts will be net settled in cash based on differentials in the indices at the time of exercise and the strike price. Certain of these contracts may also contain settlement provisions linked to interest rates. In certain instances, the Company may enter into a combination of transactions to hedge changes in equity indices within a pre-determined range through the purchase and sale of options. The Company utilizes equity index options in nonqualifying hedging relationships.

Equity variance swaps are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. In an equity variance swap, the Company agrees with another party to exchange amounts in the future, based on changes in equity volatility over a defined period. The Company utilizes equity variance swaps in nonqualifying hedging relationships.

In exchange-traded equity futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of equity securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded equity futures are used primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded equity futures in nonqualifying hedging relationships.

In an equity total return swap, the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and a benchmark interest rate, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. The Company uses equity total return swaps to hedge its equity market guarantees in certain of its insurance products. Equity total return swaps can be used as hedges or to synthetically create investments. The Company utilizes equity total return swaps in nonqualifying hedging relationships.

Other Derivatives

Longevity swaps are used by the Company primarily to mitigate risks associated with life expectancy and unanticipated changes in mortality rates. The Company utilizes longevity swaps in nonqualifying hedging relationships.

Primary Risks Managed by Derivatives

The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at:

Primary Underlying Risk Exposure · December 31,
2025 · 2024
Estimated Fair Value · Estimated Fair Value
GrossNotionalAmount · Assets · Liabilities · GrossNotionalAmount · Assets · Liabilities
(In millions)
Derivatives Designated as Hedging Instruments:
Fair value hedges:
Interest rate swapsInterest rate$4,924$923$706$5,188$1,018$666
Foreign currency swapsForeign currency exchange rate1,60733221,4543367
Foreign currency forwardsForeign currency exchange rate———150—41
Subtotal6,5319567286,7921,051774
Cash flow hedges:
Interest rate swapsInterest rate4,002—2674,154—359
Interest rate forwardsInterest rate4,389161,0494,90156880
Foreign currency swapsForeign currency exchange rate47,0972,3582,18445,8792,8581,877
Subtotal55,4882,3743,50054,9342,9143,116
NIFO hedges:
Foreign currency forwardsForeign currency exchange rate1,05232101,55342—
Currency optionsForeign currency exchange rate3,000264—3,000536—
Subtotal4,052296104,553578—
Total qualifying hedges66,0713,6264,23866,2794,5433,890
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate swapsInterest rate24,6231,4091,43429,2381,4141,263
Interest rate floorsInterest rate5,64034—6,16938—
Interest rate capsInterest rate14,89848117,9981331
Interest rate futuresInterest rate1,679131,66711
Interest rate optionsInterest rate23,82015513034,939210217
Interest rate forwardsInterest rate2,731161763,12813577
Synthetic GICsInterest rate52,664——49,599——
Foreign currency swapsForeign currency exchange rate10,2101,16717510,7081,192190
Foreign currency forwardsForeign currency exchange rate15,694851,01213,471471,277
Currency futuresForeign currency exchange rate292—13011—
Credit default swaps — purchasedCredit2,7392582,7911467
Credit default swaps — writtenCredit8,873153111,7642015
Equity futuresEquity market1,380521,84096
Equity index optionsEquity market16,25333728112,743233253
Equity variance swapsEquity market96—2114—3
Equity total return swapsEquity market2,4137341,799419
Longevity swapsLongevity1,000——1,000——
Total non-designated or nonqualifying derivatives185,0053,4193,310199,2693,6693,369
Total$251,076$7,045$7,548$265,548$8,212$7,259

Included in the table above, the Company uses various OTC and exchange traded derivatives to hedge variable annuity guarantees. The table below presents the gross notional amount, estimated fair value and primary underlying risk exposure of the derivatives hedging variable annuity guarantees accounted for as MRBs:

December 31, 2025 · December 31, 2024
Primary Underlying Risk ExposureEstimated Fair ValueEstimated Fair Value
GrossNotionalAmountAssetsLiabilitiesGrossNotionalAmountAssetsLiabilities
(In millions)
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate$8,450$10$524$8,913$11$768
Foreign currency exchange rate32829378—2
Equity market2,8441521044,294132113
$11,622$164$637$13,585$143$883

The change in estimated fair values and earned income of derivatives hedging variable annuity guarantees, recorded in net derivative gains (losses), was ($294) million and ($476) million for the years ended December 31, 2025 and 2024, respectively.

Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at either December 31, 2025 or 2024. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.

The Effects of Derivatives on the Consolidated Statements of Operations and Comprehensive Income (Loss)

The following table presents the consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, NIFO, nonqualifying hedging relationships and embedded derivatives:

NetInvestmentIncomeNetInvestmentGains(Losses)NetDerivativeGains(Losses)PolicyholderBenefits andClaimsInterestCredited toPABsOtherExpensesOCI
(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$(1)$—N/A$41$43$—N/A
Hedged items1—N/A(60)(42)—N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)(17)9N/A—125—N/A
Hedged items14(7)N/A—(126)—N/A
Amount excluded from the assessment of hedge effectiveness—(6)N/A———(24)
Subtotal(3)(4)N/A(19)——(24)
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A$(237)
Amount of gains (losses) reclassified from AOCI into income29(21)————(8)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A(819)
Amount of gains (losses) reclassified from AOCI into income51,352————(1,357)
Foreign currency transaction gains (losses) on hedged items—(1,350)—————
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A—
Amount of gains (losses) reclassified from AOCI into income—1————(1)
Subtotal34(18)————(2,422)
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)N/A—N/AN/AN/AN/A62
Non-derivative hedging instrumentsN/AN/AN/AN/AN/AN/A(1)
SubtotalN/A—N/AN/AN/AN/A61
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)—N/A(730)N/AN/AN/AN/A
Foreign currency exchange rate derivatives (1)—N/A(698)N/AN/AN/AN/A
Credit derivatives — purchased (1)—N/A(17)N/AN/AN/AN/A
Credit derivatives — written (1)—N/A24N/AN/AN/AN/A
Equity derivatives (1)(40)N/A(1,000)N/AN/AN/AN/A
Foreign currency transaction gains (losses) on hedged items—N/A220N/AN/AN/AN/A
Subtotal(40)N/A(2,201)N/AN/AN/AN/A
Earned income on derivatives145—4308(152)——
Synthetic GICsN/AN/A81N/AN/AN/AN/A
Embedded derivatives — ceded reinsuranceN/AN/A(248)N/AN/AN/AN/A
Embedded derivatives — otherN/AN/A(1)N/AN/AN/AN/A
Total$136$(22)$(1,939)$(11)$(152)$—$(2,385)
NetInvestmentIncomeNetInvestmentGains(Losses)NetDerivativeGains(Losses)PolicyholderBenefits andClaimsInterestCredited toPABsOtherExpensesOCI
(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$—$—N/A$(176)$(59)$—N/A
Hedged items——N/A15054—N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)2(44)N/A—(90)—N/A
Hedged items(1)32N/A—90—N/A
Amount excluded from the assessment of hedge effectiveness—(6)N/A———N/A
Subtotal1(18)N/A(26)(5)—N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A$(474)
Amount of gains (losses) reclassified from AOCI into income33(5)————(28)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A(95)
Amount of gains (losses) reclassified from AOCI into income4(794)———1789
Foreign currency transaction gains (losses) on hedged items—789—————
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A—
Amount of gains (losses) reclassified from AOCI into income—1————(1)
Subtotal37(9)———1191
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)N/A—N/AN/AN/AN/A395
Non-derivative hedging instrumentsN/AN/AN/AN/AN/AN/A31
SubtotalN/A—N/AN/AN/AN/A426
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)—N/A(794)N/AN/AN/AN/A
Foreign currency exchange rate derivatives (1)—N/A(1,328)N/AN/AN/AN/A
Credit derivatives — purchased (1)—N/A3N/AN/AN/AN/A
Credit derivatives — written (1)—N/A47N/AN/AN/AN/A
Equity derivatives (1)(56)N/A(519)N/AN/AN/AN/A
Foreign currency transaction gains (losses) on hedged items—N/A177N/AN/AN/AN/A
Subtotal(56)N/A(2,414)N/AN/AN/AN/A
Earned income on derivatives196—629(11)(180)——
Synthetic GICsN/AN/A76N/AN/AN/AN/A
Embedded derivatives — ceded reinsuranceN/AN/A110N/AN/AN/AN/A
Embedded derivatives — otherN/AN/A(24)N/AN/AN/AN/A
Total$178$(27)$(1,623)$(37)$(185)$1$617
NetInvestmentIncomeNetInvestmentGains(Losses)NetDerivativeGains(Losses)PolicyholderBenefits andClaimsInterestCredited toPABsOtherExpensesOCI
(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$(3)$—N/A$—$29$—N/A
Hedged items3—N/A(26)(31)—N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)(39)(41)N/A—20—N/A
Hedged items3833N/A—(24)—N/A
Amount excluded from the assessment of hedge effectiveness—(20)N/A———N/A
Subtotal(1)(28)N/A(26)(6)—N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A$109
Amount of gains (losses) reclassified from AOCI into income5090————(140)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A(1,215)
Amount of gains (losses) reclassified from AOCI into income4558———2(564)
Foreign currency transaction gains (losses) on hedged items—(547)—————
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/AN/A—
Amount of gains (losses) reclassified from AOCI into income—1————(1)
Subtotal54102———2(1,811)
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)N/A5N/AN/AN/AN/A226
Non-derivative hedging instrumentsN/AN/AN/AN/AN/AN/A20
SubtotalN/A5N/AN/AN/AN/A246
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)—N/A(979)N/AN/AN/AN/A
Foreign currency exchange rate derivatives (1)—N/A(1,443)N/AN/AN/AN/A
Credit derivatives — purchased (1)—N/A(17)N/AN/AN/AN/A
Credit derivatives — written (1)—N/A135N/AN/AN/AN/A
Equity derivatives (1)(52)N/A(1,296)N/AN/AN/AN/A
Foreign currency transaction gains (losses) on hedged items—N/A366N/AN/AN/AN/A
Subtotal(52)N/A(3,234)N/AN/AN/AN/A
Earned income on derivatives178—1,0554(149)——
Synthetic GICsN/AN/A75N/AN/AN/AN/A
Embedded derivativesN/AN/A(36)N/AN/AN/AN/A
Total$179$79$(2,140)$(22)$(155)$2$(1,565)

(1)Excludes earned income on derivatives.

Fair Value Hedges

The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments.

The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges:

Balance Sheet Line ItemCarrying Amount of the HedgedAssets/(Liabilities)Cumulative Amountof Fair Value Hedging AdjustmentsIncluded in the Carrying Amount of HedgedAssets/(Liabilities) (1)
December 31, 2025December 31, 2024December 31, 2025December 31, 2024
(In millions)
Fixed maturity securities AFS$658$241$—$—
Mortgage loans$51$130$—$(1)
FPBs$(2,509)$(2,583)$319$359
PABs$(2,559)$(2,170)$(9)$223

(1)Includes($67) million and ($91) million of hedging adjustments on discontinued hedging relationships at December 31, 2025 and 2024, respectively.

For the Company’s foreign currency forwards, changes in estimated fair value attributable to the difference between spot price and forward price are excluded from hedge effectiveness testing and are recognized in earnings. For certain foreign currency swaps, changes in estimated fair value related to cross-currency basis spreads are excluded from the effectiveness assessment and recorded in OCI. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

Cash Flow Hedges

The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed rate investments.

In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $5 million,$4 million and $31 million for the years ended December 31, 2025, 2024 and 2023, respectively.

At December 31, 2025 and 2024, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed three years andfive years, respectively.

At December 31, 2025 and 2024, the balance in AOCI associated with cash flow hedges was ($2.1) billion and $357 million, respectively.

All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

At December 31, 2025, the Company expected to reclassify ($150) million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.

NIFO Hedges

The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its NIFO against adverse movements in exchange rates. The Company also designates a portion of its foreign-denominated debt as a non-derivative hedging instrument of its NIFO. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates and assesses its non-derivative hedging instruments based upon the change in spot rates. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

When NIFOs are sold or substantially liquidated, the amounts in AOCI are reclassified to the statement of operations.

At December 31, 2025 and 2024, the cumulative foreign currency translation gain (loss) recorded in AOCI related to NIFO hedges was $1.2 billion and $1.1 billion, respectively. At December 31, 2025 and 2024, the carrying amount of debt designated as a non-derivative hedging instrument was $268 million and $267 million, respectively.

See Note 16 for additional information on foreign-denominated debt.

Credit Derivatives

In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps.

The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:

December 31,
20252024
Rating Agency Designation of ReferencedCredit Obligations (1)EstimatedFair Valueof CreditDefaultSwapsMaximumAmount ofFuturePayments underCredit DefaultSwapsWeightedAverageYears toMaturity (2)EstimatedFair Valueof CreditDefaultSwapsMaximumAmount ofFuturePayments underCredit DefaultSwapsWeightedAverageYears toMaturity (2)
(Dollars in millions)
Aaa/Aa/A
Single name credit default swaps (3)$1$592.5$1$721.9
Credit default swaps referencing indices443,7771.4724,1262.2
Subtotal453,8361.4734,1982.2
Baa
Single name credit default swaps (3)1463.811021.6
Credit default swaps referencing indices954,8074.61117,2634.1
Subtotal964,8534.61127,3654.1
Ba
Single name credit default swaps (3)——0.0—171.1
Credit default swaps referencing indices1241.02252.0
Subtotal1241.02421.6
B
Single name credit default swaps (3)—160.6——0.0
Credit default swaps referencing indices101293.0101443.7
Subtotal101452.7101443.7
Caa
Credit default swaps referencing indices—151.0(1)152.0
Subtotal—151.0(1)152.0
Total$152$8,8733.2$196$11,7643.4

(1)The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service, Inc. (“Moody’s”), S&P and Fitch Ratings Inc. If no rating is available from a rating agency, then an internally developed rating is used.

(2)The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.

(3)Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.

Credit Risk on Freestanding Derivatives

The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.

The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians.

The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives.

See Note 13 for a description of the impact of credit risk on the valuation of derivatives.

The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:

December 31,
20252024
Derivatives Subject to a Master Netting Arrangement or a Similar ArrangementAssetsLiabilitiesAssetsLiabilities
(In millions)
Gross estimated fair value of derivatives:
OTC-bilateral (1)$7,053$6,972$8,224$6,966
OTC-cleared (1)119569135299
Exchange-traded66117
Total gross estimated fair value of derivatives presented on the consolidated balance sheets (1)7,1787,5478,3707,272
Gross amounts not offset on the consolidated balance sheets:
Gross estimated fair value of derivatives: (2)
OTC-bilateral(3,015)(3,015)(3,633)(3,633)
OTC-cleared(7)(7)(5)(5)
Exchange-traded——(1)(1)
Cash collateral: (3), (4)
OTC-bilateral(1,808)—(2,597)—
OTC-cleared(105)(555)(126)(289)
Exchange-traded—(1)—(6)
Securities collateral: (5)
OTC-bilateral(2,211)(3,945)(1,955)(3,325)
OTC-cleared—(6)—(4)
Exchange-traded—(5)——
Net amount after application of master netting agreements and collateral$32$13$53$9

(1)At December 31, 2025 and 2024, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $133 million and $158 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of ($1) million and $13 million, respectively.

(2)Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.

(3)Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives.

(4)The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At December 31, 2025 and 2024, the Company received excess cash collateral of $29 million and $26 million, respectively, and provided excess cash collateral of $68 million and $86 million, respectively, which is not included in the table above due to the foregoing limitation.

(5)Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at December 31, 2025, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At December 31, 2025 and 2024, the Company received excess securities collateral with an estimated fair value of $381 million and $410 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At December 31, 2025 and 2024, the Company provided excess securities collateral with an estimated fair value of $1.3 billion and $1.2 billion, respectively, for its OTC-bilateral derivatives, $751 million and $835 million, respectively, for its OTC-cleared derivatives, and $215 million and $148 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.

The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. A small number of these arrangements also contain credit-contingent provisions that include a threshold below which collateral does not need to be posted. Such agreements provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the financial strength or credit ratings of the Company and/or the counterparty (or its guarantor, as applicable). At December 31, 2025, the amount of collateral not provided by the Company due to the existence of these thresholds was $15 million.

The Company’s netting agreements for derivatives generally contain provisions that require the counterparty (or its guarantor, if applicable) to maintain specified minimum credit ratings above investment grade level from Moody’s, S&P or both. In those agreements, if the credit rating of the counterparty (or its guarantor, if applicable) were to fall below the applicable minimum rating, that counterparty would be in violation of these provisions, and the Company could terminate the transactions and demand immediate settlement and payment based on reasonable valuation of the derivatives. A significant portion of the Company’s netting agreements for derivatives grant similar rights to the counterparty to terminate the transactions and demand immediate settlement and payment if the Company’s financial strength or credit rating were to fall below specified minimum levels above investment grade.

The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.

December 31,
20252024
Derivatives Subject to Credit-Contingent ProvisionsDerivatives Not Subject to Credit-Contingent ProvisionsTotalDerivatives Subject to Credit-Contingent ProvisionsDerivatives Not Subject to Credit-Contingent ProvisionsTotal
(In millions)
Estimated fair value of derivatives in a net liability position$3,946$11$3,957$3,213$120$3,333
Estimated fair value of collateral provided:
Fixed maturity securities AFS$4,661$11$4,672$3,829$124$3,953

The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives.

The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:

December 31,
Balance Sheet Location · 2025 · 2024
(In millions)
Embedded derivatives within liability host contracts:
Funds withheld on ceded reinsurance (1)Other liabilities$(10)$(163)
Fixed annuities with equity indexed returnsPABs67172
Total$57$9

(1)Includes $81 million at December 31, 2025 related to Chariot Re. See Note 25 for additional related party transactions.

  1. Fair Value

When developing estimated fair values, the Company considers three broad valuation approaches: (i) the market approach, (ii) the income approach, and (iii) the cost approach. The Company determines the most appropriate valuation approach to use, given what is being measured and the availability of sufficient inputs, giving priority to observable inputs. The Company categorizes its assets and liabilities measured at estimated fair value into a three-level hierarchy, based on the significant input with the lowest level in its valuation. The input levels are as follows:

Level 1Unadjusted quoted prices in active markets for identical assets or liabilities. The Company defines active markets based on average trading volume for equity securities. The size of the bid/ask spread is used as an indicator of market activity for fixed maturity securities AFS.
Level 2Quoted prices in markets that are not active or inputs that are observable either directly or indirectly. These inputs can include quoted prices for similar assets or liabilities other than quoted prices in Level 1, quoted prices in markets that are not active, or other significant inputs that are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3Unobservable inputs that are supported by little or no market activity and are significant to the determination of estimated fair value of the assets or liabilities. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.

Financial markets are susceptible to severe events evidenced by rapid depreciation in asset values accompanied by a reduction in asset liquidity. The Company’s ability to sell securities, as well as the price ultimately realized for these securities, depends upon the demand and liquidity in the market and increases the use of judgment in determining the estimated fair value of certain securities.

Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.

Recurring Fair Value Measurements

The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:

Fair Value Hierarchy
Level 1Level 2Level 3Total EstimatedFair Value
(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate$—$74,437$13,522$87,959
Foreign corporate—43,76116,82860,589
RMBS—43,4911,92745,418
Foreign government—40,6965240,748
U.S. government and agency18,73218,790—37,522
ABS & CLO—21,7471,15022,897
Municipals—11,063111,064
CMBS—9,3184169,734
Total fixed maturity securities AFS18,732263,30333,896315,931
Equity securities46477317858
Contractholder-directed equity securities and FVO securities:
Contractholder-directed equity securities7,9832,57119410,748
FVO securities6231,3231,2653,211
Total contractholder-directed equity securities and FVO securities:8,6063,8941,45913,959
Short-term investments (1)2,761537423,340
Other investments46—1,1371,183
Derivative assets: (2)
Interest rate12,601—2,602
Foreign currency exchange rate—3,905343,939
Credit—155—155
Equity market5344—349
Total derivative assets67,005347,045
MRBs——458458
Reinsured MRBs (3)——293293
Separate account assets (4)77,48873,554891151,933
Total assets (5)$108,103$348,370$38,527$495,000
Liabilities
Derivative liabilities: (2)
Interest rate$3$3,763$—$3,766
Foreign currency exchange rate13,403—3,404
Credit—59—59
Equity market23161319
Total derivative liabilities67,54117,548
Embedded derivatives within liability host contracts (6)——5757
Notes issued by CFEs——1,2061,206
MRBs——2,4062,406
Total liabilities$6$7,541$3,670$11,217
Fair Value Hierarchy
Level 1Level 2Level 3Total EstimatedFair Value
(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate$—$67,333$12,041$79,374
Foreign corporate—39,29514,46453,759
RMBS—32,7711,65034,421
Foreign government—40,2094140,250
U.S. government and agency16,67516,753—33,428
ABS & CLO—14,7555,83620,591
Municipals—9,86679,873
CMBS—8,1941,1539,347
Total fixed maturity securities AFS16,675229,17635,192281,043
Equity securities41561236712
Contractholder-directed equity securities and FVO securities:
Contractholder-directed equity securities6,8052,1351579,097
FVO securities501411,0331,575
Total contractholder-directed equity securities and FVO securities:7,3062,1761,19010,672
Short-term investments (1)4,12770254,834
Other investments37631,0101,110
Derivative assets: (2)
Interest rate13,004—3,005
Foreign currency exchange rate14,694144,709
Credit—215—215
Equity market92713283
Total derivative assets118,184178,212
MRBs——372372
Reinsured MRBs (3)——1212
Separate account assets (4)63,97974,535990139,504
Total assets (5)$92,550$314,897$39,024$446,471
Liabilities
Derivative liabilities: (2)
Interest rate$1$3,463$—$3,464
Foreign currency exchange rate—3,440123,452
Credit—72—72
Equity market6265—271
Total derivative liabilities77,240127,259
Embedded derivatives within liability host contracts (6)——99
Notes issued by CFEs————
MRBs——2,5812,581
Total liabilities$7$7,240$2,602$9,849

(1)Short-term investments as presented in the tables above differ from the amounts presented on the consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis.

(2)Derivative assets are presented within other invested assets on the consolidated balance sheets and derivative liabilities are presented within other liabilities on the consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.

(3)Reinsured MRBs are presented within premiums, reinsurance and other receivables on the consolidated balance sheets.

(4)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities.

(5)Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $41 million and $50 million at December 31, 2025 and 2024, respectively.

(6)Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the consolidated balance sheets.

The following describes the valuation methodologies used to measure assets and liabilities at fair value.

Securities, Short-term Investments and Other Investments

When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment.

When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments.

The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.

InstrumentLevel 2Observable InputsLevel 3Unobservable Inputs
Fixed maturity securities AFS
U.S. corporate and Foreign corporate securities
Valuation Approaches: Principally the market and income approaches.Valuation Approaches: Principally the market approach.
Key Inputs:Key Inputs:
•quoted prices in markets that are not active•illiquidity premium
•benchmark yields; spreads off benchmark yields; new issuances; issuer ratings•delta spread adjustments to reflect specific credit-related issues
•trades of identical or comparable securities; duration•credit spreads
•privately placed securities are valued using the additional key inputs:•quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
•market yield curve; call provisions
•observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer•independent non-binding broker quotations
•delta spread adjustments to reflect specific credit-related issues
Foreign government securities, U.S. government and agency securities and Municipals
Valuation Approaches: Principally the market approach.Valuation Approaches: Principally the market approach.
Key Inputs:Key Inputs:
•quoted prices in markets that are not active•independent non-binding broker quotations
•benchmark U.S. Treasury yield or other yields•quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
•the spread off the U.S. Treasury yield curve for the identical security
•issuer ratings and issuer spreads; broker-dealer quotations•credit spreads
•comparable securities that are actively traded
Structured Products
Valuation Approaches: Principally the market and income approaches.Valuation Approaches: Principally the market and income approaches.
Key Inputs:Key Inputs:
•quoted prices in markets that are not active•credit spreads
•spreads for actively traded securities; spreads off benchmark yields•quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
•expected prepayment speeds and volumes
•current and forecasted loss severity; ratings; geographic region•independent non-binding broker quotations
•weighted average coupon and weighted average maturity•credit ratings
•average delinquency rates; DSCR
•credit ratings
•issuance-specific information, including, but not limited to:
•collateral type; structure of the security; vintage of the loans
•payment terms of the underlying assets
•payment priority within the tranche; deal performance
InstrumentLevel 2Observable InputsLevel 3Unobservable Inputs
Equity securities
Valuation Approaches: Principally the market approach.Valuation Approaches: Principally the market and income approaches.
Key Input:Key Inputs:
•quoted prices in markets that are not considered active•credit ratings; issuance structures
•quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
•independent non-binding broker quotations
Contractholder-directed equity and FVO securities, Short-term investments and Other investments
Valuation Approaches: Principally the market and income approaches.Valuation Approaches: Principally the market and income approaches.
Key Inputs:Key Inputs:
•Contractholder-directed equity and FVO securities include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported NAV provided by the fund managers, which were based on observable inputs.•Contractholder-directed equity and FVO securities, short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments also include certain REJV and use the valuation approach and key inputs as described for OLPI below.
•Short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above.
Separate account assets and Separate account liabilities (1)
Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly
Key Input:•N/A
•quoted prices or reported NAV provided by the fund managers
OLPI
•N/AValued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate.
Key Input:
•NAV

(1)Estimated fair value equals carrying value, based on the value of the underlying assets, including mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, OLPI, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”

The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.

The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives.

Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.

The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by the counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.

Level 2 Valuation Approaches and Key Inputs:

This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.

Level 3 Valuation Approaches and Key Inputs:

These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.

Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:

InstrumentInterest RateForeign CurrencyExchange RateCreditEquity Market
Inputs common to Level 2 and Level 3 by instrument type•swap yield curves•swap yield curves•swap yield curves•swap yield curves
•basis curves•basis curves•credit curves•spot equity index levels
•interest rate volatility (1)•currency spot rates•recovery rates•dividend yield curves
•cross currency basis curves•equity volatility (1)
•currency volatility (1)
Level 3•N/A•swap yield curves (2)•N/A•dividend yield curves (2)
•basis curves (2)•equity volatility (1), (2)
•cross currency basis curves (2)•correlation between model inputs (1)
•currency correlation
•currency volatility (1)

(1)Option-based only.

(2)Extrapolation beyond the observable limits of the curve(s).

Embedded derivatives principally include equity-indexed annuity contracts and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.

The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their funds withheld hosts, in other liabilities on the consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.

The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.

Notes Issued by CFEs

The estimated fair value of these notes are based on the estimated fair value of the corresponding securities which collateralize the notes. Since the notes are valued based on referenced collateral, they are classified as Level 3.

MRBs

See Note 6 for information on the Company’s valuation approaches and key inputs for MRBs.

Transfers between Levels

Overall, transfers between levels occur when there are changes in the observability of inputs and market activity.

Transfers into or out of Level 3:

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:

December 31, 2025 · December 31, 2024 · Impact ofIncrease in Inputon EstimatedFair Value (2)
Valuation Techniques · SignificantUnobservable Inputs · Range · WeightedAverage (1) · Range · WeightedAverage (1)
Fixed maturity securities AFS (3)
U.S. corporate and foreign corporate•Matrix pricing•Offered quotes (4)32-1279447-12692Increase
•Market pricing•Quoted prices (4)—-1009113-10295Increase
•Consensus pricing•Offered quotes (4)—-1019247-10096Increase
RMBS•Market pricing•Quoted prices (4)33-11496—-12895Increase (5)
ABS & CLO•Market pricing•Quoted prices (4)3-1421014-11397Increase (5)
Derivatives
Foreign currency exchange rate•Present value techniques•Swap yield (6)154-203202131-230222Increase (7)
MRBs and Reinsured MRBs
Direct, assumed and ceded guaranteed minimum benefits•Option pricing techniques•Mortality rates:
Ages 0 - 400%-0.15%0.05%0%-0.15%0.05%(8)
Ages 41 - 600.04%-0.79%0.22%0.04%-0.79%0.22%(8)
Ages 61 - 1150%-100%1.23%0%-100%1.14%(8)
• · Lapse rates:
Durations 1 - 100.15%-20.10%13.37%0.14%-20.10%12.86%Decrease (9)
Durations 11 - 200.38%-15%8.17%0.39%-15%6.05%Decrease (9)
Durations 21 - 1160.38%-15%7.48%0.39%-15%8.20%Decrease (9)
•Utilization rates0.20%-16.25%0.54%0.20%-22%0.79%Increase (10)
•Withdrawal rates0%-20%4.92%0%-20%4.77%(11)
•Long-term equity volatilities14.29%-22.49%18.96%14.23%-22.27%18.77%Increase (12)
•Nonperformance risk spread0.10%-1.41%0.58%0.11%-1.46%0.64%Decrease (13)

(1)The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data.

(2)The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.

(3)Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations.

(4)Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par.

(5)Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.

(6)Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.

(7)Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.

(8)Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on Company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs.

(9)Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(10)The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(11)The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.

(12)Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(13)Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs.

All other classes of securities classified within Level 3, including those within Unit-linked and FVO securities, Other investments, Separate account assets, Notes issued by CFEs, and Embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.”

The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 6):

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Fixed Maturity Securities AFS
Corporate (6)ForeignGovernmentStructuredProductsEquitySecuritiesContractholder-directed and FVO Securities
(In millions)
Balance, January 1, 2024$28,345$51$4,551$249$1,103
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(143)(1)34(32)131
Total realized/unrealized gains (losses) included in AOCI(1,177)(2)246——
Purchases (3)5,58723,01453141
Sales (3)(2,236)(1)(2,080)(34)(166)
Issuances (3)—————
Settlements (3)—————
Transfers into Level 3 (4)232—3,163——
Transfers out of Level 3 (4)(4,103)(8)(289)—(19)
Balance, December 31, 202426,505418,6392361,190
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(93)11020197
Total realized/unrealized gains (losses) included in AOCI1,528562——
Purchases (3)4,944122,065133291
Sales (3)(2,538)(6)(1,829)(67)(219)
Issuances (3)—————
Settlements (3)—————
Transfers into Level 3 (4)336—591—
Transfers out of Level 3 (4)(332)(1)(5,513)(6)—
Balance, December 31, 2025$30,350$52$3,493$317$1,459
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2023 (5)$(10)$2$10$—$136
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2024 (5)$(82)$(1)$40$(48)$135
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2025 (5)$(62)$—$7$2$188
Changes in unrealized gains (losses) included in AOCI for theinstruments still held at December 31, 2023 (5)$1,371$(3)$14$—$—
Changes in unrealized gains (losses) included in AOCI for theinstruments still held at December 31, 2024 (5)$(1,189)$(2)$209$—$—
Changes in unrealized gains (losses) included in AOCI for theinstruments still held at December 31, 2025 (5)$1,450$6$49$—$—
Gains (Losses) Data for the year ended December 31, 2023:
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)$(35)$2$(11)$9$138
Total realized/unrealized gains (losses) included in AOCI$1,413$(3)$33$—$—
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Short-termInvestmentsOtherInvestmentsNetDerivatives (7)Net EmbeddedDerivatives (8)SeparateAccounts (9)Notes Issued by CFEs
(In millions)
Balance, January 1, 2024$27$975$(143)$(93)$1,147$—
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)—14(23)86(51)—
Total realized/unrealized gains (losses) included in AOCI(1)—(31)———
Purchases (3)572——134—
Sales (3)(26)(282)——(226)—
Issuances (3)——————
Settlements (3)——213(2)——
Transfers into Level 3 (4)—231————
Transfers out of Level 3 (4)——(11)—(14)—
Balance, December 31, 202451,0105(9)990—
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(14)(64)27(154)(9)—
Total realized/unrealized gains (losses) included in AOCI5—2———
Purchases (3)51307——97(1,206)
Sales (3)(5)(137)——(185)—
Issuances (3)———(51)——
Settlements (3)———157——
Transfers into Level 3 (4)—21——4—
Transfers out of Level 3 (4)——(1)—(6)—
Balance, December 31, 2025$42$1,137$33$(57)$891$(1,206)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2023 (5)$—$23$(39)$(36)$—$—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2024 (5)$—$13$(15)$86$—$—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2025 (5)$(14)$(76)$26$(153)$—$—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2023 (5)$—$—$(5)$—$—$—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2024 (5)$—$—$—$—$—$—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2025 (5)$5$—$—$—$—$—
Gains (Losses) Data for the year ended December 31, 2023:
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)$—$22$(39)$(36)$(60)$—
Total realized/unrealized gains (losses) included in AOCI$1$—$(5)$—$—$—

(1)Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of Unit-linked and FVO securities are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(2)Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.

(3)Items purchased/issued and then sold/settled in the same period are excluded from the rollforward.

(4)Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.

(5)Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(6)Comprised of U.S. and foreign corporate securities.

(7)Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.

(8)Embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(9)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward.

Fair Value Option

The Company has elected the FVO for certain invested assets held by, and notes issued by, CFEs. See Note 3.

At December 31, 2025, the unpaid principal balance on the invested assets held by CFEs exceeded the estimated fair value by $33 million.

At December 31, 2025, the unpaid principal balance on the notes issued by CFEs exceeded the estimated fair value by $1 million.

Nonrecurring Fair Value Measurements

The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3).

December 31,
20252024
(In millions)
Carrying value after measurement:
Mortgage loans (1)$1,583$1,075
Other invested assets (2)$—$63
Years Ended December 31,
202520242023
(In millions)
Net investment gains (losses):
Mortgage loans (1)$(590)$(217)$(215)
Other invested assets (2)$—$—$(136)

(1)Estimated fair values of impaired mortgage loans are based on the underlying collateral or discounted cash flows. See Note 11.

(2)The Company recognized an impairment loss for the year ended December 31, 2023 related to AmMetLife Insurance Berhad (Malaysia) and AmMetLife Takaful Berhad (Malaysia) (collectively, “MetLife Malaysia”).

Fair Value of Financial Instruments Carried at Other Than Fair Value

The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. The following tables exclude cash and cash equivalents, which are primarily classified as Level 1, and accrued investment income, payables for collateral under securities loaned and other transactions, short-term debt and those short-term investments that are not securities (i.e., time deposits), which are primarily classified as Level 2. The Company believes that due to the short-term nature of these excluded financial instruments, the estimated fair value approximates carrying value.

The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:

Fair Value Hierarchy
CarryingValueLevel 1Level 2Level 3TotalEstimatedFair Value
(In millions)
Assets
Mortgage loans$84,593$—$—$82,933$82,933
Policy loans$8,547$—$—$9,083$9,083
Other invested assets$895$—$700$195$895
Premiums, reinsurance and other receivables$8,681$—$1,252$6,835$8,087
Other assets$247$—$53$202$255
Liabilities
PABs$147,826$—$—$145,695$145,695
Long-term debt$14,461$—$14,143$—$14,143
Collateral financing arrangement$352$—$—$322$322
Subordinated debt securities$4,155$—$4,707$—$4,707
Other liabilities$11,993$—$842$10,747$11,589
Separate account liabilities$80,164$—$80,164$—$80,164
Fair Value Hierarchy
CarryingValueLevel 1Level 2Level 3TotalEstimatedFair Value
(In millions)
Assets
Mortgage loans$89,012$—$—$84,217$84,217
Policy loans$8,545$—$—$9,058$9,058
Other invested assets$1,202$—$704$498$1,202
Premiums, reinsurance and other receivables$4,831$—$881$3,917$4,798
Other assets$228$—$69$167$236
Liabilities
PABs$139,882$—$—$134,612$134,612
Long-term debt$15,080$—$14,498$—$14,498
Collateral financing arrangement$476$—$—$425$425
Subordinated debt securities$3,164$—$3,587$—$3,587
Other liabilities$9,635$—$734$8,570$9,304
Separate account liabilities$70,359$—$70,359$—$70,359
  1. Leases

The Company, as lessee, has entered into various lease and sublease agreements primarily for office space. The Company has operating leases with remaining lease terms of less thanone year to 12 years. The remaining lease terms for the subleases are less thanone year tonine years.

ROU Assets and Lease Liabilities

ROU assets and lease liabilities for operating leases were:

December 31, 2025December 31, 2024
(In millions)
ROU assets$984$928
Lease liabilities$1,138$1,079

Lease Costs

The components of operating lease costs were as follows:

Years Ended December 31,
202520242023
(In millions)
Operating lease cost$234$226$244
Variable lease cost525252
Sublease income(87)(87)(95)
Net lease cost$199$191$201

Other Information

Supplemental other information related to operating leases was as follows:

December 31, 2025December 31, 2024
(Dollars in millions)
Cash paid for amounts included in the measurement of lease liability - operating cash flows$234$244
ROU assets obtained in exchange for new lease liabilities (1)$120$52
Weighted-average remaining lease term8 years8 years
Weighted-average discount rate4.7%4.4%

(1)See Note 3 for additional ROU assets and lease liabilities recorded as part of the acquisition of PineBridge.

  1. Leases (continued)

Maturities of Lease Liabilities

Maturities of operating lease liabilities were as follows:

(In millions)
2026$218
2027215
2028183
2029131
2030100
Thereafter429
Total undiscounted cash flows1,276
Less: interest138
Present value of lease liability$1,138

See Notes 11 and 16 for information about the Company’s investments in leased real estate and financing lease obligations.

  1. Goodwill

Information regarding goodwill by segment, as well as Corporate & Other, was as follows:

GroupBenefitsRISAsiaLatinAmericaEMEAMIM (1)Corporate& Other (1)Total
(In millions)
Goodwill$1,158$912$4,309$980$908$143$1,567$9,977
Accumulated impairment——————(680)(680)
Total goodwill, net1,1589124,3099809081438879,297
Acquisitions—————30—30
Effect of foreign currency translation and other——(95)(4)8——(91)
Goodwill1,1589124,2149769161731,5679,916
Accumulated impairment——————(680)(680)
Total goodwill, net1,1589124,2149769161738879,236
Dispositions—————(26)—(26)
Effect of foreign currency translation and other——(167)(120)(21)(1)—(309)
Goodwill1,1589124,0478568951461,5679,581
Accumulated impairment——————(680)(680)
Total goodwill, net1,1589124,0478568951468878,901
Acquisitions—————569—569
Effect of foreign currency translation and other——2088323—143
Goodwill1,1589124,0679449277181,56710,293
Accumulated impairment——————(680)(680)
Total goodwill, net$1,158$912$4,067$944$927$718$887$9,613
  1. Long-term and Short-term Debt

Long-term and short-term debt outstanding was as follows:

December 31,
2025 · 2024
Interest Rates (1) · Maturity · FaceValue · UnamortizedDiscount and Issuance Costs · CarryingValue · FaceValue · UnamortizedDiscount and Issuance Costs · CarryingValue
(In millions)
Senior notes0.50%-6.50%2026-2059$14,095$(96)$13,999$14,530$(99)$14,431
Surplus notes7.80%-7.80%2025———250—250
Other notes (2)3.52%-7.41%2026-2035463(1)462401(2)399
Financing lease obligations6—66—6
Total long-term debt14,564(97)14,46715,187(101)15,086
Total short-term debt355—355465—465
Total$14,919$(97)$14,822$15,652$(101)$15,551

(1)Range of interest rates are for the year ended December 31, 2025.

(2)Includes $75 million of long-term borrowings related to repurchase agreements, secured by CLO Investments. At December 31, 2025, the Company pledged securities with a carrying value of $80 million to collateralize these repurchase agreements. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge these securities.

The aggregate maturities of long-term debt at December 31, 2025 for the next five years and thereafter are $172 million in 2026, $81 million in 2027, $300 million in 2028, $459 million in 2029, $996 million in 2030 and $12.5 billion thereafter.

Financing lease obligations are collateralized and rank highest in priority, followed by unsecured senior notes and other notes. The $1.0 billion aggregate principal amount of 6.350% Fixed-to-Fixed Reset Rate Subordinated Debentures due March 2055, payable semi-annually, issued by MetLife, Inc, in March 2025 (the “6.350% Subordinated Debt”) ranks below these instruments but remains senior to junior subordinated debt securities (see Note 18). Payments of interest and principal on the Company’s surplus notes, which are subordinate to all other obligations of the operating company issuing the notes and are senior to obligations of MetLife, Inc., may be made only with the prior approval of the insurance department of the state of domicile of the issuer of the notes. The Company’s collateral financing arrangement (see Note 17) is supported by surplus notes of a subsidiary and, accordingly, has priority consistent with surplus notes.

Certain of the Company’s debt instruments and committed facilities, as well as its $3.0 billion unsecured revolving credit facility (the “Credit Facility”), contain various administrative, reporting, legal and financial covenants. The Company believes it was in compliance with all applicable financial covenants at December 31, 2025.

Senior Notes

In June 2025, in a private placement transaction, MetLife, Inc. issued the following fixed rate senior notes totaling $612 million, interest on which is payable semi-annually:

¥10.0 billion due June 2032 which bear interest annually at 2.140%;

¥15.0 billion due June 2035 which bear interest annually at 2.460%;

¥10.7 billion due June 2037 which bear interest annually at 2.590%;

¥12.1 billion due June 2040 which bear interest annually at 2.830%;

¥23.6 billion due June 2045 which bear interest annually at 3.290%; and

¥16.4 billion due June 2055 which bear interest annually at 3.620%.

In connection with the issuances, MetLife, Inc. incurred $5 million of related costs which will be amortized over the applicable term of each series of senior notes.

In June and September 2024, MetLife, Inc. issued $500 million and $250 million, respectively, of senior notes due December 2034, which form a single series and bear interest at a fixed rate of 5.300%, payable semi-annually. In connection with the June and September issuances, MetLife, Inc. incurred $4 million and $2 million, respectively, of related costs, which in each case will be amortized over the term of the applicable senior notes.

In April 2024, MetLife, Inc. redeemed for $438 million in cash all of its £350 million aggregate principal amount outstanding 5.375% senior notes due December 2024.

In March 2024, MetLife, Inc. issued the following fixed rate senior notes totaling $752 million, interest on which is payable semi-annually:

¥7.1 billion due March 2029 which bear interest annually at 1.009%;

¥23.1 billion due March 2031 which bear interest annually at 1.415%;

¥16.7 billion due March 2034 which bear interest annually at 1.670%;

¥11.2 billion due March 2039 which bear interest annually at 1.953%;

¥15.5 billion due March 2044 which bear interest annually at 2.195%;

¥23.5 billion due March 2054 which bear interest annually at 2.390%; and

¥15.2 billion due March 2059 which bear interest annually at 2.448%.

In connection with the March 2024 issuances, MetLife, Inc. incurred $6 million of related costs which will be amortized over the applicable term of each series of the senior notes.

In July 2023, MetLife, Inc. issued $1.0 billion of senior notes due July 2033 which bear interest at a fixed rate of 5.375%, payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $6 million of related costs which will be amortized over the term of the senior notes.

In February 2023, MetLife, Inc. redeemed for cash and canceled $1.0 billion aggregate principal amount of its outstanding 4.368% senior notes due September 2023.

In January 2023, MetLife, Inc. issued $1.0 billion of senior notes due January 2054 which bear interest at a fixed rate of 5.250%, payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $11 million of related costs which will be amortized over the term of the senior notes.

Facility Agreement for Senior Debt Issuances

In March 2025, MetLife, Inc. entered into a 30-year facility agreement (the “Facility Agreement”) with a Delaware trust (the “Trust”), upon the completion of the sale of Trust securities by the Trust for $1,250 million in private placements under Rule 144A of the Securities Act of 1933. The Trust invested the proceeds from the sale of its securities in a portfolio of principal and interest strips of U.S. Treasury securities (the “STRIPS”).

The Facility Agreement provides the Company the right to issue and sell to the Trust from time to time up to $1,250 million of its 5.740% Senior Notes due February 15, 2055 (the “5.740% Senior Notes”) in exchange for a corresponding amount of the STRIPS held by the Trust. In return, the Company agreed to pay a semi-annual facility fee to the Trust at a rate of 1.2373% per annum applied to the maximum amount of senior notes that MetLife, Inc. could issue and sell to the Trust. The Company can redeem the 5.740% Senior Notes at any time, in whole or in part, at a price equal to the greater of par or a make-whole redemption price. At December 31, 2025, the Company had no senior note issuances under the Facility Agreement.

The Company incurred $13 million of related costs, which were capitalized in other assets and will be amortized over the term of the Facility Agreement. Total fees associated with the facility were $13 million for the year ended December 31, 2025.

Short-term Debt

Short-term debt with maturities of one year or less was as follows:

December 31,
20252024
(Dollars in millions)
Short-term debt (1), (2)$355$465
Average daily balance$394$270
Average days outstanding72 days82 days

(1)Includes $238 million and $465 million at December 31, 2025 and 2024, respectively, of short-term debt related to repurchase agreements, secured by assets of subsidiaries.

(2)Includes $117 million and $133 million at December 31, 2025 and 2024, respectively, of short-term debt related to VIEs.

For the years ended December 31, 2025, 2024 and 2023, the weighted average interest rate on short-term debt was 5.21%,6.65% and 8.63%, respectively.

Interest expense on long-term and short-term debt was $724 million, $738 million and $740 million for the years ended December 31, 2025, 2024 and 2023, respectively, which is included in other expenses. Such amounts do not include interest expense on long-term debt related to the collateral financing arrangement or subordinated debt securities. See Notes 17 and 18.

Credit and Committed Facilities

At December 31, 2025, the Company maintained the Credit Facility, as well as certain committed facilities aggregating $3.2 billion (the “Committed Facilities”). When drawn upon, these facilities bear interest at varying rates in accordance with the respective agreements.

Credit Facility

The Company’s Credit Facility is used for general corporate purposes, to support the borrowers’ commercial paper programs and for the issuance of letters of credit. Total fees associated with the Credit Facility were $7 million, $7 million and $6 million for the years ended December 31, 2025, 2024 and 2023, respectively, and were included in other expenses.

Information on the Credit Facility at December 31, 2025 was as follows:

Borrower(s) · Expiration · MaximumCapacity · Letters ofCreditIssued · Drawdowns · UnusedCommitments
(In millions)
MetLife, Inc. and MetLife Funding, Inc.May 2028(1)$3,000$304$—$2,696

(1)All borrowings under the Credit Facility must be repaid by May 8, 2028, except that letters of credit outstanding on that date may remain outstanding until no later than May 8, 2029.

Committed Facilities

Letters of credit issued under the Committed Facilities are used for collateral for certain of the Company’s affiliated reinsurance liabilities. Total fees associated with the Committed Facilities, included in other expenses, were $9 million for each of the years ended December 31, 2025, 2024 and 2023.

Information on the Committed Facilities at December 31, 2025 was as follows:

Account Party/Borrower(s) · Expiration · MaximumCapacity · Letters ofCreditIssued · Drawdowns · UnusedCommitments
(In millions)
MetLife Reinsurance Company of Vermont (“MRV”) and MetLife, Inc.November 2026(1), (2)$350$350$—$—
MRV and MetLife, Inc.December 2037(1), (3)2,8912,456—435
Total$3,241$2,806$—$435

(1)MetLife, Inc. is a guarantor under the applicable facility.

(2)The issuance of additional letters of credit is at the discretion of the counterparty.

(3)Capacity at December 31, 2025 of $2.9 billion decreases gradually between 2026 and 2037 to $2.0 billion, and the facility expires in December 2037. Unused commitment of $435 million is based on maximum capacity. At December 31, 2025, Brighthouse Financial, Inc. and its subsidiaries (“Brighthouse”), a former subsidiary of MetLife, Inc., is a beneficiary of $2.5 billion of letters of credit issued under this facility and, in consideration, Brighthouse reimburses MetLife, Inc. for a portion of the letter of credit fees.

  1. Collateral Financing Arrangement

Information related to the collateral financing arrangement associated with the closed block (See Note 10) was as follows at:

December 31,
20252024
(In millions)
Surplus notes outstanding (1)$352$476
Receivable from unaffiliated financial institution (1)$46$62
Collateral (pledged) received (2)$18$—
Assets held in trust (2)$1,304$1,330

(1)At carrying value.

(2)At estimated fair value.

In December 2007, MLIC reinsured a portion of its closed block liabilities to MetLife Reinsurance Company of Charleston (“MRC”), a wholly-owned subsidiary of MetLife, Inc. In connection with this transaction, MRC issued, to investors placed by an unaffiliated financial institution, $2.5 billion in aggregate principal amount of 35-year surplus notes to provide statutory reserve support for the assumed closed block liabilities. Interest on the surplus notes accrued at an annual rate ofthree-month London Interbank Offered Rate (“LIBOR”) plus 0.55%, payable quarterly. For interest periods that commenced after June 30, 2023, three-month LIBOR was replaced with the CME Term Secured Overnight Financing Rate (“SOFR”) published for athree-month tenor plus a spread adjustment of 0.26161%. The ability of MRC to make interest and principal payments on the surplus notes is contingent upon South Carolina regulatory approval.

  1. Collateral Financing Arrangement (continued)

Simultaneously with the issuance of the surplus notes, MetLife, Inc. entered into an agreement with the unaffiliated financial institution, under which MetLife, Inc. received interest payable by MRC on the surplus notes in exchange for the payment ofthree-month LIBOR plus 1.12%, payable quarterly on such amount as adjusted, as described below. For interest periods that commenced after June 30, 2023, three-month LIBOR under the agreement was replaced with compounded SOFR calculated in arrears plus a spread adjustment of 0.26161%. MetLife, Inc. may also be required to pledge collateral or make payments to the unaffiliated financial institution related to any decline in the estimated fair value of the surplus notes. Any such payments are accounted for as a receivable and included in other assets on the Company’s consolidated balance sheets and do not reduce the principal amount outstanding of the surplus notes. Such payments, however, reduce the amount of interest payments due from MetLife, Inc. under the agreement. Any payment received from the unaffiliated financial institution reduces the receivable by an amount equal to such payment and also increases the amount of interest payments due from MetLife, Inc. under the agreement. In addition, the unaffiliated financial institution may be required to pledge collateral to MetLife, Inc. related to any increase in the estimated fair value of the surplus notes.

For the years ended December 31, 2025, 2024 and 2023, following regulatory approval, MRC repurchased$124 million, $161 million and $79 million, respectively, in aggregate principal amount of the surplus notes. Payments made by the Company in 2025, 2024 and 2023 associated with the repurchases were exclusive of accrued interest on the surplus notes. In connection with the repurchases for the years ended December 31, 2025, 2024 and 2023, the Company received payments in the aggregate amount of $16 million, $23 million and $8 million, respectively, from the unaffiliated financial institution, which reduced the amount receivable from the unaffiliated financial institution by the same amounts. No other payments related to an increase or decrease in the estimated fair value of the surplus notes were made by MetLife, Inc. or received from the unaffiliated financial institution for the years ended December 31, 2025, 2024 or 2023.

A majority of the proceeds from the offering of the surplus notes was placed in a trust, which is consolidated by the Company, to support MRC’s statutory obligations associated with the assumed closed block liabilities. The assets are principally invested in fixed maturity securities AFS and are presented as such within the Company’s consolidated balance sheets, with the related income included within net investment income on the Company’s consolidated statements of operations.

Interest expense on the collateral financing arrangement was $25 million,$38 million and $44 million for the years ended December 31, 2025, 2024 and 2023, respectively, which is included in other expenses.

  1. Subordinated Debt Securities

Outstanding Junior Subordinated Debt Securities

Outstanding junior subordinated debt securities and exchangeable surplus trust securities which are exchangeable for junior subordinated debt securities prior to redemption or repayment (collectively, the “junior subordinated debt securities”), were as follows:

December 31,
2025 · 2024
IssuerIssueDateInterestRate (1)ScheduledRedemptionDateInterest RateSubsequent toScheduledRedemptionDate (2)FinalMaturityFaceValueUnamortizedDiscountand Issuance CostsCarryingValueFaceValueUnamortizedDiscountand Issuance CostsCarryingValue
(In millions)
MetLife, Inc.December 20066.400%December 2036SOFR + 0.26161% + 2.205%December 2066$1,250$(12)$1,238$1,250$(13)$1,237
MetLife Capital Trust IV (3)December 20077.875%December 2037SOFR + 0.26161% + 3.960%December 2067700(10)690700(11)689
MetLife, Inc.April 20089.250%April 2038SOFR + 0.26161% + 5.540%April 2068750(7)743750(7)743
MetLife, Inc.July 200910.750%August 2039SOFR + 0.26161% + 7.548%August 2069500(4)496500(5)495
Total$3,200$(33)$3,167$3,200$(36)$3,164

(1)Prior to the scheduled redemption date, interest is payable semiannually in arrears.

(2)In the event the securities are not redeemed on or before the scheduled redemption date, interest will accrue after such date at an annual rate based on thethree-month CME Term SOFR plus 0.26161% and the indicated margin, payable quarterly in arrears.

(3)MetLife Capital Trust IV is a VIE which is consolidated on the financial statements of the Company. The securities issued by this entity are exchangeable surplus trust securities, which are exchangeable for a like amount of MetLife, Inc.’s junior subordinated debt securities on the scheduled redemption date, mandatorily under certain circumstances, and at any time upon MetLife, Inc. exercising its option to redeem the securities.

In connection with each of the junior subordinated debt securities, MetLife, Inc. may redeem or may cause the redemption of such securities (i) in whole or in part, at any time on or after the date five years prior to the scheduled redemption date at 100% of their principal amount, or (ii) in certain circumstances, in whole or in part, prior to the date five years prior to the scheduled redemption date at 100% of their principal amount or, if greater, a make-whole price, in each case, plus accrued and unpaid interest to, but excluding the date of redemption. MetLife, Inc. also has the right to, and in certain circumstances the requirement to, defer interest payments on these securities for a period up to 10 years. Interest compounds during such periods of deferral, if any. If interest is deferred for more than five consecutive years, MetLife, Inc. is required to use proceeds from the sale of its common stock or warrants on common stock to satisfy this interest payment obligation.

Subordinated Debt Issuance

In March 2025, MetLife, Inc. issued the 6.350% Subordinated Debt (together with the junior subordinated debt securities, the “subordinated debt securities”). MetLife, Inc. may redeem the 6.350% Subordinated Debt in whole, at any time, or in part, from time to time (i) on any interest payment date on or after March 15, 2035, the scheduled redemption date, at a redemption price equal to 100% of their principal amount, or (ii) prior to March 15, 2035, at a redemption price equal to 100% of their principal amount plus a make-whole amount, in each case, plus accrued and unpaid interest to, but excluding, the date of redemption. MetLife, Inc. may also redeem the 6.350% Subordinated Debt in whole, but not in part, depending on the specific circumstances at a redemption price equal to (i)100% of their principal amount or (ii)102% of their principal amount, in each case, plus accrued and unpaid interest to, but excluding, the date of redemption. MetLife, Inc. also has the right to defer interest payments on the 6.350% Subordinated Debt for periods of up to five years. Interest compounds during such periods of deferral, if any. In connection with the issuance, MetLife, Inc. incurred $12 million of related costs which

  1. Subordinated Debt Securities (continued)

will be amortized over the term of the 6.350% Subordinated Debt. At December 31, 2025, the carrying value of the 6.350% Subordinated Debt was$988 million, net of$12 million of unamortized costs and discounts.

The 6.350% Subordinated Debt ranks higher in priority than MetLife, Inc.’s junior subordinated debt securities and subordinate to its senior notes.

Replacement Capital Covenants

In connection with each of the junior subordinated debt securities described above, MetLife, Inc. entered into a separate replacement capital covenant (“RCC”) for the benefit of the holders of a designated series of MetLife, Inc.’s other indebtedness (the “Covered Debt”). Initially, the Covered Debt for each of the junior subordinated debt securities was MetLife, Inc.’s 5.700% senior notes due 2035 (the “5.700% Senior Notes”). As a result of the issuance of MetLife, Inc.’s 10.750% Fixed-to-Floating Rate Junior Subordinated Debentures due 2069 (the “10.750% JSDs”), the 10.750% JSDs became the Covered Debt with respect to, and in accordance with, the terms of the RCC relating to MetLife, Inc.’s 6.40% Fixed-to-Floating Rate Junior Subordinated Debentures due 2066 (the “6.40% JSDs”). Pursuant to the terms of the RCCs relating to all junior subordinated debt securities other than the 6.40% JSDs, the 6.350% Subordinated Debt, as of its issuance date in March 2025, became Covered Debt under each such RCC, and the 5.700% Senior Notes were no longer Covered Debt under such RCCs. As the holders of the Covered Debt under such RCCs, the holders of the 6.350% Subordinated Debt terminated these RCCs. The 10.750% JSDs remain the Covered Debt with respect to, and in accordance with, the terms of the remaining RCC relating to the 6.40% JSDs. As part of the RCC relating to the 6.40% JSDs, MetLife, Inc. agreed that it will not repay, redeem, or purchase the securities on or before a date 10 years prior to the final maturity date of the 6.40% JSDs, unless, subject to certain limitations, it has received cash proceeds during a specified period from the sale of specified replacement securities. The RCC relating to the 6.40% JSDs will terminate upon the occurrence of certain events, including an acceleration of the 6.40% JSDs due to the occurrence of an event of default. The RCC relating to the 6.40% JSDs is not intended for the benefit of holders of the 6.40% JSDs and may not be enforced by them. As part of this RCC, MetLife, Inc. is required, during the six-month period prior to the applicable scheduled redemption date, to use commercially reasonable efforts to raise replacement capital to permit repayment of such securities through the issuance of certain qualifying capital securities.

Interest expense on outstanding subordinated debt securities was$312 million,$261 million and $261 million for the years ended December 31, 2025, 2024 and 2023, respectively, which is included in other expenses.

  1. Equity

Preferred Stock

Preferred stock authorized, issued and outstanding was as follows:

December 31, 2025December 31, 2024
SeriesSharesAuthorizedShares Issued andOutstandingSharesAuthorizedShares Issued andOutstanding
Series A preferred stock27,600,00024,000,00027,600,00024,000,000
Series D preferred stock500,000500,000500,000500,000
Series E preferred stock32,20032,20032,20032,200
Series F preferred stock40,00040,00040,00040,000
Series G preferred stock——1,000,0001,000,000
Series A Junior Participating Preferred Stock10,000,000—10,000,000—
Not designated161,827,800—160,827,800—
Total200,000,00024,572,200200,000,00025,572,200

In September 2025, MetLife, Inc. delivered a notice of redemption to the holders of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share (“Series G preferred stock”), pursuant to which it would redeem 1,000,000 shares of Series G preferred stock at a redemption price of $1,000 per share. All outstanding shares of Series G preferred stock were redeemed on the dividend payment date of September 15, 2025 for an aggregate redemption price of $1.0 billion in cash. In connection with the redemption, MetLife, Inc. recognized a preferred stock redemption premium of $12 million (calculated as the difference between the carrying value of the Series G preferred stock and the total amount paid by MetLife, Inc. to the holders of the Series G preferred stock in connection with the redemption), which was recorded as a reduction of retained earnings at September 30, 2025.

In October 2025, MetLife, Inc. filed a Certificate of Elimination (the “Certificate of Elimination”) of Series G preferred stock with the Secretary of State of the State of Delaware to eliminate all references to the Series G preferred stock in MetLife, Inc.’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), including the related Certificate of Designations. As a result of the filing of the Certificate of Elimination, MetLife, Inc.’s Certificate of Incorporation was amended to eliminate all references therein to the Series G preferred stock, and the shares that were designated to such series were returned to the status of authorized but unissued shares of preferred stock, par value $0.01 per share, of MetLife, Inc., without designation as to series. The Certificate of Elimination does not affect the total number of authorized shares of capital stock of MetLife, Inc. or the total number of authorized shares of preferred stock.

The outstanding preferred stock ranks senior to MetLife, Inc.’s common stock with respect to the payment of dividends and distributions upon liquidation, dissolution or winding-up. Holders of the outstanding preferred stock are entitled to receive dividend payments only when, as and if declared by MetLife, Inc.’s Board of Directors or a duly authorized committee thereof. Dividends on the preferred stock are not cumulative or mandatory. Accordingly, if dividends are not declared on the preferred stock of the applicable series for any dividend period, then any accrued dividends for that dividend period will cease to accrue and be payable. If a dividend is not declared before the dividend payment date for any such dividend period, MetLife, Inc. will have no obligation to pay dividends accrued for such dividend period whether or not dividends are declared for any future period. No dividends may be paid or declared on MetLife, Inc.’s common stock (or any other securities ranking junior to the preferred stock) and MetLife, Inc. may not purchase, redeem, or otherwise acquire its common stock (or other such junior stock) unless the full dividends for the latest completed dividend period on all outstanding shares of preferred stock, and any parity stock, have been declared and paid or provided for.

The table below presents the dividend rates of MetLife, Inc.’s preferred stock outstanding at December 31, 2025:

SeriesPer Annum Dividend Rate
AThree-month CME Term SOFR plus a spread adjustment of 0.26161% + 1.000%, with floor of 4.000%, payable quarterly in March, June, September and December
D5.875% from issuance date to, but excluding, March 15, 2028, payable semiannually in March and September; three-month CME Term SOFR plus a spread adjustment of 0.26161% + 2.959% payable quarterly in March, June, September and December, thereafter
E5.625% from issuance date, payable quarterly in March, June, September and December
F4.750% from issuance date, payable quarterly in March, June, September and December

In the table above, dividends on each series of preferred stock are payable in arrears for the periods specified, if declared.

MetLife, Inc. is prohibited from declaring dividends on the Floating Rate Non-Cumulative Preferred Stock, Series A (the “Series A preferred stock”) if it fails to meet specified capital adequacy, net income and stockholders’ equity levels. See “— Dividend Restrictions — MetLife, Inc.”

Holders of the preferred stock do not have voting rights except in certain circumstances, including where the dividends have not been paid for a specified number of dividend payment periods whether or not those periods are consecutive. Under such circumstances, the holders of the preferred stock have certain voting rights with respect to members of the Board of Directors of MetLife, Inc.

The preferred stock is not subject to any mandatory redemption, sinking fund, retirement fund, purchase fund or similar provisions.

The Series A preferred stock is redeemable at MetLife, Inc.’s option in whole or in part, at a redemption price of $25 per share of Series A preferred stock, plus declared and unpaid dividends.

MetLife, Inc. may, at its option, redeem the 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D (the “Series D preferred stock”), (i) in whole but not in part at any time prior to March 15, 2028, within 90 days after the occurrence of a “rating agency event,” at a redemption price equal to $1,020 per share of Series D preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date; (ii) in whole but not in part, at any time prior to March 15, 2028, within 90 days after the occurrence of a “regulatory capital event;” and (iii) in whole or in part, at any time or from time to time, on or after March 15, 2028, in the case of (ii) or (iii), at a redemption price equal to $1,000 per share of Series D preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date.

MetLife, Inc. may, at its option, redeem the 5.625% Non-Cumulative Preferred Stock, Series E (the “Series E preferred stock”), in whole or in part, at any time or from time to time, at a redemption price equal to $25,000 per share of Series E preferred stock (equivalent to $25 per depositary share, each Series E depositary share representing a 1/1,000th interest in a share of the Series E preferred stock), plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date.

MetLife, Inc. may, at its option, redeem the 4.75% Non-Cumulative Preferred Stock, Series F (the “Series F preferred stock”) in whole or in part, at any time or from time to time, at a redemption price equal to $25,000 per share of Series F preferred stock (equivalent to $25 per Series F depositary share, each Series F depositary share representing a 1/1,000th interest in a share of the Series F preferred stock), plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date.

A “rating agency event” means that any nationally recognized statistical rating organization that then publishes a rating for MetLife, Inc. amends, clarifies or changes the criteria used to assign equity credit to securities like the Series D preferred stock, Series E preferred stock or Series F preferred stock, which results in the lowering of the equity credit assigned to the security, or shortens the length of time that the security is assigned a particular level of equity credit. A “regulatory capital event” could occur as a result of a change or proposed change in laws, rules, regulations or regulatory standards, including capital adequacy rules (or the interpretation or application thereof) of the United States or any political subdivision thereof, including any capital regulator, including but not limited to the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the Federal Insurance Office, the National Association of Insurance Commissioners (“NAIC”) or any state insurance regulator as may then have group-wide oversight of MetLife, Inc.’s regulatory capital, from those laws, rules, regulations or regulatory standards (or the interpretation or application thereof) in effect as of March 22, 2018, in the case of the Series D preferred stock, that would create a more than insubstantial risk, as determined by MetLife, Inc., that the security would not be treated as “Tier 1 capital” or as capital with attributes similar to those of Tier 1 capital, except that a “regulatory capital event” will not include a change or proposed change (or the interpretation or application thereof) that would result in the adoption of any criteria substantially the same as the criteria in the capital adequacy rules of the Federal Reserve Board applicable to bank holding companies as of March 22, 2018, in the case of the Series D preferred stock.

The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows:

Years Ended December 31,
2025 · 2024 · 2023
Series · Per Share · Aggregate · Per Share · Aggregate · Per Share · Aggregate
(In millions, except per share data)
A$1.394$33$1.659$39$1.577$37
D$58.75029$58.75029$58.75029
E$1,406.25245$1,406.25245$1,406.25245
F$1,187.50048$1,187.50048$1,187.50048
G$38.50039$38.50039$38.50039
Total$194$200$198

Common Stock

Issuances

For the years ended December 31, 2025, 2024 and 2023, MetLife, Inc. issued 1,418,562 shares,2,344,977 shares and 1,992,180 shares of its common stock for $41 million, $105 million and $110 million, respectively, in connection with stock option exercises and other stock-based awards. There wereno shares of common stock issued from treasury stock for any of the years ended December 31, 2025, 2024 or 2023.

Repurchase Authorizations

MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows:

Announcement DateAuthorization AmountAuthorization Remaining atDecember 31, 2025 (1)
(In millions)
April 30, 2025$3,000$2,072
May 1, 2024$3,000$—
May 25, 2023$1,000$—
May 3, 2023$3,000$—

(1)The Inflation Reduction Act, signed into law on August 16, 2022, imposes a one percent excise tax, net of any allowable offsets, on certain corporate stock buybacks made after December 31, 2022. The authorization remaining at December 31, 2025 does not reflect the applicable excise tax payable.

Under these authorizations, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934), and in privately negotiated transactions. Common stock repurchases are subject to the discretion of MetLife, Inc.’s Board of Directors and will depend upon the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors.

For the years ended December 31, 2025, 2024 and 2023, MetLife, Inc. repurchased 35,295,854 shares,43,955,023 shares and 50,269,483 shares of its common stock, respectively, through open market purchases for $2.9 billion, $3.2 billion, and $3.1 billion, respectively, excluding applicable excise tax. The excise tax is reflected in treasury stock as part of the cost basis of the common stock repurchased.

Dividends

For the years ended December 31, 2025, 2024 and 2023, MetLife, Inc. paid dividends on its common stock of $1.5 billion, $1.5 billion and $1.6 billion, respectively. The payment of dividends by MetLife, Inc. to its shareholders is subject to restrictions. See “— Dividend Restrictions — MetLife, Inc.”

The funding of the cash dividends and operating expenses of MetLife, Inc. is primarily provided by cash dividends from MetLife, Inc.’s insurance subsidiaries. The statutory capital and surplus, or net assets, of MetLife, Inc.’s insurance subsidiaries are subject to regulatory restrictions except to the extent that dividends are allowed to be paid in a given year without prior regulatory approval. Dividends exceeding these limitations can generally be made subject to regulatory approval. The nature and amount of these dividend restrictions, as well as the statutory capital and surplus of MetLife, Inc.’s U.S. insurance subsidiaries, are disclosed in “— Statutory Equity and Income” and “— Dividend Restrictions — Insurance Operations.” MetLife, Inc.’s principal non-U.S. insurance operations are branches or subsidiaries of American Life Insurance Company (“American Life”), a U.S. insurance subsidiary of the Company.

Stock-Based Compensation Plans

2025 Stock Plan and Predecessor Plans

The MetLife, Inc. 2025 Stock and Incentive Compensation Plan (the “2025 Stock Plan”) serves as the successor plan to the MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”), which expired on January 1, 2025, and the MetLife, Inc. 2015 Non-Management Director Stock Compensation Plan (the “2015 Director Stock Plan”), which was terminated by MetLife, Inc.’s Board of Directors effective December 31, 2024. Under the 2025 Stock Plan, MetLife, Inc. may grant awards to employees, non-management directors and agents in the form of Stock Options, Stock Appreciation Rights, Performance Shares, Performance Units, Restricted Stock, Restricted Stock Units, Cash-Based Awards and Stock-Based Awards (each, as defined in the 2025 Stock Plan) with reference to shares of MetLife, Inc.’s common stock (“Shares”), as applicable. During 2025, MetLife, Inc. granted all awards to employees, non-management directors and agents under the 2025 Stock Plan.

At December 31, 2025, awards were outstanding under the 2025 Stock Plan and the 2015 Stock Plan (related to grants made prior to its expiration). No awards were outstanding under the 2015 Director Stock Plan at December 31, 2025, since MetLife, Inc. only issued fully-vested Shares to non-management directors during the term of this plan.

The aggregate number of Shares available for issuance under the 2025 Stock Plan at December 31, 2025 was 21,489,793.

The aggregate number of Shares that remain subject to outstanding stock awards previously granted under the 2015 Stock Plan at December 31, 2025 was 5,475,798.

Awards granted under the 2025 Stock Plan, the 2015 Stock Plan, the 2015 Director Stock Plan, the MetLife, Inc. 2005 Stock and Incentive Compensation Plan, and the MetLife, Inc. 2005 Non-Management Director Stock Compensation Plan, and earlier plans that have become payable in Shares, but the issuance of which has been deferred (“Deferred Shares”) equaled 894,394 Shares at December 31, 2025.

Compensation Expense Related to Stock-Based Compensation

MetLife, Inc. recognizes compensation expense related to each award under the 2025 Stock Plan and the 2015 Stock Plan in one of the following ways:

For cash-settled awards (referred to herein as “Phantom Stock-Based Awards”), MetLife remeasures the compensation expense quarterly.

For stock-settled awards (referred to herein as “Stock-Based Awards”) granted to non-management Directors, MetLife recognizes an expense based on the number of Shares awarded and the Share price on the grant date.

For other Stock-Based Awards, MetLife recognizes an expense based on the number of awards it expects to vest, which represents the awards granted less expected forfeitures over the life of the award, as estimated at the date of grant.

The components of compensation expense related to stock-based compensation include:

Years Ended December 31,
202520242023
(In millions)
Stock Options and Unit Options (1)$2$7$7
Performance Shares and Performance Units (2)538798
Restricted Stock Units and Restricted Units767466
Total compensation expense$131$168$171
Income tax benefit$28$35$36

(1)Although Stock Options and Unit Options may be granted under the 2025 Stock Plan, the Company ceased granting Stock Options and Unit Options for periods after 2024.

(2)The Company may further adjust the number of Performance Shares and Performance Units it expects to vest, and the related compensation expense, if management changes its estimate of the most likely final performance factor.

The following table presents the total unrecognized compensation expense related to Stock-Based Awards and the expected weighted average period over which these expenses will be recognized at:

December 31, 2025
ExpenseWeighted AveragePeriod
(In millions)(Years)
Stock Options$11.05
Performance Shares$251.70
Restricted Stock Units$552.24

Equity Awards (Stock-Based Awards)

Stock Options

Stock Options are the contingent right of awardholders to purchase Shares at the applicable exercise price for a limited time. All Stock Options have an exercise price equal to the closing price of a Share reported on the New York Stock Exchange (“NYSE”) on the date of grant and have a maximum term of 10 years. The majority of Stock Options that MetLife, Inc. has granted have become or will become exercisable at a rate of one-third of each award on each of the first three anniversaries of the grant date. Other Stock Options have become or will become exercisable on the third anniversary of the grant date. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances.

Stock Option Activity

A summary of the activity related to Stock Options was as follows:

SharesUnderOptionWeightedAverageExercisePriceWeightedAverageRemainingContractualTermAggregateIntrinsicValue (1)
(Years) · (In millions)
Outstanding at January 1, 20252,994,371$55.795.51$78
Granted (2)—$—
Exercised (3)(300,422)$45.71
Expired (4)(4,182)$71.73
Forfeited (5)(7,154)$69.91
Outstanding at December 31, 20252,682,613$56.854.76$59
Vested and expected to vest at December 31, 20252,680,975$56.844.76$59
Exercisable at December 31, 20252,313,107$54.754.26$56

(1)The aggregate intrinsic value of all outstanding Stock Options is computed using the closing Share price on December 31, 2025 of $78.94 and December 31, 2024 of $81.88, as applicable.

(2)The Company ceased granting Stock Options for periods after 2024.

(3)The intrinsic value of each Stock Option is the closing price on a particular date less the exercise price of the Stock Option, provided the difference is greater than zero.

(4)Expired Stock Options were exercisable, but unexercised, as of their expiration date.

(5)Forfeited awards were either (a) unvested at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards.

MetLife estimates the fair value of Stock Options on the date of grant using a binomial lattice model. The significant assumptions the Company uses in its binomial lattice model include: expected volatility of the price of Shares; risk-free rate of return; dividend yield on Shares; exercise multiple; and the post-vesting termination rate.

MetLife bases expected volatility on an analysis of historical prices of Shares and call options on Shares traded on the open market. The Company uses a weighted-average of the implied volatility for publicly traded call options with the longest remaining maturity nearest to the money as of each valuation date and the historical volatility, calculated using monthly closing prices of Shares. The Company chose a monthly measurement interval for historical volatility as this interval reflects the Company’s view that employee option exercise decisions are based on longer-term trends in the price of the underlying Shares rather than on daily price movements.

The Company’s binomial lattice model incorporates different risk-free rates based on the imputed forward rates for U.S. Treasury STRIPS for each year over the contractual term of the option. The table below presents the full range of rates that were used for options granted during the respective periods.

The Company determines dividend yield based on historical dividend distributions compared to the price of the underlying Shares as of the valuation date and held constant over the life of the Stock Option.

The Company’s binomial lattice model incorporates the term of the Stock Options, expected exercise behavior and a post-vesting termination rate, or the rate at which vested options are exercised or expire prematurely due to termination of employment. From these factors, the model derives an expected life of the Stock Option. The model’s exercise behavior is a multiple that reflects the ratio of stock price at the time of exercise over the exercise price of the Stock Option at the time the model expects holders to exercise. The model derives the exercise multiple from actual exercise activity. The model determines the post-vesting termination rate from actual exercise experience and expiration activity under the incentive plans.

The following table presents the weighted average assumptions used to estimate the fair value of the unexercised Stock Options using the binomial lattice model. The Company ceased granting Stock Options for periods after 2024.

Years Ended December 31,
20242023
Dividend yield3.01%2.79%
Risk-free rate of return5.03% - 4.22%5.02% - 3.47%
Expected volatility26.36%25.73%
Exercise multiple1.451.45
Post-vesting termination rate3.33%3.47%
Contractual term (years)1010
Expected life (years)66
Weighted average exercise price of stock options granted$69.16$71.73
Weighted average fair value of stock options granted$17.13$17.56

The following table presents a summary of Stock Option exercise activity:

Years Ended December 31,
202520242023
(In millions)
Total intrinsic value of stock options exercised$10$25$6
Cash received from exercise of stock options$14$40$11
Income tax benefit realized from stock options exercised$2$5$1

Performance Shares

Performance Shares are units that, if they vest, are multiplied by a performance factor to produce a number of final Shares payable. MetLife accounts for Performance Shares as equity awards. MetLife, Inc. does not credit Performance Shares with dividend-equivalents for dividends paid on Shares. Performance Share awards normally vest in their entirety at the end of thethree-year performance period. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances.

For awards granted for the 2019 – 2021 and later performance periods in progress through December 31, 2025, the vested Performance Shares will be multiplied by a performance factor of 0% to 175% that the MetLife, Inc. Compensation Committee will determine by (a) the Company’s annual adjusted return on equity performance over the three-year period compared to the Company’s three-year business plan goal; (b) the Company’s total shareholder return over the same three-year period compared to a peer group of companies; and (c) a cap of 100% if the Company’s total shareholder return for the three-year period is zero or less. Per the terms of the award, the Compensation Committee will exclude the impact of a “Significant Event” from the Company’s adjusted return on equity or the business plan goal, to the extent the Committee determines in its informed judgment that the event changed the adjusted return on equity performance result by one percent or more. “Significant Events” include accounting changes, business combinations, restructuring, nonrecurring tax events, common share issuance or repurchases, catastrophes, litigation and regulatory settlements, asbestos and environmental events, certain specified classes of non-coupon investments, and other significant nonrecurring, infrequent, or unusual items.

The performance factor for the 2022 - 2024 performance period was 114.3%.

Restricted Stock Units

Restricted Stock Units are units that, if they vest, are payable in an equal number of Shares. MetLife accounts for Restricted Stock Units as equity awards. MetLife, Inc. does not credit Restricted Stock Units with dividend-equivalents for dividends paid on Shares. Accordingly, the estimated fair value of Restricted Stock Units is based upon the closing price of Shares on the date of grant, reduced by the present value of estimated dividends to be paid on that stock.

The majority of Restricted Stock Units normally vest in thirds on or shortly after the first three anniversaries of their grant date. Other Restricted Stock Units normally vest in their entirety on the third or later anniversary of their grant date. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances.

Performance Share and Restricted Stock Unit Activity

The following table presents a summary of Performance Share and Restricted Stock Unit activity:

Performance Shares · Restricted Stock Units
SharesWeightedAverageFair Value (1)UnitsWeightedAverageFair Value (1)
Outstanding at January 1, 20252,754,817$63.801,811,591$63.72
Granted884,619$75.551,218,471$74.55
Forfeited (2)(58,594)$67.11(71,984)$68.52
Payable (3)(873,665)$62.83(815,112)$63.77
Outstanding at December 31, 20252,707,177$67.882,142,966$69.70
Vested and expected to vest at December 31, 20252,673,938$67.842,082,439$69.65

(1)Values for awards outstanding at January 1, 2025, represent weighted average number of awards multiplied by their fair value per Share at December 31, 2024. Otherwise, all values represent weighted average of number of awards multiplied by the fair value per Share at December 31, 2025. Fair value of Performance Shares and Restricted Stock Units on December 31, 2025 was equal to Grant Date fair value.

(2)Forfeited awards were either (a) unvested at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards.

(3)Includes both Shares paid and Deferred Shares.

Performance Share amounts above represent aggregate awards at target, and do not reflect potential increases or decreases that may result from the performance factor. At December 31, 2025, the performance period for the 2023 - 2025 Performance Share grants was completed, but the performance factor had not yet been determined. Included in the immediately preceding table are 906,696 outstanding Performance Shares to which the 2023 - 2025 performance factor will be applied.

Liability Awards (Phantom Stock-Based Awards)

Certain MetLife subsidiaries have a liability for Phantom Stock-Based Awards in the form of Unit Options, Performance Units, and/or Restricted Units. These Share-based cash-settled awards are recorded as liabilities until MetLife makes payment. The fair value of unsettled or unvested liability awards is re-measured at the end of each reporting period based on the change in fair value of one Share. The liability and corresponding expense are adjusted accordingly until the awards are settled.

Unit Options

Unit Options are the contingent right of awardholders to receive for a limited time a cash payment equal to the closing price of a Share on the exercise date, less the applicable exercise price provided the difference is greater than zero. All Unit Options have an exercise price equal to the closing price of a Share reported on the NYSE on the date of grant and have a maximum term of 10 years. The majority of Unit Options have become or will become eligible for exercise at a rate of one-third of each award on each of the first three anniversaries of the grant date. Other Unit Options have become or will become eligible for exercise on the third anniversary of the grant date. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances.

Performance Units

Performance Units are units that, if they vest, are multiplied by a performance factor to produce a number of final Performance Units which are payable in cash equal to the closing price of a Share on a date following the last day of the three-year performance period. Performance Units are accounted for as liability awards. MetLife, Inc. does not credit them with dividend-equivalents for dividends paid on Shares. Accordingly, the estimated fair value of Performance Units is based upon the closing price of a Share on the date of grant, reduced by the present value of estimated dividends to be paid on that stock during the performance period. MetLife determines each performance period’s performance factor in the same way it does for the same performance period’s Performance Shares.

See “— Equity Awards (Stock-Based Awards) — Performance Shares” for a discussion of the Performance Shares vesting period and performance factor calculation, which are also used for Performance Units.

Restricted Units

Restricted Units are units that, if they vest, are payable in cash equal to the closing price of a Share on the last day of the restriction period. The majority of Restricted Units normally vest in thirds on or shortly after the first three anniversaries of their grant date. Other Restricted Units normally vest in their entirety on the third or later anniversary of their grant date. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances. Restricted Units are accounted for as liability awards. MetLife, Inc. does not credit Restricted Units with dividend-equivalents for dividends paid on Shares. Accordingly, the estimated fair value of Restricted Units is based upon the closing price of a Share on the date of grant, reduced by the present value of estimated dividends to be paid on that stock during the performance period.

Phantom Stock-Based Award Activity

The following table presents a summary of Phantom Stock-Based Awards activity:

UnitOptionsPerformanceUnitsRestrictedUnits
Outstanding at January 1, 202540,738346,261398,950
Granted (1)—110,213278,436
Exercised—(102,582)(193,941)
Expired (2)———
Forfeited (3)—(9,323)(13,633)
Paid———
Outstanding at December 31, 202540,738344,569469,812
Vested and expected to vest at December 31, 202540,562338,221452,990

(1)The Company ceased granting Unit Options for periods after 2024.

(2)Expired Unit Options were exercisable, but unexercised, as of their expiration date.

(3)Forfeited awards were either (a) unvested or unexercisable at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause, as defined in the terms of the awards.

Performance Unit amounts above represent aggregate awards at target, and do not reflect potential increases or decreases that may result from the performance factor. At December 31, 2025, the performance period for the 2023 - 2025 Performance Unit grants was completed, but the performance factor had not yet been determined. Included in the immediately preceding table are 107,041 outstanding Performance Units to which the 2023 - 2025 performance factor will be applied.

Statutory Equity and Income

The states of domicile of MetLife, Inc.’s U.S. insurance subsidiaries each impose risk-based capital (“RBC”) requirements that were developed by the NAIC. American Life does not write business in Delaware or any other U.S. state and, as such, is exempt from RBC requirements by Delaware law. Regulatory compliance is determined by a ratio of a company’s total adjusted capital, calculated in the manner prescribed by the NAIC (“TAC”), to its authorized control level RBC, calculated in the manner prescribed by the NAIC (“authorized control level RBC”), based on the statutory-based financial statements. Companies below specific trigger levels or ratios are classified by their respective levels, each of which requires specified corrective action. The minimum level of TAC before corrective action commences is twice authorized control level RBC (“Company Action Level RBC”). While not required by or filed with insurance regulators, the Company also calculates an internally defined combined RBC ratio (“Statement-Based Combined RBC Ratio”), which is determined by dividing the sum of TAC for MetLife, Inc.’s principal U.S. insurance subsidiaries, excluding American Life, by the sum of Company Action Level RBC for such subsidiaries. The Company’s Statement-Based Combined RBC Ratio wasin excess of 350% andin excess of 360% at December 31, 2025 and 2024, respectively. In addition, all non-exempted U.S. insurance subsidiaries individually exceeded Company Action Level RBC for all periods presented.

MetLife, Inc.’s foreign insurance operations are regulated by applicable authorities of the jurisdictions in which each entity operates and are subject to minimum capital and solvency requirements in those jurisdictions before corrective action commences. At both December 31, 2025 and 2024, the adjusted capital of American Life’s insurance subsidiary in Japan, the Company’s largest foreign insurance operation, wasin excess of three times the 200% solvency margin ratio that would require corrective action. Excluding Japan, the aggregate required and actual capital and surplus of the Company’s other foreign insurance operations was $3.8 billion and $10.5 billion, respectively, as of the date of the most recent fiscal year-end capital adequacy calculation for each jurisdiction, exceeding the respective minimum capital and solvency requirements.

MetLife, Inc.’s insurance subsidiaries prepare statutory-basis financial statements in accordance with statutory accounting practices prescribed or permitted by the insurance department of the state of domicile or applicable foreign jurisdiction. The NAIC has adopted the Codification of Statutory Accounting Principles (“Statutory Codification”). Statutory Codification is intended to standardize regulatory accounting and reporting to state insurance departments. However, statutory accounting principles continue to be established by individual state laws and permitted practices. Modifications by the various state insurance departments may impact the effect of Statutory Codification on the statutory capital and surplus of MetLife, Inc.’s U.S. insurance subsidiaries.

Statutory accounting principles differ from GAAP primarily by charging policy acquisition costs to expense as incurred, establishing FPBs using different actuarial assumptions, reporting surplus notes as surplus instead of debt and valuing securities on a different basis.

In addition, certain assets are not admitted under statutory accounting principles and are charged directly to surplus. The most significant assets not admitted by the Company are net deferred income tax assets resulting from temporary differences between statutory accounting principles basis and tax basis not expected to reverse and become recoverable within three years. Further, statutory accounting principles do not give recognition to purchase accounting adjustments. MetLife, Inc.’s U.S. insurance subsidiaries have no material state prescribed accounting practices, except as described below.

New York has adopted certain prescribed accounting practices, primarily consisting of the continuous Commissioners’ Annuity Reserve Valuation Method, which impacts deferred annuities, and the New York Special Considerations Letter, which mandates certain assumptions in asset adequacy testing. The collective impact of these prescribed accounting practices decreased the statutory capital and surplus of MLIC by $1.2 billion and $1.5 billion at December 31, 2025 and 2024, respectively, compared to what capital and surplus would have been had it been measured under NAIC guidance.

American Life calculates its policyholder reserves on insurance written in each foreign jurisdiction in accordance with the reserve standards required by such jurisdiction. Additionally, American Life’s insurance subsidiaries are valued based on each respective subsidiary’s underlying local statutory equity, adjusted in a manner consistent with the reporting prescribed for its branch operations. The prescribed practice exempts American Life from calculating and disclosing the impact to its statutory capital and surplus.

The tables below present amounts for MetLife, Inc.’s U.S. insurance subsidiaries, prepared in accordance with statutory accounting practices prescribed or permitted by the insurance department of the state of domicile.

Statutory net income (loss) was as follows:

Years Ended December 31,
CompanyState of Domicile202520242023
(In millions)
MLICNew York$1,189$2,457$3,407
American LifeDelaware$2,251$365$767
Metropolitan Tower Life Insurance Company (“MTL”)Nebraska$528$361$411
OtherVarious$32$65$53

Statutory capital and surplus was as follows at:

December 31,
Company20252024
(In millions)
MLIC$8,623$9,787
American Life$7,391$7,555
MTL$2,242$2,247
Other$342$347

The Company’s U.S. captive life reinsurance subsidiaries, which reinsure risks including the closed block, level premium term life and ULSG assumed from other MetLife subsidiaries, have no state prescribed accounting practices, except for MRV.

MRV, with the explicit permission of the Commissioner of Insurance of the State of Vermont, has included, as admitted assets, the value of letters of credit serving as collateral for reinsurance credit taken by various affiliated cedants, in connection with reinsurance agreements entered into between MRV and the various affiliated cedants, which resulted in higher statutory capital and surplus of $2.0 billion at both December 31, 2025 and 2024. MRV’s RBC would have triggered a regulatory event without the use of the state prescribed practice.

The combined statutory net income (loss) of MetLife, Inc.’s U.S. captive life reinsurance subsidiaries was $119 million, $92 million and $63 million for the years ended December 2025, 2024 and 2023, respectively, and the combined statutory capital and surplus, reflecting the aforementioned prescribed accounting practice, was $602 million and $655 million at December 31, 2025 and 2024, respectively.

Dividend Restrictions

Insurance Operations

The table below sets forth the dividends permitted to be paid by MetLife, Inc.’s primary insurance subsidiaries without insurance regulatory approval and the actual dividends paid:

202620252024
CompanyPermitted WithoutApproval (1)Paid (2)Paid (2)
(In millions)
MLIC$2,121$2,332$3,476
American Life$2,219$400$1,485
MTL$547$760$373

(1)Reflects dividend amounts that may be paid by the end of 2026 without prior regulatory approval.

(2)Reflects all amounts paid, including those where regulatory approval was obtained as required.

Under the New York State Insurance Law, MLIC is permitted, without prior insurance regulatory clearance, to pay stockholder dividends to MetLife, Inc. in any calendar year based on either of two standards. Under one standard, MLIC is permitted, without prior insurance regulatory clearance, to pay dividends out of earned surplus (defined as positive unassigned funds (surplus), excluding 85% of the change in net unrealized capital gains or losses (less capital gains tax), for the immediately preceding calendar year), in an amount up to the greater of: (i) 10% of its surplus to policyholders as of the end of the immediately preceding calendar year, or (ii) its statutory net gain from operations for the immediately preceding calendar year (excluding realized capital gains), not to exceed 30% of surplus to policyholders as of the end of the immediately preceding calendar year. In addition, under this standard, MLIC may not, without prior insurance regulatory clearance, pay any dividends in any calendar year immediately following a calendar year for which its net gain from operations, excluding realized capital gains, was negative. Under the second standard, if dividends are paid out of other than earned surplus, MLIC may, without prior insurance regulatory clearance, pay an amount up to the lesser of: (i) 10% of its surplus to policyholders as of the end of the immediately preceding calendar year, or (ii) its statutory net gain from operations for the immediately preceding calendar year (excluding realized capital gains). In addition, MLIC will be permitted to pay a dividend to MetLife, Inc. in excess of the amounts allowed under both standards only if it files notice of its intention to declare such a dividend and the amount thereof with the New York Superintendent of Financial Services (the “Superintendent”) and the Superintendent either approves the distribution of the dividend or does not disapprove the dividend within 30 days of its filing. Under the New York State Insurance Law, the Superintendent has broad discretion in determining whether the financial condition of a stock life insurance company would support the payment of such dividends to its stockholder.

Under the Delaware Insurance Code, American Life is permitted, without prior insurance regulatory clearance, to pay a stockholder dividend to MetLife, Inc. as long as the amount of the dividend, when aggregated with all other dividends in the preceding 12 months, does not exceed the greater of: (i) 10% of its surplus to policyholders as of the end of the immediately preceding calendar year, or (ii) its statutory net gain from operations for the immediately preceding calendar year (excluding realized capital gains), not including pro rata distributions of American Life’s own securities. American Life will be permitted to pay a dividend to MetLife, Inc. in excess of the greater of such two amounts only if it files notice of the declaration of such a dividend and the amount thereof with the Delaware Commissioner of Insurance (the “Delaware Commissioner”) and the Delaware Commissioner either approves the distribution of the dividend or does not disapprove the dividend within 30 days of its filing. In addition, any dividend that exceeds earned surplus (defined as “unassigned funds (surplus)”) as of the immediately preceding calendar year requires insurance regulatory approval. Under the Delaware Insurance Code, the Delaware Commissioner has broad discretion in determining whether the financial condition of a stock life insurance company would support the payment of such dividends to its stockholders.

Under the Nebraska Insurance Code, MTL is permitted, without prior insurance regulatory clearance, to pay a stockholder dividend to MetLife, Inc. as long as the amount of the dividend, when aggregated with all other dividends in the preceding 12 months, does not exceed the greater of: (i) 10% of its surplus to policyholders as of the end of the immediately preceding calendar year, or (ii) its statutory net gain from operations for the immediately preceding calendar year (excluding realized capital gains), not including pro rata distributions of MTL’s own securities. MTL will be permitted to pay a dividend to MetLife, Inc. in excess of the greater of such two amounts only if it files notice of the declaration of such a dividend and the amount thereof with the Director of the Nebraska Department of Insurance (the “Nebraska Director”) and the Nebraska Director either approves the distribution of the dividend or does not disapprove the dividend within 30 days of its filing. In addition, any dividend that exceeds earned surplus (defined as “unassigned funds (surplus)” excluding unrealized capital gains) as of the immediately preceding calendar year requires insurance regulatory approval. Under the Nebraska Insurance Code, the Nebraska Director has broad discretion in determining whether the financial condition of a stock life insurance company would support the payment of such dividends to its stockholders.

The declaration and payment of dividends are subject to the discretion of MetLife, Inc.’s Board of Directors and will depend on its financial condition, results of operations, cash requirements, future prospects, regulatory restrictions on the payment of dividends by MetLife, Inc.’s insurance subsidiaries and other factors deemed relevant by the Board of Directors. In addition, the payment of dividends on MetLife, Inc.’s common stock, and MetLife, Inc.’s ability to repurchase its common stock, may be subject to restrictions described below arising under the terms of MetLife, Inc.’s Series A preferred stock and its junior subordinated debt securities in situations where MetLife, Inc. may be experiencing financial stress, as described below.

“Dividend Stopper” Provisions in the Preferred Stock and Subordinated Debt Securities

If MetLife, Inc. has not paid the full dividends on its preferred stock for the latest completed dividend period, MetLife, Inc. may not repurchase or pay dividends on instruments junior to those instruments, including its common stock, during a dividend period under so-called “dividend stopper” provisions. Further, MetLife, Inc.’s Series A preferred stock and its junior subordinated debt securities contain provisions that would suspend the payment of preferred stock dividends and interest on the junior subordinated debt securities if MetLife, Inc. fails to meet certain RBC ratio, net income and stockholders’ equity tests at specified times, except to the extent of the net proceeds from the issuance of certain securities during specified periods. If Series A preferred stock dividends or interest on subordinated debt securities, including the 6.350% Subordinated Debt, are not paid, certain provisions in those instruments (including under “dividend stopper” provisions) may restrict MetLife, Inc. from repurchasing its common or preferred stock or paying dividends on its common or preferred stock and interest on its junior subordinated debt securities.

The subordinated debt securities further provide that MetLife, Inc. may, at its option and provided that certain conditions are met, defer payment of interest without giving rise to an event of default for periods of up to 10 years, with respect to the junior subordinated debt securities and five years with respect to the 6.350% Subordinated Debt. In the case of the junior subordinated debt securities, after five years MetLife, Inc. would be obligated to use commercially reasonable efforts to sell equity securities to raise proceeds to pay the interest. MetLife, Inc. would not be subject to limitations on the number of deferral periods that MetLife, Inc. could begin, so long as all accrued and unpaid interest is paid with respect to prior deferral periods. If MetLife, Inc. were to defer payments of interest, the “dividend stopper” provisions in the subordinated debt securities would thus prevent MetLife, Inc. from repurchasing or paying dividends on its common stock or other capital stock (including the preferred stock) during the period of deferral, subject to exceptions.

MetLife, Inc. is a party to an RCC which limits its ability to eliminate these restrictions on the 6.40% JSDs through the repayment, redemption or purchase of the 6.40% JSDs by requiring MetLife, Inc., with some limitations, to receive cash proceeds during a specified period from the sale of specified replacement securities prior to any repayment, redemption or purchase. See Note 18 for a description of such RCC.

AOCI

Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows:

UnrealizedInvestment Gains(Losses), Net ofRelated Offsets (1)Deferred Gains(Losses) onDerivativesFPBs Discount Rate Remeasurement Gains (Losses)MRBs Instrument-Specific Credit RiskRemeasurementGains (Losses)ForeignCurrencyTranslationAdjustmentsDefinedBenefitPlansAdjustmentTotal
(In millions)
Balance at December 31, 2022$(22,646)$1,557$6,115$107$(6,377)$(1,377)$(22,621)
OCI before reclassifications7,820(1,106)(4,361)(102)296(207)2,340
Deferred income tax benefit (expense)(1,666)26790422(77)45(505)
AOCI before reclassifications, net of income tax(16,492)7182,65827(6,158)(1,539)(20,786)
Amounts reclassified from AOCI2,523(705)———1191,937
Deferred income tax benefit (expense)(537)170———(26)(393)
Amounts reclassified from AOCI, net of income tax1,986(535)———931,544
Balance at December 31, 2023(14,506)1832,65827(6,158)(1,446)(19,242)
OCI before reclassifications(7,280)(549)4,997(124)(858)(123)(3,937)
Deferred income tax benefit (expense)1,809144(1,126)26(154)31730
AOCI before reclassifications, net of income tax(19,977)(222)6,529(71)(7,170)(1,538)(22,449)
Amounts reclassified from AOCI752760———1281,640
Deferred income tax benefit (expense)(177)(168)———(32)(377)
Amounts reclassified from AOCI, net of income tax575592———961,263
Balance at December 31, 2024(19,402)3706,529(71)(7,170)(1,442)(21,186)
Cumulative effects of change in accounting principles for equity method investees at January 1, 202570—(1,144)———(1,074)
OCI before reclassifications4,164(1,095)2,021(31)952(34)5,977
Deferred income tax benefit (expense)(836)225(535)5(45)9(1,177)
AOCI before reclassifications, net of income tax(16,004)(500)6,871(97)(6,263)(1,467)(17,460)
Amounts reclassified from AOCI495(1,366)———97(774)
Deferred income tax benefit (expense)(105)278———(23)150
Amounts reclassified from AOCI, net of income tax390(1,088)———74(624)
Balance at December 31, 2025$(15,614)$(1,588)$6,871$(97)$(6,263)$(1,393)$(18,084)

(1)Primarily unrealized gains (losses) on fixed maturity securities.

Information regarding amounts reclassified out of each component of AOCI was as follows:

Years Ended December 31,
2025 · 2024 · 2023
AOCI Components · Amounts Reclassified from AOCI · Consolidated Statements ofOperations Locations
(In millions)
Unrealized investment gains (losses):
Unrealized investment gains (losses)$(554)$(784)$(2,620)Net investment gains (losses)
Unrealized investment gains (losses)(11)28Net investment income
Unrealized investment gains (losses)703089Net derivative gains (losses)
Unrealized investment gains (losses), before income tax(495)(752)(2,523)
Income tax (expense) benefit105177537
Unrealized investment gains (losses), net of income tax(390)(575)(1,986)
Deferred gains (losses) on derivatives — cash flow hedges:
Interest rate derivatives293350Net investment income
Interest rate derivatives(21)(5)90Net investment gains (losses)
Foreign currency exchange rate derivatives544Net investment income
Foreign currency exchange rate derivatives1,352(794)558Net investment gains (losses)
Foreign currency exchange rate derivatives—12Other expenses
Credit derivatives111Net investment gains (losses)
Gains (losses) on cash flow hedges, before income tax1,366(760)705
Income tax (expense) benefit(278)168(170)
Gains (losses) on cash flow hedges, net of income tax1,088(592)535
Defined benefit plans adjustment: (1)
Amortization of net actuarial gains (losses)(108)(139)(130)
Amortization of prior service (costs) credit111111
Amortization of defined benefit plan items, before income tax(97)(128)(119)
Income tax (expense) benefit233226
Amortization of defined benefit plan items, net of income tax(74)(96)(93)
Total reclassifications, net of income tax$624$(1,263)$(1,544)

(1)These AOCI components are included in the computation of net periodic benefit costs. See Note 21.

  1. Other Revenues and Other Expenses

Other Revenues

Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows:

Years Ended December 31,
202520242023
(In millions)
Vision fee for service arrangements$561$536$598
Prepaid legal plans637572516
Institutional Client asset management fees (1)369301316
ASO contracts295273259
Recordkeeping and administrative services (2)142151150
Other revenue related to service contracts from customers (1) (3)432412390
Total revenues related to service contracts from customers2,4362,2452,229
Other391356297
Total other revenues$2,827$2,601$2,526

(1)As a result of the Strategic Reorganization, the presentation of the components of other revenues was revised to report MIM segment Institutional Client asset management fees herein and, as a result, $93 million and $92 million of revenue for the years ended December 31, 2024 and 2023, respectively, were reclassified to other revenue related to service contracts from customers.

(2)Related to products and businesses no longer actively marketed by the Company.

(3)Includes $48 million, $48 million and $50 million for the years ended December 31, 2025, 2024 and 2023, respectively, for asset management fees from management of general account equity method investments. See Note 25 for additional related party transactions.

Receivables for revenues related to service contracts from customers were $272 million and $238 million at December 31, 2025 and 2024, respectively.

Other Expenses

Information on other expenses was as follows:

Years Ended December 31,
202520242023
(In millions)
Amortization of DAC, VOBA and negative VOBA$2,114$2,021$1,926
Interest expense on debt1,0611,0371,045
Direct:
Employee-related costs (1)3,8343,6973,626
Third party staffing costs1,6031,5471,477
General and administrative expenses560481828
Commissions and other variable expenses6,7916,0185,819
Capitalization of DAC(3,219)(2,833)(2,917)
Premium taxes, other taxes, and licenses & fees837783660
Pension, postretirement and postemployment benefit costs279266246
Total other expenses$13,860$13,017$12,710
  1. Other Revenues and Other Expenses (continued)

(1)Includes ($173) million, ($139) million and ($140) million for the years ended December 31, 2025, 2024 and 2023, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

Capitalization of DAC and Amortization of DAC and VOBA

See Note 8 for additional information on DAC and VOBA including impacts of capitalization and amortization. See also Note 10 for a description of the DAC amortization impact associated with the closed block.

Expenses related to Debt

See Notes 16, 17, and 18 for attribution of interest expense by debt issuance and other expenses related to debt transactions.

  1. Employee Benefit Plans

Pension and Other Postretirement Benefit Plans

Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. U.S. pension benefits are provided utilizing either a traditional formula or cash balance formula. The traditional formula provides benefits that are primarily based upon years of credited service and final average earnings. The cash balance formula utilizes hypothetical or notional accounts which credit participants with benefits equal to a percentage of eligible pay, as well as interest credits, determined annually based upon the annual rate of interest on 30-year U.S. Treasury securities, for each account balance. Effective January 1, 2023, U.S. qualified and nonqualified defined benefit pension plans were amended to provide benefits accruals for all active participants under the cash balance formula and to cease future accruals under the traditional formula. The U.S. nonqualified pension plans provide supplemental benefits in excess of limits applicable to a qualified plan. The non-U.S. pension plans generally provide benefits based upon either years of credited service and earnings preceding retirement or points earned on job grades and other factors in years of service.

These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees. U.S. employees of these subsidiaries who were hired prior to 2003 (or, in certain cases, rehired during or after 2003) and meet age and service criteria while working for one of the subsidiaries may become eligible for these other postretirement benefits, at various levels, in accordance with the applicable plans. Virtually all retirees, or their beneficiaries, contribute a portion of the total costs of postretirement medical benefits. U.S. employees hired after 2003 are not eligible for any employer subsidy for postretirement medical benefits. Effective January 1, 2023, the accrual of the employer subsidy credits for eligible employees was discontinued.

The benefit obligations, funded status and net periodic benefit costs related to these pension and other postretirement benefits were comprised of the following:

December 31, 2025 · December 31, 2024
Pension BenefitsOther PostretirementBenefitsPension BenefitsOther PostretirementBenefits
U.S.PlansNon-U.S.PlansTotalU.S.PlansNon-U.S.PlansTotalU.S.PlansNon-U.S.PlansTotalU.S.PlansNon-U.S.PlansTotal
(In millions)
Benefit obligations$8,440$732$9,172$736$45$781$8,320$757$9,077$693$37$730
Estimated fair value of plan assets7,5534908,043624266507,3704667,8361,302271,329
Over (under) funded status$(887)$(242)$(1,129)$(112)$(19)$(131)$(950)$(291)$(1,241)$609$(10)$599
Net periodic benefit costs$289$52$341$(47)$7$(40)$257$60$317$(43)$3$(40)

Obligations and Funded Status

December 31,
20252024
PensionBenefits (1)OtherPostretirementBenefitsPensionBenefits (1)OtherPostretirementBenefits
(In millions)
Change in benefit obligations:
Benefit obligations at January 1,$9,077$730$9,498$765
Service costs14831563
Interest costs4794346040
Plan participants’ contributions—27—29
Plan amendments——3—
Net actuarial (gains) losses (2)15861(281)(16)
Acquisition, divestitures, settlements and curtailments(39)(6)(36)(2)
Benefits paid(660)(81)(638)(83)
Effect of foreign currency translation94(85)(6)
Benefit obligations at December 31,9,1727819,077730
Change in plan assets:
Estimated fair value of plan assets at January 1,7,8361,3298,2701,334
Actual return on plan assets611463959
Acquisition, divestitures and settlements(39)(6)(36)(2)
Plan participants’ contributions—26—29
Employer contributions (3)289(665)256(5)
Benefits paid(660)(81)(638)(83)
Effect of foreign currency translation61(55)(3)
Estimated fair value of plan assets at December 31,8,0436507,8361,329
Over (under) funded status at December 31,$(1,129)$(131)$(1,241)$599
Amounts recognized on the consolidated balance sheets:
Other assets$239$126$132$907
Other liabilities(1,368)(257)(1,373)(308)
Net amount recognized$(1,129)$(131)$(1,241)$599
AOCI:
Net actuarial (gains) losses$2,154$(400)$2,331$(502)
Prior service costs (credit)——(11)—
AOCI, before income tax$2,154$(400)$2,320$(502)
Accumulated benefit obligation$9,066N/A$8,969N/A

(1)Includes nonqualified unfunded plans, for which the aggregate PBO was $1.0 billion at both December 31, 2025 and 2024.

(2)For the year ended December 31, 2025, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of $93 million and $38 million, respectively, demographic assumptions of $4 million and ($2) million, respectively, and plan experience of $61 million and $25 million, respectively. For the year ended December 31, 2024, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of ($386) million and ($15) million, respectively, demographic assumptions of ($2) million and $0, respectively, and plan experience of $107 million and ($1) million, respectively.

(3)The Company contributes to a voluntary employee benefit association trust to fund certain U.S. retiree health and welfare benefit obligations (the “Retiree VEBA”). In order to repurpose the over-funded portion of the Retiree VEBA, the Company amended the Retiree VEBA on April 1, 2025 to create a sub-trust using the surplus. The assets of the sub-trust may be used to pay the medical benefits for pre-Medicare eligible retirees, as well as the medical and dental benefits for active employees. To the extent the sub-trust was used to fund the medical and dental expenses for active employees during 2025, such segregation of assets is reported as a negative employer contribution in the change in other postretirement benefit plan assets.

Information regarding pension plans and other postretirement benefit plans with PBOs and/or accumulated benefit obligations (“ABO”) or APBO in excess of plan assets was as follows at:

December 31,
202520242025202420252024
PBO Exceeds Estimated Fair Valueof Plan Assets · ABO Exceeds Estimated Fair Valueof Plan Assets · APBO Exceeds Estimated Fair Valueof Plan Assets
(In millions)
PBO$1,391$1,388$1,370$1,376N/AN/A
ABO$1,332$1,337$1,330$1,337N/AN/A
APBON/AN/AN/AN/A$565$549
Estimated fair value of plan assets$20$12$4$2$314$244

Net Periodic Benefit Costs

The components of net periodic benefit costs and other changes in plan assets and benefit obligations recognized in OCI were as follows:

Years Ended December 31,
202520242023
PensionBenefitsOther Postretirement BenefitsPensionBenefitsOther Postretirement BenefitsPensionBenefitsOther Postretirement Benefits
(In millions)
Net periodic benefit costs:
Service costs$148$3$156$3$143$3
Interest costs479434604047443
Settlement and curtailment (gains) losses33516—
Expected return on plan assets(442)(33)(460)(56)(480)(54)
Amortization of net actuarial (gains) losses164(56)167(28)159(30)
Amortization of prior service costs (credit)(11)—(11)—(11)—
Total net periodic benefit costs (credit)341(40)317(40)291(38)
Other changes in plan assets and benefit obligations recognized in OCI:
Net actuarial (gains) losses(12)48141(20)250(41)
Prior service costs (credit)——3———
Amortization of net actuarial gains (losses)(164)56(167)28(159)30
Amortization of prior service (costs) credit11—11—11—
Settlement and curtailment (gains) losses(3)(3)(5)(1)(6)—
Exchange rate changes212—(2)—
Total recognized in OCI(166)102(15)794(11)
Total recognized in net periodic benefit costs and OCI$175$62$302$(33)$385$(49)

Assumptions

Assumptions used in determining benefit obligations for the U.S. plans were as follows:

Pension Benefits · Other Postretirement Benefits
Weighted average discount rate5.50%5.60%
Weighted average interest crediting rate4.32%N/A
Rate of compensation increase2.50%-8.00%N/A
Weighted average discount rate5.70%5.80%
Weighted average interest crediting rate4.31%N/A
Rate of compensation increase2.50%-8.00%N/A

Assumptions used in determining net periodic benefit costs for the U.S. plans were as follows:

Pension Benefits · Other Postretirement Benefits
Weighted average discount rate5.70%5.77%
Weighted average interest crediting rate4.31%N/A
Weighted average expected rate of return on plan assets6.00%4.46%
Rate of compensation increase2.50%-8.00%N/A
Weighted average discount rate5.25%5.35%
Weighted average interest crediting rate4.30%N/A
Weighted average expected rate of return on plan assets6.00%4.25%
Rate of compensation increase2.50%-8.00%N/A
Weighted average discount rate5.60%5.70%
Weighted average interest crediting rate4.00%N/A
Weighted average expected rate of return on plan assets6.25%4.25%
Rate of compensation increase2.50%-8.00%N/A

The weighted average discount rate for the U.S. plans is determined annually based on the yield, measured on a yield to worst basis, of a hypothetical portfolio constructed of high quality debt instruments available on the measurement date, which would provide the necessary future cash flows to pay the aggregate PBO when due.

The weighted average expected rate of return on plan assets for the U.S. plans is based on anticipated performance of the various asset sectors in which the plans invest, weighted by target allocation percentages. Anticipated future performance is based on long-term historical returns of the plan assets by sector, adjusted for the long-term expectations on the performance of the markets. While the precise expected rate of return derived using this approach will fluctuate from year to year, the policy is to hold this long-term assumption constant as long as it remains within reasonable tolerance from the derived rate.

The weighted average expected rate of return on plan assets for 2026 is currently anticipated to be 6.00% for U.S. pension benefits and 4.70% for U.S. other postretirement benefits.

The weighted average interest crediting rate is determined annually based on the plan selected rate, long-term financial forecasts of that rate and the demographics of the plan participants.

The assumed healthcare costs trend rates used in measuring the APBO and net periodic benefit costs were as follows:

December 31,
20252024
BeforeAge 65Age 65 andolderBeforeAge 65Age 65 andolder
Following year7.7%18.8%6.1%8.3%
Ultimate rate to which cost increase is assumed to decline3.7%4.4%3.7%4.5%
Year in which the ultimate trend rate is reached2073210420742089

Plan Assets

Certain U.S. subsidiaries provide employees with benefits under various Employee Retirement Income Security Act of 1974 (“ERISA”) benefit plans. These include qualified pension plans, postretirement medical plans and certain retiree life insurance coverage. The assets of these U.S. subsidiaries’ qualified pension plans are held in insurance group annuity contracts, and the vast majority of the assets of the postretirement medical plan are held in a trust which largely utilizes insurance contracts to hold the assets. All of these contracts are issued by the Company and the assets under the contracts are held in insurance separate accounts. The underlying assets of the separate accounts are principally comprised of cash and cash equivalents, short-term investments, fixed maturity securities AFS, equity securities, derivatives, real estate and private equity investments. The assets backing the retiree life coverage also utilize insurance contracts issued by the Company’s insurance affiliate and are held in a general account Life Insurance Funding Agreement.

The insurance contract provider engages investment management firms (“Managers”) to serve as sub-advisors for the separate accounts based on the specific investment needs and requests identified by the plan fiduciary. These Managers have portfolio management discretion over the purchasing and selling of securities and other investment assets pursuant to the respective investment management agreements and guidelines established for each insurance separate account. The assets of the qualified pension plans and postretirement medical plans (the “Invested Plans”) are well diversified across multiple asset categories and across a number of different Managers, with the intent of minimizing risk concentrations within any given asset category or with any of the given Managers.

The Invested Plans, other than those held in participant directed investment accounts, are managed in accordance with investment policies consistent with the longer-term nature of related benefit obligations and within prudent risk parameters. Specifically, investment policies are oriented toward (i) maximizing the Invested Plan’s funded status; (ii) minimizing the volatility of the Invested Plan’s funded status; (iii) generating asset returns that exceed liability increases; and (iv) targeting rates of return in excess of a custom benchmark and industry standards over appropriate reference time periods. These goals are expected to be met through identifying appropriate and diversified asset classes and allocations, ensuring adequate liquidity to pay benefits and expenses when due and controlling the costs of administering and managing the Invested Plan’s investments. Independent investment consultants are periodically used to evaluate the investment risk of the Invested Plan’s assets relative to liabilities, analyze the economic and portfolio impact of various asset allocations and management strategies and recommend asset allocations.

Derivative contracts may be used to reduce investment risk, to manage duration and to replicate the risk/return profile of an asset or asset class. Derivatives may not be used to leverage a portfolio in any manner, such as to magnify exposure to an asset, asset class, interest rates or any other financial variable. Derivatives are also prohibited for use in creating exposures to securities, currencies, indices or any other financial variable that is otherwise restricted.

The table below summarizes the actual weighted average allocation of the estimated fair value of total plan assets by asset class at December 31 for the years indicated and the approved target allocation by major asset class at December 31, 2025 for the Invested Plans:

December 31,
2025 · 2024
U.S. PensionBenefits · U.S. OtherPostretirementBenefits (1) · U.S. PensionBenefits · U.S. OtherPostretirementBenefits (1)
TargetActualAllocationTargetActualAllocationActualAllocationActualAllocation
Asset Class
Fixed maturity securities AFS85%84%91%93%83%94%
Equity securities (2)7%7%9%7%7%6%
Alternative securities (3)8%9%—%—%10%—%
Total assets100%100%100%100%

(1)U.S. other postretirement benefits do not reflect postretirement life’s plan assets invested in fixed maturity securities AFS.

(2)Equity securities percentage includes derivative assets.

(3)Alternative securities primarily include private equity and real estate funds.

Estimated Fair Value

The pension and other postretirement benefit plan assets are categorized into a three-level fair value hierarchy, as described in Note 13, based upon the significant input with the lowest level in its valuation. The Level 2 asset category includes certain separate accounts that are primarily invested in liquid and readily marketable securities. The estimated fair value of such separate accounts is based upon reported NAV provided by fund managers and this value represents the amount at which transfers into and out of the respective separate account are effected. These separate accounts provide reasonable levels of price transparency and can be corroborated through observable market data. Directly held investments are primarily invested in U.S. and foreign government and corporate securities. The Level 3 asset category includes separate accounts that are invested in assets that provide little or no price transparency due to the infrequency with which the underlying assets trade and generally require additional time to liquidate in an orderly manner. Accordingly, the values for separate accounts invested in these alternative asset classes are based on inputs that cannot be readily derived from or corroborated by observable market data.

The pension and other postretirement plan assets measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are summarized as follows:

Pension Benefits · Other Postretirement Benefits
Fair Value HierarchyFair Value Hierarchy
Level 1Level 2Level 3TotalEstimatedFair ValueLevel 1Level 2Level 3TotalEstimatedFair Value
(In millions)
Assets
Fixed maturity securities AFS:
Corporate$—$2,838$64$2,902$—$163$—$163
U.S. government bonds1,80538—1,843877—94
Foreign bonds—635—635—23—23
Federal agencies—26—26—1—1
Municipals—75—75—2—2
Short-term investments—112—11227238—265
Other (1)24186451,1103932—71
Total fixed maturity securities AFS2,0464,588696,703153466—619
Equity securities52688862230——30
Other investments3086767141——1
Derivative assets31—4————
Total assets$2,605$4,685$753$8,043$184$466$—$650
Pension Benefits · Other Postretirement Benefits
Fair Value HierarchyFair Value Hierarchy
Level 1Level 2Level 3TotalEstimatedFair ValueLevel 1Level 2Level 3TotalEstimatedFair Value
(In millions)
Assets
Fixed maturity securities AFS:
Corporate$—$3,025$56$3,081$—$175$—$175
U.S. government bonds1,69330—1,7231027—109
Foreign bonds—7292731—38—38
Federal agencies9683—17911—2
Municipals—79—79—5—5
Short-term investments2168—170469406—875
Other (1)17327124461056—66
Total fixed maturity securities AFS1,9644,385606,409582688—1,270
Equity securities489198869558——58
Other investments4256807271——1
Derivative assets41—5————
Total assets$2,499$4,589$748$7,836$641$688$—$1,329

(1)Other primarily includes money market securities, mortgage-backed securities, collateralized mortgage obligations and ABS & CLO.

A rollforward of all pension and other postretirement benefit plan assets measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs was as follows:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Fixed Maturity Securities AFS:
Foreign BondsCorporateOtherEquity SecuritiesOtherInvestments
(In millions)
Balance, January 1, 2024$2$54$8$12$828
Realized gains (losses)—————
Unrealized gains (losses)—(2)(1)—(24)
Purchases, sales, issuances and settlements, net—16(4)(4)(124)
Transfers into and/or out of Level 3—(12)(1)——
Balance, December 31, 202425628680
Realized gains (losses)————1
Unrealized gains (losses)(2)5(1)—(19)
Purchases, sales, issuances and settlements, net—31—14
Transfers into and/or out of Level 3——3——
Balance, December 31, 2025$—$64$5$8$676

Expected Future Contributions and Benefit Payments

It is the subsidiaries’ practice to make contributions to the U.S. qualified pension plan to comply with minimum funding requirements of ERISA and to ensure that the plan assets continue to be sufficient to meet plan liabilities. In accordance with such practice, a discretionary contribution of $175 million is expected to be paid to the qualified pension plan in 2026. No contributions are expected to be required in 2026 to meet the minimum funding requirements of ERISA. For information on employer contributions, see “— Obligations and Funded Status.”

Benefit payments due under the U.S. nonqualified pension plans are primarily funded from the subsidiaries’ general assets as they become due under the provisions of the plans, and therefore benefit payments equal employer contributions. The U.S. subsidiaries expect to make contributions of $79 million to fund the benefit payments in 2026.

Postretirement benefits are either: (i) not vested under law; (ii) a non-funded obligation of the subsidiaries; or (iii) both. Current regulations do not require funding for these benefits. The subsidiaries use their general assets, net of participant’s contributions, to pay postretirement medical claims as they come due. As permitted under the terms of the governing trust document, the subsidiaries may be reimbursed from plan assets for postretirement medical claims paid from their general assets. The U.S. subsidiaries expect to make contributions of $19 million towards benefit obligations in 2026 to pay postretirement medical claims.

Gross benefit payments for the next 10 years, which reflect expected future service where appropriate, are expected to be as follows:

Pension Benefits · Other Postretirement Benefits
(In millions)
2026$722$65
2027$733$65
2028$748$65
2029$774$64
2030$751$62
2031-2035$3,714$285

Defined Contribution Plans

Certain subsidiaries sponsor defined contribution plans under which a portion of employee contributions are matched. These subsidiaries contributed $90 million for each of the years ended December 31, 2025, 2024 and 2023.

  1. Income Tax

The Company’s provision for income tax was as follows:

Years Ended December 31,
202520242023
(In millions)
Current:
U.S. federal$179$707$381
U.S. state and local809046
Non-U.S.9921,1471,240
Subtotal1,2511,9441,667
Deferred:
U.S. federal(89)(56)(591)
U.S. state and local(3)—(4)
Non-U.S.99(710)(512)
Subtotal7(766)(1,107)
Provision for income tax expense (benefit)$1,258$1,178$560

The Company’s income (loss) before income tax expense (benefit) was as follows:

Years Ended December 31,
202520242023
(In millions)
Income (loss):
U.S.$599$3,955$(95)
Non-U.S.4,0621,6672,257
Total$4,661$5,622$2,162

The table below presents the reconciliation of the income tax provision at the U.S. statutory rate to the provision for income tax as reported. See Note 1 for further information on the ASU recently adopted on a prospective basis by the Company.

Year Ended December 31,
2025
Amount% Income (Loss)
(Dollars in millions)
Income (loss) before provision for income tax$4,661
Tax provision at U.S. statutory rate97921.0%
U.S. state and local, net of U.S. federal (1)551.2%
Foreign tax effects:
Japan
Statutory tax rate difference between Japan & U.S.1262.7%
Other430.9%
Mexico
Statutory tax rate difference between Mexico & U.S.671.4%
Other(9)(0.2)%
Other foreign jurisdictions190.4%
Effects of cross border tax laws661.4%
Tax credits(53)(1.1)%
Nontaxable or nondeductible items
Tax-exempt income(79)(1.7)%
Other(1)—%
Changes in unrecognized tax benefits(13)(0.3)%
Other adjustments
Prior period adjustments871.9%
Other(29)(0.6)%
Provision for income tax expense (benefit) and effective tax rate$1,25827.0%

(1)State and local taxes in New York and New York City made up the majority (greater than 50%) of the tax effect in this category.

Years Ended December 31,
20242023
(In millions)
Tax provision at U.S. statutory rate$1,181$454
Tax effect of:
Dividend received deduction(19)(18)
Tax-exempt income(43)(34)
Prior year tax (1)44(12)
Low income housing tax credits6(116)
Other tax credits(38)(39)
Foreign tax rate differential (2), (3)22312
Changes in tax law (4)—(198)
Change in valuation allowance (4)6187
Other, net1924
Provision for income tax expense (benefit)$1,178$560

(1)As discussed further below, prior year tax primarily includes non-cash charges related to an uncertain tax position of $57 million for the year ended December 31, 2024.

(2)For the year ended December 31, 2024, foreign tax rate differential includes tax charges of $5 million related to the U.S. tax on Global Intangible Low-Taxed Income (“GILTI”) of which $33 million is a tax charge, offset by a $28 million tax benefit revising the 2023 estimate.

(3)For the year ended December 31, 2023, foreign tax rate differential includes tax charges of $28 million related to MetLife Malaysia and $22 million related to the U.S. tax on GILTI of which $28 million is a tax charge, offset by a $6 million tax benefit revising the 2022 estimate.

(4)For the year ended December 31, 2023, changes in tax law include tax benefits of $198 million and a change in valuation allowance includes a tax charge of $198 million related to adjustments of deferred taxes due to the enactment of the Bermuda Corporate Income Tax.

The Company paid income taxes, net of refunds, of $1.6 billion during the year ended December 31, 2025. Of this amount, U.S. federal income taxes paid were $555 million, U.S. state income taxes paid were $19 million and foreign income taxes paid were $990 million. Within foreign income taxes paid, net of refunds, $453 million, $241 million and $85 million were paid in Japan, Mexico and Korea, respectively.

Deferred income tax represents the tax effect of the differences between the book and tax bases of assets and liabilities. Net deferred income tax assets and liabilities consisted of the following at:

December 31,
20252024
(In millions)
Deferred income tax assets:
Policyholder liabilities and receivables$4,500$4,233
Net operating loss carryforwards (1)298247
Employee benefits575519
Capital loss carryforwards2731
Tax credit carryforwards (2)406299
Net unrealized investment losses5,4475,879
Litigation-related and government mandated107103
Other277260
Total gross deferred income tax assets11,63711,571
Less: Valuation allowance (3)601685
Total net deferred income tax assets11,03610,886
Deferred income tax liabilities:
Investments, including derivatives3,9913,469
Intangibles933836
DAC4,0633,719
Total deferred income tax liabilities8,9878,024
Net deferred income tax asset (liability)$2,049$2,862

(1)The Company has recorded a deferred tax asset of $298 million related to U.S. state and non-U.S. net operating loss carryforwards and an offsetting valuation allowance for the year ended December 31, 2025. Certain net operating loss carryforwards will expire between 2026 and 2044, whereas others have an unlimited carryforward period.

(2)Tax credit carryforwards for the year ended December 31, 2025 primarily reflect foreign tax credits. Certain foreign tax credits will expire between 2035 and 2038, whereas others have no expiration date.

(3)The Company’s deferred tax asset for the year ended December 31, 2025 includes an offsetting valuation allowance primarily related to other non-U.S. jurisdictions.

The Company has not provided for U.S. deferred taxes on the remaining excess of book bases over tax bases of certain investments in non-U.S. subsidiaries that are essentially permanent in duration. The amount of deferred tax liability related to the Company’s remaining basis difference in these non-U.S. subsidiaries was $54 million at December 31, 2025.

The Company files income tax returns with the U.S. federal government and various U.S. state and local jurisdictions, as well as non-U.S. jurisdictions. The Company is under continuous examination by the Internal Revenue Service (“IRS”) and other tax authorities in jurisdictions in which the Company has significant business operations. The income tax years under examination vary by jurisdiction and subsidiary. The Company is no longer subject to U.S. federal, state, or local income tax examinations for years prior to 2017. In material non-U.S. jurisdictions, the Company is no longer subject to income tax examinations for years prior to 2017.

In 2025, related to a federal income tax audit of MetLife, Inc. and its subsidiaries for tax years 2017, 2018 and 2019, the Company and the IRS entered into agreements resulting in the resolution of most audit issues. Accordingly, the Company recorded a non-cash expense to net income of $66 million, net of tax, comprised of a $61 million tax expense recorded in provision for income tax expense and a $6 million interest expense ($5 million, net of tax) included in other expenses.

The Company’s overall liability for unrecognized tax benefits may increase or decrease in the next 12 months. For example, U.S. federal tax legislation and regulation could impact unrecognized tax benefits. A reasonable estimate of the increase or decrease cannot be made at this time. However, the Company continues to believe that the ultimate resolution of the pending issues will not result in a material change to its consolidated financial statements, although the resolution of income tax matters could impact the Company’s effective tax rate for a particular future period.

A reconciliation of the beginning and ending amount of unrecognized tax benefits was as follows:

Years Ended December 31,
202520242023
(In millions)
Balance at January 1,$218$131$129
Additions for tax positions of prior years (1)2812727
Reductions for tax positions of prior years(17)(43)(30)
Additions for tax positions of current year1545
Reductions for tax positions of current year———
Settlements with tax authorities(46)(1)—
Balance at December 31,$198$218$131
Unrecognized tax benefits that, if recognized, would impact the effective rate$147$162$90

(1)For the year ended December 31, 2024, primarily includes the addition of state reserves and International Financial Reporting Standard 17 related reserves in foreign jurisdictions.

The Company classifies interest accrued related to unrecognized tax benefits in interest expense, included within other expenses.

Interest was as follows:

Years Ended December 31,
2025 · 2024 · 2023
(In millions)
Interest expense (benefit) recognized on the consolidated statements of operations$18$7$7
December 31,
2025 · 2024
(In millions)
Interest included in other liabilities on the consolidated balance sheets$47$29
  1. Earnings Per Common Share

The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share:

Years Ended December 31,
202520242023
(In millions, except per share data)
Weighted Average Shares:
Weighted average common stock outstanding - basic668.9706.4757.7
Incremental common shares from assumed exercise or issuance of stock-based awards4.44.74.6
Weighted average common stock outstanding - diluted673.3711.1762.3
Net Income (Loss):
Net income (loss)$3,403$4,444$1,602
Less: Net income (loss) attributable to noncontrolling interests241824
Less: Preferred stock dividends194200198
Preferred stock redemption premium12——
Net income (loss) available to MetLife, Inc.’s common shareholders$3,173$4,226$1,380
Basic$4.74$5.98$1.82
Diluted$4.71$5.94$1.81
  1. Contingencies, Commitments and Guarantees

Contingencies

Litigation

The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lender, employer, investor, investment advisor, broker-dealer, and taxpayer.

The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries.

It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at December 31, 2025. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.

Matters as to Which an Estimate Can Be Made

For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of December 31, 2025, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million.

Matters as to Which an Estimate Cannot Be Made

For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.

Asbestos-Related Claims

MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing or selling asbestos-containing products, nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920s through approximately the 1950s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC.

MLIC’s defenses include that: (i) MLIC owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.

The approximate total number of asbestos personal injury claims pending against MLIC as of the dates indicated, the approximate number of new claims during the years ended on those dates and the approximate total settlement payments made to resolve asbestos personal injury claims at or during those years are set forth in the following table:

December 31,
202520242023
(In millions, except number of claims)
Asbestos personal injury claims at year end57,60157,76057,488
Number of new claims during the year2,7822,9362,565
Settlement payments during the year (1)$43.6$47.4$50.6

(1)Settlement payments represent payments made by MLIC during the year in connection with settlements made in that year and in prior years. Amounts do not include MLIC’s attorneys’ fees and expenses.

The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.

The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.

The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position.

The Company believes adequate provision has been made in its consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis.

MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its recorded liability for asbestos-related claims. The frequency of claims relating to asbestos has not declined as expected, and MLIC has reflected this in its provisions. Accordingly, MLIC increased its recorded liability for asbestos-related claims to $427 million at December 31, 2025. The recorded liability was $406 million at December 31, 2024.

Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017)

Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., MLIC, and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. In December 2020, the Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and MLIC’s motion to dismiss and remanded the case. The Relator filed a Fourth Amended Complaint in January 2023. On October 13, 2024, the trial court denied the defendant’s motion to dismiss the complaint. The Company intends to defend the action vigorously.

Insolvency Assessments

Many jurisdictions in which the Company is admitted to transact business require insurers doing business within the jurisdiction to participate in guaranty associations, which are organized to pay contractual benefits owed pursuant to insurance policies issued by impaired, insolvent or failed insurers or those that may become impaired, insolvent or fail. These associations levy assessments, up to prescribed limits, on all member insurers in a particular jurisdiction on the basis of the proportionate share of the premiums written by member insurers in the lines of business in which the impaired, insolvent or failed insurer engaged. In addition, certain jurisdictions have government owned or controlled organizations providing life, health and property and casualty insurance to their citizens, whose activities could place additional stress on the adequacy of guaranty fund assessments. Many of these organizations have the power to levy assessments similar to those of the guaranty associations. Some jurisdictions permit member insurers to recover assessments paid through full or partial premium tax offsets.

Assets and liabilities held for insolvency assessments are as follows:

December 31,
20252024
(In millions)
Other Assets:
Premium tax offset for future discounted and undiscounted assessments$47$51
Premium tax offset currently available for paid assessments7685
$123$136
Other Liabilities:
Insolvency assessments$63$68

Commitments

Mortgage Loan Commitments

The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.4 billion and $1.9 billion at December 31, 2025 and 2024, respectively.

Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments

The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were$11.1 billion and $8.1 billion at December 31, 2025 and 2024, respectively. See Note 25 for additional information on commitments to related parties.

Guarantees

In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $329 million, with a cumulative maximum of $628 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees.

In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.

The Company also has minimum fund yield requirements on certain pension funds. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future.

The Company’s recorded liabilities were $19 million at both December 31, 2025 and 2024, for indemnities and guarantees.

  1. Related Party Transactions

In the third quarter of 2025, the Company invested $216 million in Chariot Holding Company, LP (“Chariot”), a Bermuda registered exempted limited partnership. The Company invested an additional $20 million into Chariot in the fourth quarter of 2025. Additionally, the Company has unfunded contingent capital commitments to Chariot of $94 million. The Company accounts for its investment in Chariot under the equity method of accounting.

In 2025, a subsidiary of the Company entered into reinsurance agreements with Chariot Re, a subsidiary of Chariot. See Notes 9 and 12 for further information regarding the Company’s reinsurance transactions with Chariot Re.

In addition, MetLife Investment Management, LLC entered into investment management and advisory agreements with Chariot Re to manage a portion of Chariot Re’s assets. The Company recognized asset management fees from Chariot Re of $13 million for the year ended December 31, 2025.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.